Page last updated: 2024-08-23

etoposide and paclitaxel

etoposide has been researched along with paclitaxel in 682 studies

Research

Studies (682)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.15)18.7374
1990's143 (20.97)18.2507
2000's300 (43.99)29.6817
2010's206 (30.21)24.3611
2020's32 (4.69)2.80

Authors

AuthorsStudies
Barrows, LR; Ireland, CM; Kokoshka, JM1
Heijn, M; Hooijberg, JH; Lankelma, J; Scheffer, GL; Szabó, G; Westerhoff, HV1
Corbett, TH; Edelstein, M; Hazeldine, ST; Horwitz, JP; Kushner, J; Palomino, E; Paluch, J; Polin, L; White, K1
Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z1
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA1
Belinsky, MG; Chen, ZS; Hopper-Borge, E; Kotova, E; Kruh, GD; Shchaveleva, I1
Thakker, DR; Troutman, MD1
Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M1
Gibbons, S; Kaatz, GW; Zloh, M1
Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Bacherikov, VA; Chen, CH; Chou, TC; Lin, YW; Liu, LF; Su, TL; Tsai, TJ; Zhang, X1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J1
Lombardo, F; Obach, RS; Waters, NJ1
Bednarski, PJ; Kaufmann, D; Kühne, S; Müller, C; Pfaller, T; Pojarová, M; Vogel, S; von Angerer, E1
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Chang, CY; Chang, JY; Chiang, YK; Coumar, MS; Hsieh, HP; Kuo, CC; Lai, MJ; Liou, JP; Reddy, GR; Tan, UK; Wu, SY; Yeh, JY1
Chen, GQ; Han, QB; Huang, SX; Pu, JX; Sun, HD; Wu, YL; Xiao, WL; Yang, LB; Zhao, Y1
Bae, MA; Choi, SU; Choi, YL; Heo, JN; Kim, BT; Kim, JK; Min, YK1
Chen, GQ; Ding, LS; Huang, SX; Li, X; Pu, JX; Sun, HD; Wu, YL; Xiao, WL; Yang, LB; Zhao, Y1
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L1
Béliveau, R; Castaigne, JP; Ché, C; Currie, JC; Demeule, M; Lacoste, MC; Régina, A; Thiot, C; Yang, G1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, X; Lin, X; Skolnik, S; Wang, J1
Calvo, A; Font, M; Ibáñez, E; Palop, JA; Plano, D; Prior, C; Sanmartín, C1
Bo, J; Chen, S; Cheng, H; Liu, J; Liu, Y; Wan, J; Wang, J; Yang, F; Yang, J; Zhou, GC1
Cikotiene, I; Díaz-Rodríguez, E; Domínguez-Kelly, R; Freire, R; León, LG; Padrón, JM; Pandiella, A; Ríos-Luci, C1
Chang, CY; Chang, JY; Kuo, CC; Lai, WY; Lee, HY; Liou, JP; Nien, CY; Shih, KH; Wu, CH1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P1
Huang, J; Jiang, S; Li, N; Li, X; Wang, JH; Wang, Y; Xiao, W; Zhang, P1
Font, M; Ibáñez, E; Lizarraga, E; Palop, JA; Plano, D; Sanmartín, C1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Budovská, M; Mezencev, R; Mojžiš, J; Pilátová, M; Varinská, L1
Chang, CY; Chang, JY; Chang, YT; Kuo, CC; Lai, MJ; Lee, HY; Liou, JP; Liu, YM; Mehndiratta, S; Nien, CY; Pan, SL; Su, MC; Wu, JS; Wu, SY1
Chen, H; Ding, G; Li, L; Liu, X; Song, B; Wang, H; Zhang, H; Zou, Z1
Chang, CY; Chang, JY; Chuang, HY; Kuo, CC; Lee, HY; Liou, JP; Yeh, TK1
Chai, HB; Deng, Y; Fuchs, JR; Gallucci, JC; Kanagasabai, R; Kinghorn, AD; Lantvit, DD; Ninh, TN; Ren, Y; Soejarto, DD; Swanson, SM; Yalowich, JC; Yu, J1
Ganga Reddy, V; Jain, N; Kamal, A; Paidakula, S; Polepalli, S; Shankaraiah, N; Srinivasa Reddy, T; Srinivasulu, V1
Ji, XY; Jin, J; Li, ZR; Shen, JJ; Wang, Z; Wu, LT; Xue, ST; Zhan, YC1
Chang, CY; Chang, JY; Chen, MC; Chiang, YF; Kuo, CC; Lai, MJ; Lee, HY; Liou, JP; Mehndiratta, S1
Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV1
Babaev, VM; Belenok, MG; Kataev, VE; Mironov, VF; Rizvanov, IKh; Semenov, VV; Semenova, MN; Strobykina, IY1
Chang, CY; Chang, JY; Chuang, HY; Kuo, CC; Lai, MJ; Lee, HY; Liou, JP1
Alim, Z; Beydemir, Ş1
Bahulayan, AK; Kabeer, FA; Madhusoodhanan, AR; Nair, MS; Prakasan, N; Prathapan, R; Rajalekshmi, DS; Varughese, S1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Han, HW; Hu, C; Lu, GH; Qi, JL; Qiu, HY; Sun, WX; Wang, XM; Yang, RW; Yang, YH1
Bagul, C; Bhattacharjee, D; Jain, N; Kamal, A; Kapure, JS; Shaik, SP; Subba Rao, AV; Sultana, F; Vishnuvardhan, MVPS1
Chen, SW; Feng, SL; Guan, XW; Hui, L; Ma, YZ; Xu, XH1
Han, HW; Ji, YJ; Lin, HY; Lu, GH; Qi, JL; Sun, WX; Wan, Y; Wang, XM; Yang, YH1
Cho, WJ; Han, J; Jin, Y; Khadka, DB; Kwon, Y; Park, S1
Chen, JT; Ma, R; Mu, Q; Sun, SC; Xu, XL; Zhu, XF1
Burdette, JE; Chai, HB; Cole, MS; Fuchs, JR; Herrera, D; Huntsman, AC; Kanagasabai, R; Karmahapatra, S; Kinghorn, AD; Patel, PA; Ren, Y; Woodard, JL; Yalowich, JC; Young, AN1
Guan, YF; Lam, CS; Lee, KM; Lee, MML; Liu, KL; Pan, WH; Tai, WCS; Tsang, SW; Wong, WY; Xia, YX; Xie, WJ; Xu, XY; Zhang, HJ1
Capuzzi, SJ; Chang, LC; Goto, M; Hsieh, KY; Hsu, PL; Lee, KH; Li, J; Li, KP; Morris-Natschke, SL; Zhang, YC1
Xu, Z; Zhang, L1
Jana, K; Manna, T; Misra, AK; Pal, K1
Liu, Y; Xu, Z; Zhao, SJ1
Bong Oh, K; Ho Lee, G; Hong, S; Jang, K; Ju Han, H; Kook Lee, S; Kyung Kim, W; Lee, J; Park, HG; Shin, J; Sub Byun, W; Woo Ha, M; Yang, J; Yang, S1
Kolonias, D; Lampidis, TJ; Rubin, RW; Savaraj, N1
Gottesman, MM; Mickisch, GH; Pai, LH; Pastan, I1
Abel, G; Kelland, LR1
Kudo, R; Sagae, S1
Weiss, RB1
Hatae, M; Hokanishi, H; Kume, H; Maeda, Y; Nakagawa, S; Onishi, Y1
Jampel, HD; Koya, P; Leong, K; Quigley, HA1
Yalowich, JC1
Bunn, PA; Kelly, KL1
Fujiwara, Y; Inomata, M; Kaneko, A; Kawashima, K; Kunikane, H; Saijo, N; Tanaka, Y1
Chiang, Y; Cowan, KH; Dunbar, CE; Goldspiel, B; Kohler, D; McDonagh, KT; Nienhuis, AW; O'Shaughnessy, JA; Sorrentino, BP; Wilson, W1
Ireland, CM; Pittman, SM1
Green, MR; Lilenbaum, RC; MacManus, DA1
Carey, RW; Elias, AD; Grossbard, ML; Jacobs, C; Jauss, S; Kwiatkowski, DJ; Lynch, TJ; Shulman, LN; Strauss, GM; Sugarbaker, DJ1
Johnson, DH1
Asbury, RF; Boros, L; Chang, AY; Garrow, GC1
Bonomi, P; Faber, LP; Lincoln, S; Recine, D1
Greco, FA; Hainsworth, JD; Stroup, SL2
Adler, KM; Brophy, NA; Fisher, GA; Halsey, J; Lum, BL; Sikic, BI; Yahanda, AM1
Ettinger, DS; Finkelstein, DM; Johnson, DH; Sarma, RP1
Haller, U; Koechli, OR; Perras, JP; Rodriguez, M; Schaer, GN; Schenk, V; Sevin, BU; Steren, A; Untch, M1
Chang, AY; Ettinger, DS; Johnson, DH1
Friedland, D; Gorman, G; Treat, J1
Bosl, GJ; Chou, TC; Motzer, RJ; Tong, Y1
Cook, J; Fisher, J; Goldspiel, B; Hahn, SM; Kaufman, D; Liebmann, JE; Mitchell, JB; Venzon, D1
Jampel, HD; Leong, KW; Quigley, HA; Thibault, D; Uppal, P1
Tritton, TR; Vichi, PJ1
Goodin, S; Gosland, M; Hoffman, T; Tsuboi, C; Vore, M1
Bollag, D; Lazarides, E; McQueney, PA; Woods, CM; Zhu, J1
Ashby, J1
Ariyoshi, Y; Hida, T; Miyara, H; Morishita, M; Nishida, K; Sugiura, T; Takahashi, T; Ueda, R1
Elfenbein, GJ; Fields, KK; Moscinski, LC; Perkins, JB1
Daxenbichler, G; Lang, T; Marth, C; Müller-Holzner, E; Widschwendter, M1
Aziz, SM; Crooks, PA; Gillespie, MN; Gosland, MP; Olson, JW; Tofiq, S; Tsuboi, CP1
Gray, JR; Greco, FA; Hainsworth, JD; Stroup, SL1
Balkenende, AY; Slaper-Cortenbach, IC; van den Berg, H; van der Schoot, CE; Van Leeuwen, EF; Vervoordeldonk, SF; von dem Borne, AE1
Jones, WB; Lewis, JL; Schneider, J; Shapiro, F1
Greco, FA; Hainsworth, JD5
Holm, B; Jensen, PB; Sehested, M1
Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L1
Harstrick, A; Klaassen, U; Schleucher, N; Schröder, J; Seeber, S; Vanhoefer, U; Wilke, H1
Lehr, JE; Naik, H; Pienta, KJ1
Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM1
Ogretmen, B; Safa, AR1
Baughman, TM; Bumol, TF; Cao, J; Dantzig, AH; Ehlhardt, WJ; Law, KL; Shepard, RL; Starling, JJ1
Anteby, SO; Edelman, DZ; Peretz, T1
Gallant, G; Tsao, MS; Viallet, J1
Basu, A; Saijo, N; Weixel, K1
Crilly, R; Fromm, D; Kessel, D; Luo, Y; Webber, J1
Cannistra, SA; Korsmeyer, S; Strobel, T; Swanson, L1
Fennelly, D; Gogas, H1
Davey, MW; Davey, RA; Marks, DC; Su, GM1
Alberts, DS; Brooks, DJ1
Buckwalter, CA; Perez, EA; Reid, JP1
Bunn, PA; Kelly, K2
Bunn, PA1
Brown, JM; Dorie, MJ1
Beesley, JS; Hamilton, TC; Johnson, SW; Laub, PB; Ozols, RF1
Armistead, DM; Boger, J; Duffy, JP; Galullo, V; Germann, UA; Harding, MW; Mason, VS; Saunders, JO; Shlyakhter, D; Zelle, RE1
Alken, P; Köhrmann, KU; Kreukler, C; Nebe, T; Siegsmund, MJ; Steidler, A1
Linsenmeyer, ME; Millward, MJ; Rischin, D; Urch, ME; Webster, LK; Woodcock, DM1
Bonomi, P; Johnson, D; Kim, K; Kusler, J1
Oliver, RT1
Bertola, A; Boiocchi, M; Corona, G; Sorio, R; Toffoli, G1
Erland, JB; Greco, FA; Hainsworth, JD; Kalman, LA; Schreeder, MT1
Boyer, MJ; McKeage, MJ; Millward, MJ; Olver, IN; Richardson, G; Zalcberg, J1
Bible, KC; Kaufmann, SH1
Harstrick, A; Kasimir-Bauer, S; Stahl, M1
Murray, N1
Benito, D; Camps, C; Felip, E; González-Larriba, JL; López-Cabrerizo, MP; Massuti, B; Puerto-Pica, J; Rosell, R; Salamanca, O1
Carey, RW; Elias, AD; Grossbard, ML; Herbst, R; Jacobs, C; Kwiatkowski, DJ; Leong, T; Lynch, C; Lynch, TJ; Skarin, AT; Strauss, GM1
Bonomi, P; Faber, LP; LaFollette, S; Lincoln, S; Recine, D; Sharma, M; Warren, W1
Clamon, GH; Crawford, J; Green, MR; Miller, AA; Neill, HB; Perry, MC1
Birch, R; Bobo, C; Greco, FA; Hainsworth, JD; Weaver, CH1
Gatzemeier, U; Jagos, U; Kaukel, E; Koschel, G; von Pawel, J1
Aebi, S; de las Alas, MM; Fink, D; Howell, SB; Los, G1
Colvin, OM1
Pienta, KJ; Smith, DC2
Motzer, RJ1
Ozols, RF1
Benaim, E; Blakley, RL; Galipeau, J; Sorrentino, BP; Spencer, HT1
Negoro, S1
Gray, JR; Greco, FA; Hainsworth, JD; Hopkins, LG; Kalman, LA; Patten, JE; Stroup, SL; Thomas, M1
Kaufmann, SH; Rowinsky, EK1
Berg, M; Leutz, M; Schlimmer, P; Sybrecht, GW; Ukena, D; Zell, L1
Aebi, S; Fink, D; Haas, M; Howell, SB; Kim, HK; Nebel, S; Norris, PS1
Greco, FA; Hainsworth, JD; Hopkins, LG; Thomas, M1
Ettinger, DS2
Eisenhauer, E; Shepherd, FA1
Engstrom, C; Green, M; Lilenbaum, RC; MacManus, D1
Buckwalter, CA; Perez, EA1
Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Heimenz, JW; Kronish, LA; Partyka, JS; Perkins, JB; Saez, RA; Sullivan, DM1
Davey, MW; Davey, RA; Su, GM1
Gehl, J; Mir, LM; Skovsgaard, T1
Ain, KB; Aziz, SM; Crooks, PA; Worthen, DR; Yatin, M1
Bhalla, KN; Chang, BS; Fang, G; Kim, CN; Perkins, C; Thompson, CB1
Emanuele, S; Giuliano, M; Lauricella, M; Tesoriere, G; Vento, R1
Anderson, N; Bern, M; Coco, F; Dow, E; Gotthardt, S; Lokich, J; Oliynyk, P1
Anderson, N; Bern, M; Coco, F; Dow, E; Lokich, J; Moore, C; Sonneborn, H; Strong, D1
Adhikari, D; Banerjee, D; Bertino, JR; Fu, JZ; Schnieders, B; Zhao, SC1
Bhalla, KN; Fang, G; Kim, CN; Perkins, C1
Battaglia, A; Bonanno, G; Fattorossi, A; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Scambia, G1
Aebi, S; Fink, D; Fink, JL; Gordon, R; Howell, SB; Kim, HK; Zheng, H1
Gottesman, MM; Okochi, E; Sugimoto, Y; Suzuki, M; Tsukahara, S; Tsuruo, T1
Bhalla, K; Bullock, G; Huang, Y; Maria Ibrado, A; Miyashita, T; Ray, S; Reed, J1
Budman, DR; Calabro, A; Kreis, W1
Baselga, J; Benito, D; Camps, C; Felip, E; González-Larriba, JL; Isla, D; López-Cabrerizo, MP; Massuti, B; Moyano, A; Puerto-Pica, J; Rosell, R; Salamanca, O1
Ajani, JA1
Fujii, H; Igarashi, T; Itoh, K; Minami, H; Ohtsu, T; Saijo, N; Sasaki, Y1
Kalemkerian, GP; Ou, X1
Armand, JP; Couteau, C1
Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, H; Rodriguez, MA; Romaguera, JE; Sarris, AH; Weber, D; Younes, A1
Jobe, DR; Kuhn, J; Rizzo, J; Schreeder, MT; Walton, GD1
Chikazawa, H; Fujimoto, S1
Corey, EJ; Martinez, EJ; Owa, T; Schreiber, SL1
Hoffman, M; Lesser, M; Rai, K; Xu, JC1
Gibson, S; Johnson, GL; Widmann, C1
Passaniti, A; Wang, W1
Baly, D; Beryt, M; Coombs, D; Hsu, S; Kabbinavar, F; Lewis, G; Pegram, M; Pietras, R; Slamon, D; Sliwkowski, M1
Anderson, NR; Bern, MM; Coco, FV; Dow, E; Lokich, JJ; Oliynyk, P; Sonneborn, H1
Cruz, E; Espinoza, AM; Maldonado, V; Melendez-Zajgla, J1
Bishop, WR; Izbicka, E; Lawrence, RA; Petit, T; Von Hoff, DD; Weitman, S1
Beijnen, JH; de Wit, R; Lieverst, J; Nannan Panday, VR; Rosing, H; Schellens, JH; Schornagel, JH; Schot, M; ten Bokkel Huinink, WW1
Inoue, H; Kim, R; Ohi, Y; Toge, T1
Batrakova, EV; Kabanov, AV; Li, S; Miller, DW1
Akutsu, M; Kano, Y; Mori, K; Suzuki, K; Tsunoda, S; Yazawa, Y1
Esper, P; Pienta, KJ; Redman, B; Smith, DC; Strawderman, M1
Fossella, FV; Fox, NJ; Glisson, BS; Hong, WK; Kurie, JM; Lee, JS; Murphy, WK; Nyberg, DA; Perez-Soler, R; Pisters, KM; Ross, MB; Shin, DM1
Balaña, C; Martin, C; Rosell, R1
Langer, CJ; Socinski, MA1
Bunn, PA; Kelly, K; Murphy, J; Pan, Z; Wood, ME1
de Mulder, PH; de Wit, R; Louwerens, M; Rodenhuis, S; Schornagel, J; Verweij, J1
Bonomi, P; Cella, D; Fairclough, D; Jiroutek, M; Johnson, D; Kim, K; Kugler, J; Rowinsky, E1
Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A1
Boisdron-Celle, M; Boulanger, N; Gamelin, E1
Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Kazierad, D; Khan, AM; Khan, IA; Rodriguez-Pinero, F; Tutschka, PJ1
Chang, A; Craffey, M; DeVore, R; Dowlati, A; Jett, J; Johnson, D; Levitan, N; Mackay, W; Remick, SC; Shina, D1
Bianco, AR; Caputo, R; Ciardiello, F; De Laurentiis, M; De Placido, S; Pomatico, G; Tortora, G1
Bains, M; Bajorin, DF; Bosl, GJ; Flombaum, C; Macapinlac, HA; Mariani, T; Mazumdar, M; Motzer, RJ; Reich, L; Sheinfeld, J; Tong, WP1
Choy, H; Cmelak, AJ; Johnson, DH; Mohr, PJ; Shyr, Y1
Ausema, B; Kamps, W; Kok, JW; Kolk, D; Nijhof, W; Sietsma, H; Veldman, RJ; Vellenga, E1
Bhalla, KN; Fang, G; Kim, CN; Perkins, CL1
Cal, C; Gunaydin, G; Omay, SB; Ozyurt, C; Uslu, R1
Bamias, A; Katsimbri, P; Pavlidis, N1
Berkowitz, R; Cannistra, SA; Kim, Y; Matulonis, U; Niloff, J; Quartulli, M; Seiden, M; Tung, N1
Bilgrami, S; Bona, RD; Edwards, RL; Feingold, JM; Kapur, D; Khan, AM; Rodriguez-Pinero, F; Tutschka, PJ1
Barret, JM; Etiévant, C; Hill, BT1
Filipeanu, CM; Klappe, K; Kok, JW; Koning, H; Müller, M; Veldman, RJ1
Alderson, PO; Cannon, P; Katz, J; Kline, RP; Petrylak, DP; Szabolcs, M; Weisfeldt, ML; Wu, EX1
Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kiamouris, C; Kosmidis, P; Papadimitriou, C; Papakostas, P; Pavlidis, N; Sikiotis, K; Skarlos, DV1
Fowler, JM; Greer, BE; Horowitz, IR; McGuire, WP; Rodriguez, M; Rose, PG; Waggoner, S1
Beketic-Oreskovic, L; Chen, GK; Durán, GE; Mangili, A; Sikic, BI1
Andrews, DF; Gilmore, GL; Lister, J; Shadduck, RK; Zeigler, ZR1
Connor, TH; Singleton, LC1
Ikeda, J1
Bukowski, RM; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Tabata, M; Tabata, R1
Burris, HA; Erland, JB; Gray, JR; Greco, FA; Hainsworth, JD; Kalman, LA; Schreeder, MT1
Amo-Takyi, BK; Boabang, P; Kohlhagen, H; Kurbacher, CM; Waida, A1
Gallagher, CJ; Gupta, RK; Kelsey, S; Lister, TA; Newland, AC; O'Doherty, CA; Oliver, RT; Shamash, J1
Dowell, JE; Garrett, AM; Hande, KR; Johnson, DH; Shyr, Y1
Balaguer-Martínez, JV; Castillo-Pallarés, FJ; Ferrer Albiach, C; Pallardó-Calatayud, J; Romero-de-Avila, C; Ruiz Hernández, G1
Baker, SD; Fleming, GF; Fracasso, PM; Look, KY; McGuire, WP; Muggia, FM; Roth, BJ; Sutton, GP1
Bonomi, P; Shirazi, W1
Belani, CP; Calvo, AR1
Capuano, G; D'Alessandro, V; Lelli, G; Morelli, F; Nanni, L; Palomba, G; Piano, A; Rinaldi, B; Simeon, A; Sirotovà, Z1
Cantoni, C; Daga, A; Lunardi, C; Millo, R; Oliveri, M; Puccetti, A1
Matsuoka, Y; Shimizu, S; Shinohara, Y; Tsujimoto, Y; Yoneda, Y1
Boyer, MJ; Clarke, SJ; Davis, I; Goldstein, D; Millward, MJ; Mitchell, P; Olver, IN; Richardson, G1
Chao, Y; Chen, LT; Huang, TS; Shu, CH1
Malik, IA1
Dingemans, AC; Giaccone, G; Postmus, PE; Scagliotti, GV; Span, S; van Ark-Otte, J; van der Valk, P1
Crosby, L; Dowlati, A; Levitan, N; Makkar, V; Remick, SC1
Goehle, S; Lamb, JR; Ludlow, C; Simon, JA1
Biden, TJ; Carpenter, L; Humphries, MJ; Matassa, AA; Reyland, ME1
Beyer, J; Bokemeyer, C; Rick, O; Siegert, W1
Ratain, MJ; Sawyer, M1
Agelidou, M; Bania, E; Georgoulias, V; Jordanoglou, J; Kakolyris, S; Kouroussis, C; Mavroudis, D; Papadakis, E; Stavrakakis, J; Tsiafaki, X; Veslemes, M; Vlachonicolis, J1
Lorenz, SA; Maziarz, EP; Wood, TD1
Brugarolas, A; García-Rayo, S; Inogés, S; Martín-Algarra, S; Martínez-Aguillo, M; Ordóñez, JM; Pérez-Calvo, J; Ramón y Cajal, T; Santisteban, M; Subirá, ML1
Burris, HA; Greco, FA; Hainsworth, JD1
Aasebø, U; Bremnes, RM; Sundstrøm, S; Vilsvik, J1
Baudin, B; Bénéteau-Burnat, B; Bruneel, A; Grenet, K; Mailloux, A; Vaubourdolle, M1
Bunn, PA; Crowley, JJ; Gandara, DR; Kelly, K; Livingston, RB; Lovato, L; Roychowdhury, D; Taylor, SA; Zangmeister, J1
Bilgrami, S; Bona, RD; Clive, J; Edwards, RL; Fox, J; Furlong, F; Li, Z; Naqvi, B; Shaikh, A; Tutschka, PJ1
Hudes, GR; Obasaju, C1
Bilgrami, SA; Bona, RD; Clive, J; Edwards, RL; Feingold, JM; Naqvi, B; Tutschka, PJ1
Azinovic, I; Brugarolas, A; Fernández-Hidalgo, O; García-Rayo, S; Martín-Algarra, S; Martínez-Aguillo, M; Martínez-Monge, R; Pérez-Calvo, J; Rebollo, J; Subirá, L1
Bloomer, WD; Ji, M; Papadopoulou, MV1
Le Chevalier, T; Novello, S1
Fujita, S; Hasegawa, T; Ikeda, A; Kaneshiro, E; Katakami, N; Nishimura, T; Nishio, C; Okazaki, M; Umeda, B1
Aboud, M; Ben-Aroya, Z; Butovsky, E; Flügel, RM; Grunspan, A; Hallak, M; Kedar, I; Livneh, E; Löchelt, M; Torgeman, A; Wolfson, M; Zelin, E1
Cliby, WA; Kaufmann, SH; Lewis, KA; Lilly, KK1
Bensinger, WI; Gooley, T; Heimfeld, S; Holmberg, L; Maloney, D; Rowley, SD; Yu, J1
Hassan, SB; Jonsson, E; Karlsson, MO; Larsson, R1
Bogush, EA; Bogush, TA; Khrustalev, SA; Koldaeva, EY; Konyaeva, OI; Smirnova, GB1
du Bois, A1
Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S1
Hinterleitner, T; Kerbl, R; Schwinger, W; Smolle Juettner, FM; Urban, C; Zotter, H1
De Giorgi, U; Marangolo, M; Papiani, G; Rosti, G1
Bernardo, P; Bonomi, P; Cella, D; Johnson, DH; Kugler, JW; Langer, CJ; Manola, J1
Thigpen, T1
Bookman, MA2
Newton, HB; Santi, M; Stevens, C1
Leslie, KK1
Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T1
Beyer, J; Rick, O; Siegert, W1
Cowan, DS; Egorin, MJ; Lee, CM; Tannock, IF; Tunggal, JK1
Martín, M1
Asakuma, J; Asano, T; Hayakawa, M; Kuroki, T; Ohba, M; Sumitomo, M1
Christodoulou, C; Efstathiou, E; Klouvas, G; Papazachariou, E; Plyta, M; Skarlos, DV; Zervakis, D1
Boletis, J; Chiras, T; Kosmas, C; Kostakis, A; Tsavaris, NB; Vadiaka, M1
Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K1
Chung, CW; Jo, DG; Jung, YK; Kim, BJ; Kim, IK; Kim, KW; Kwon, YK; Song, YH; Woo, HN1
Bunn, PA; Chan, DC; Chan, KK; Covey, JM; Feng, WY; Gera, L; Helfrich, B; Stewart, JM; Zhao, TL1
Aebi, S; Betticher, DC; Calderoni, A; Solenthaler, M; von Briel, C1
Hwang, PH; Lee, DY; Oh, Y; Yi, HK1
Hensley, ML1
Akeshima, R; Iba, T; Itamochi, H; Kamazawa, S; Kanamori, Y; Kigawa, J; Sultana, H; Terakawa, N1
Nathan, C; Shen, C1
Takeda, K1
Watanabe, H1
Okamoto, H; Watanabe, K1
Matsui, H; Nagai, Y; Seki, K; Sekiya, S; Suzuka, K; Tanaka, N1
Arnt, CR; Chiorean, MV; Gores, GJ; Heldebrant, MP; Kaufmann, SH1
Cosaert, J; Quoix, E1
Boldt, S; Kolch, W; Weidle, UH1
Krüger, I; Lindenfelser, R; Scherwitz, P1
D'Orazio, A; Gibson, AD1
Gerinière, L; Souquet, PJ1
Chen, XB; Li, DX1
Clark, AS; Dennis, PA; Streicher, S; West, K1
Choy, H; Gandara, D; Mattson, K; Vokes, EE1
Friberg, LE; Henningsson, A; Karlsson, MO; Maas, H; Nguyen, L1
Gatzemeier, U; Grunwald, F; Hessler, S; Jagos, U; Kaukel, E; Koschel, G; Reck, M; von Pawel, J1
Antón, LM; Constenla, M; Domínguez, S; Dorta, J; Esteban, E; García-Girón, C; Gómez Aldavarí, JL; Gonzalez-Barón, M; Gracia, M; Lacave, AJ; López, E; López, R; Martín, G; Mel, JR; Peláez, I; Rodríguez, R; Sevilla, I; Valladares, M; Vieitez, JM1
Miao, L; Wang, Y; Wu, M; Yi, P; Zhai, Z; Zhang, W1
Naito, K1
Cannon, MW; Jones, D; Kuebler, JP; Lee, SJ; Logothetis, CJ; Millikan, R; Thall, PF; Wade, J1
Hirai, I; Honda, K; Kokawa, Y; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T1
Bunn, PA; Simon, GR1
Beitler, JJ1
Bélanger, MM; Couet, J; Roussel, E1
Bonomi, P; Cella, D; Eton, DT; Fairclough, DL; Johnson, DH; Yount, SE1
Bauman, MD; Hatfield, AK; Hillman, S; Jett, JR; Kugler, JW; Levitt, R; Mailliard, JA; Marks, RS; Morton, RF1
Albain, KS; Bearden, JD; Burris, H; Chansky, K; Crowley, J; Gandara, DR; Gaspar, LE; Gumerlock, P; Kuebler, JP; Lara, PN; Leigh, BR; Livingston, R1
Coldman, BJ; Fossella, FV; Glisson, BS; Komaki, R; Kurie, JM; Lee, JS; Lu, C; Palmer, JL; Pisters, KM; Shin, DM1
Dou, QP; Kuhn, DJ; Pross, S; Smith, DM; Whiteside, TL1
Chay, CH; Dunn, RL; Esper, P; Fardig, J; Olson, K; Pienta, KJ; Smith, DC1
Hara, N; Moritake, K; Osago, H; Shingu, T; Terashima, M; Tsuchiya, M; Uemura, T; Yamada, K; Yamasaki, T1
Chuang, TC; Kao, MC; Law, SL; Lee, YJ; Li, JW; Lin, YS; Liu, JY; Wang, V1
Albertsson, P; Lennernäs, B; Lennernäs, H; Norrby, K1
Johnson, DH; Laskin, J; Sandler, A1
Bonnet, R; Deppermann, KM; Gatzemeier, U; Hessler, S; Kaukel, E; Macha, HN; Reck, M; Ulm, K; von Pawel, J2
Davey, MW; Davey, RA; Locke, VL1
Aquino-Parsons, C; Hoskins, PJ; Lee, N; Lim, P; Pike, JA; Swenerton, KD; Wong, F1
Fiorica, JV1
Asim, M; Chen, X; Shankar, S; Singh, TR; Srivastava, RK1
Bar-Sela, G; Gaitini, D; Haim, N; Steiner, M; Tsalic, M1
Choi, HJ; Jin, YH; Lee, SK; Park, BD; Yim, H1
Carty, M; Gilmore, PM; Harkin, DP; Johnston, PG; Kennedy, RD; Mullan, PB; Quinn, JE1
Greco, FA1
Ball, ED; Chen, J; Mokotoff, M; Shultz, LD; Zhong, R; Zhou, J1
La Mura, N; Lombardi, D; Sorio, R; Spazzapan, S; Tabaro, G; Veronesi, A1
Syed, S1
Butts, JA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH; Raefsky, EL; Steis, RG1
Christodoulou, J; Haferlach, T; Schnittger, S; Schoch, C1
Chansky, K; Crowley, J; Edelman, MJ; Gandara, DR; Gaspar, LE; Leigh, B; Livingston, R; Taylor, SA; Weiss, GR1
Gabbert, HE; Gerharz, CD; Reinecke, P; Schmitz, M; Steckstor, M1
Ali, K; Fung, MF; Hopkins, L; Le, T; Leis, A; Pahwa, P; Reeder, B; Wright, K1
Francia, G; Green, SK; Isidoro, C; Kerbel, RS1
Barceló, R; Ferreiro, J; Fuente, N; López Vivanco, G; Muñoz, A; Rubio, I1
Basu, A; Huang, J; Kumar Biswas, S; Persaud, S1
Driver, D; Giles, C; Harland, SJ; Haynes, R; Kanfer, EJ; McNeish, IA; Newlands, ES; Rustin, GJ; Seckl, MJ1
Shimizu, E1
MacLeod, P; Maziak, DE; Shamji, FM; Stewart, DJ; Tomiak, E1
Farr, GH; Geoffroy, FJ; Hatfield, AK; Hillman, S; Johnson, EA; Krook, JE; Levitt, R; Maillard, JA; Marks, RS; Perez, EA; Tazelarr, HD1
Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA1
Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H1
Beyer, J; Bokemeyer, C; Braun, T; Hartmann, JT; Hartmann, M; Pottek, T; Rachud, B; Rick, O; Schirren, J; Siegert, W; Weinknecht, S; Weissbach, L1
Covens, A; Gerulath, A; Merchandani, DE; Mirchandani, D; Osborne, R1
Doyle, A; Edelman, MJ; Gamliel, Z; Hausner, P; Krasna, M; Patel, AB; Sonett, JR; Suntharalingam, M1
Hatae, M; Nakamura, T; Onishi, Y1
Agner, J; Bartek, J; Falck, J; Lukas, J1
Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA1
Chen, LK; Liang, Y; Liu, JL; Xu, GC; Yang, QY; Zhang, LN1
Herzog, TJ1
Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Kuczyk, M; Metzner, B; Schleicher, J; Schleucher, N; Wierecky, J1
Kang, WK; Ko, U; Lee, I; Park, C1
Biron, P; Bui, B; Caty, A; Culine, S; Curé, H; De Revel, T; Delva, R; Droz, JP; Duclos, B; Fizazi, K; Gligorov, J; Gomez, F; Gravis, G; Guillemaut, S; Lotz, JP; Peny, J; Provent, S; Ségura, C; Théodore, C; Viens, P1
Hausmaninger, H; Heilmann, V; Huebner, G; Nitsch, T; Possinger, K; Schippinger, W; Schmid, P; Schultze, W; Wischnewsky, M1
Sugiyama, T1
Mikami, K; Miki, T; Mizutani, Y1
André, A; Braekman, JC; Bruyneel, F; Darro, F; Decaestecker, C; Dewelle, J; El Yazidi, M; Guissou, P; Kiss, R; Nacoulma, O; Simon, G; Tuti, J; Van Quaquebeke, E1
Akbulut, H; Altinbas, M; Baltali, E; Boruban, C; Büyükcelik, A; Coşkun, S; Demirkazik, A; Erkisi, M; Icli, F; Komurcu, S; Onur, H; Sak, SD; Sencan, O; Senler, FC; Uner, A; Yalcin, B; Zengin, N1
Hu, H; Ip, C; Jiang, C; Lü, J; Rustum, YM1
Castine, M; Greco, FA; Hainsworth, JD; Kalman, L; Sylvester, L1
Debatin, KM; Fulda, S1
Bushman, F; Groschel, B1
Díaz-Montero, CM; McIntyre, BW1
Epstein, AL; Hu, P; Khawli, LA1
Beijnen, JH; Chhatta, AA; Huisman, MT; Schinkel, AH; van Tellingen, O1
Ansari, R; Belani, CP; Lee, JS; Lilenbaum, R; Natale, RB; Robert, F; Rowland, K; Socinski, MA; Waterhouse, D1
Brown, J; Burke, TW; Deavers, MT; Gershenson, DM; Munsell, MF; Ramondetta, LM; Shvartsman, HS1
Bakalarz, R; Banasik, A; Góźdź, S; Lankoff, A; Lesisz, D; Lisowska, H; Padjas, A; Wojcik, A1
De, S; Miller, DW; Robinson, DH1
Kekre, N; McLachlan, A; McNulty, J; Pandey, S1
Ansari, RH; Ellerton, J; Green, MR; Herndon, JE; Kelly, K; Marks, RS; Miller, AA; Niell, HB; Otterson, G; Perry, MC; Sandler, AB; Vokes, EE; Watson, DM1
Balis, F; Bates, S; Cole, D; Egorin, MJ; Flynn, BM; Fojo, T; Knutsen, T; Langham, G; Rao, VK; Ried, T; Steinberg, SM; Wangsa, D1
Abrams, RA; Berkey, BA; Byhardt, RW; Curran, WJ; Duncan, PJ; Ettinger, DS; Fontanesi, J; Machtay, M; Movsas, B1
Besse, B; Le Chevalier, T; Soria, JC1
Broggini, M; Kei Lee, M; Sabapathy, K; Siddique, MM; Vikhanskaya, F1
Farmakis, D; Pectasides, D; Pectasides, M1
Lin, C; Liu, ZR; Yang, L1
Muehlbauer, PA; Schuler, MJ1
Adjei, AA; Creagan, ET; Croghan, G; Frytak, S; Giordano, KF; Jatoi, A; Jett, JR; Marks, R; Molina, J; Okuno, S; Richardson, RL1
Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC1
Mimata, H; Nomura, T; Nomura, Y; Yamasaki, M1
Kekre, N; McNulty, J; Naderi, J; Pandey, S1
Alshehadat, S; Sahmoun, AE1
Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Yano, S1
Kaneda, T; Narita, Y; Suzuki, A; Takahashi, N; Tsunematsu, K1
Brody, JR; Cunningham, SC; DeMarzo, AM; Dezentje, DA; Gallmeier, E; Hruban, RH; Isacoff, WH; Kern, SE; Offerhaus, GJ; Swartz, MJ; van der Heijden, MS1
Burris, HA; Corso, SW; Erland, JB; Greco, FA; Hainsworth, JD; Joseph, G; Morrissey, LH; Spigel, DR; Spremulli, E; Thompson, DS1
Rexer, FH1
Alvarnas, J; Chow, W; Doroshow, JH; Frankel, P; Kogut, N; Leong, LA; Lim, D; Margolin, KA; McNamara, M; Morgan, RJ; Schriber, J; Shibata, S; Somlo, G; Stalter, S; Twardowski, P; Yen, Y1
Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Grillo, R1
Hiramatsu, Y; Hongo, A; Kodama, J; Nakamura, K; Ojima, Y; Seki, N1
Baas, P; Belderbos, JS; Burgers, JA; Kwa, HB; Senan, S; van Bochove, A; van Meerbeeck, JP; van Tinteren, H1
Gibson, SB; Henson, ES; Hu, X1
Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T1
Jankovic, D; Kanazir, S; Markovic, ID; Markovic, JZ; Pesic, M; Rakic, L; Ruzdijic, S1
Amikura, T; Aoki, Y; Banzai, C; Nishikawa, N; Sekine, M; Suzuki, M; Tanaka, K; Yokoo, T1
Eberhardt, W; Pöttgen, C; Stuschke, M1
Baldini, E; Conte, PF; Del Freo, A; Fabbri, A; Falcone, A; Innocenti, F; Pennucci, MC; Prochilo, T; Russo, F; Tibaldi, C1
Agelidou, A; Agelidou, M; Androulakis, N; Argyraki, A; Christophylakis, Ch; Georgoulias, V; Geroyianni, A; Kakolyris, S; Karvounis, N; Kouroussis, Ch; Tsaroucha, E; Veslemes, M1
Depierre, A1
Blumenthal, DK; Chen, J; Cheung, AK; Lee, RM; Li, L; Liu, J; Masaki, T; Yang, HS1
Li, Z; Liu, Z; Thiele, CJ; Woo, CW; Zhang, J1
Daly, BD; Dipetrillo, TA; Fernando, HC; Kachnic, LA; Ketchedjian, A; Morelli, DM; Shemin, RJ1
Anai, H; Anegawa, G; Honda, M; Kai, T; Kaneko, S; Masuda, T; Nakamura, Y; Ohta, R; Saeki, H; Yokoyama, S1
Greco, FA; Hainsworth, JD; Litchy, S; Spigel, DR1
Guo, W; Tang, S; Tang, XD; Yang, Y1
Cheng, JQ; He, L; Kruk, P; Nicosia, SV; Yang, H1
Scorilas, A; Talieri, M; Thomadaki, H1
Katakami, N1
Fukumori, T; Harada, A; Hayashi, H; Izaki, H; Kanayama, HO; Kishimoto, T; Nishitani, MA; Takahashi, M; Tanimoto, S; Taue, R; Yamamoto, Y1
Berdel, WE; Frickhofen, N; Haas, R; Heimpel, H; Hinke, A; Hossfeld, DK; Kreienberg, R; Kuhn, W; Möbus, V; Opri, F; Sandherr, M; Schneeweiss, A; Thomssen, C1
Fangusaro, J; Finlay, J; Rook, J; Rosser, T1
Chatelut, E; Henningsson, A; Karlsson, MO; Kloft, C; Wallin, J1
Arellano, M; Flowers, C; Heffner, LT; Hutcherson, D; Jo Lechowicz, M; Langston, A; Lonial, S; Waller, EK; Winton, E1
Chansky, K; Crowley, JJ; Davies, AM; Gandara, DR; Gaspar, LE; Lau, DH; Leigh, BR; Weiss, GR; Wozniak, AJ1
Hagan, CR; Rudin, CM1
Goldman, A; Pommier, Y; Sordet, O1
Atweh, GF; Mistry, SJ1
Bacik, J; Bains, M; Bajorin, D; Bosl, GJ; Budnick, A; Deluca, J; Ishill, N; Kondagunta, GV; Mazumdar, M; Motzer, RJ; Reich, L; Sheinfeld, J1
Ling, MT; Wang, X; Wong, YC; Zhang, X1
Backendorf, C; Noteborn, MH; Olijslagers, SJ; Zhang, YH1
Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Nakamura, R; Ohta, F; Okamura, Y; Oura, S; Tamaki, T; Tanino, H; Yoshimasu, T1
Coley, HM; Hughes, MP; Labeed, FH; Thomas, H1
Banerjee, S; Chiritescu, G; Dahrouge, S; Stewart, DJ; Tomiak, EM1
Kim, DM; Lee, S; Lim, SK; Park, SY; Park, YN; Rhee, Y; Song, SY; Youn, JC1
Bot, BM; Garces, YI; Jett, JR; Kozelsky, TF; Mandrekar, SJ; Martens, JM; Moore, DF; Okuno, SH; Schild, SE; Soori, GS; Wender, DB1
Gaucher, G; Leroux, JC; Poreba, M; Ravenelle, F1
Feng, YL; Li, JD; Li, MD; Liu, JH; Shi, HL; Xiao, Y1
Yoneda, S1
Brozmanová, K; Hlavatá, Z; Koza, I; Mardiak, J; Mego, M; Obertová, J; Recková, M; Risnyovzská, Z; Sálek, T; Svetlovská, D; Sycová-Milá, Z1
Droz, JP; Fléchon, A1
Frank, H; Fuchs, J; Heitmann, H; Herberts, T; Ruck, P; Seitz, G; Warmann, SW1
Bogart, JA; Green, MR; Hodgson, LD; Miller, AA; Radford, JE; Rocha Lima, CM; Vokes, EE; Wang, XF1
Chen, A; Ding, F; Liu, Z; Luo, A; Ren, S; Yu, Z; Zhang, L; Zhang, S1
Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC1
Fujiwara, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Tsuta, K; Yamada, K; Yamamoto, N1
Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Murakawa, Y; Nishino, Y; Ohori, H; Ohtsuka, K; Sakayori, M; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T1
Biesterfeld, S; Hoffarth, S; Huber, C; Kröll, M; Schuler, M; Wesarg, E; Wiewrodt, R1
Biesma, B; de Jong, WK; Groen, HJ; Koolen, MG; Kwa, HB; Smit, EF; van Bochove, A; van Tinteren, H; Willems, LN1
Seto, T1
Fu, J; Liang, M; Su, DM; Zhang, P1
Chen, JJ; Fan, DM; Li, TT; Liu, YW; Liu, ZG; Zhao, LN1
Aydin, Y; Cicin, I; Eralp, Y; Ozluk, Y; Saip, P; Selam, M; Topuz, E; Topuz, S1
Guang, ZZ; Jiang, WQ; Li, ZM; Liu, ZC; Yang, DJ; Zhou, JM; Zhu, XF; Zhu, ZY1
Bae, SN; Jung, SG; Kim, CJ; Kim, SJ; Lee, C; Na, YJ1
Marwaha, S; North, SA; Venner, PM1
Galsky, MD; Kondagunta, V; Sonpavde, G1
Brown, MA; Logothetis, C; Millikan, RE; Pagliaro, LC; Thall, PF; Wen, S; Williams, D1
Lehoczky, O; Pulay, T1
Beyer, J; Bokemeyer, C; Casper, J; Derigs, G; Gauler, T; Gerl, A; Hartmann, JT; Horger, M; Kuczyk, MA; Mayer-Steinacker, R; Metzner, B; Rick, O; Schleicher, J1
Benoit, JP; Garcion, E; Lacoeuille, F; Lamprecht, A1
Hsu, PC; Hung, HC; Liao, YF; Liu, CC; Liu, GY; Tsay, GJ1
Bosl, GJ; Feldman, DR; Ishill, N; Jathavedam, A; Motzer, RJ; Patil, S; Turkula, S; Weinstock, DM1
Lindsay, I; Newlands, ES; Savage, PM; Schmid, P; Sebire, NJ; Seckl, MJ; Short, D; Wang, J1
Ahn, JS; Ahn, MJ; Ahn, YC; Han, J; Hwang, IG; Kim, J; Lee, S; Park, BB; Park, K; Shim, YM1
Gao, J; He, Z; Li, X; Li, Y; Liu, M; Tang, H; Wang, Q; Zheng, J1
Castino, R; Démoz, M; Isidoro, C; Nicotra, G; Peracchio, C; Salini, A; Trincheri, NF; Valente, G1
Broggini, M; Carrassa, L; Crippa, F; Damia, G; Ganzinelli, M; Tavecchio, M1
Castleberry, R; Kletzel, M; Kretschmar, C; London, WB; Marcus, R; Murray, K; Zage, PE; Zhang, Y1
Algara, M; Fernández-Velilla, E; Foro, P; Lacruz, M; López, JL; Lozano, J; Membrive, I; Quera, J; Reig, A; Rodríguez, N; Sanz, X1
Scorilas, A; Thomadaki, H1
Friedrichs, N; Gorschlüter, M; Gressner, O; Mey, U; Popp, H; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J1
Antoniou, D; Athanasiadis, A; Dimitroulis, J; Giamboudakis, P; Karaindros, D; Katis, K; Koutantos, J; Rapti, A; Rigatos, S; Stathopoulos, GP; Stathopoulos, J; Toumbis, M; Tsikritsaki, K1
Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R1
Asbell, SO; Bae, K; Kerlin, KJ; Michalski, JM; Pienta, KJ; Rajan, R; Rosenthal, SA; Sandler, HM; Sobczak, ML1
Bernardo, P; Horn, L; Johnson, DH; Levitan, N; Levitt, ML; Sandler, A; Wagner, H1
Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ1
Berek, JS; Brady, M; Hutson, A; Markman, M1
Aruga, C; Aubrecht, J; Bauer, D; Boitier, E; Deng, S; Dickinson, D; Ellinger-Ziegelbauer, H; Fornace, AJ; Fostel, JM; Grenet, O; Gu, Y; Hoflack, JC; Le Fevre, AC; Shiiyama, M; Smith, R; Snyder, RD; Spire, C; Tanaka, G1
Lv, L; Song, B; Song, X; Wang, X; Wei, L; Xie, L; Yu, J1
Borovskaya, TG; Gol'dberg, VE; Pachomova, AV; Perova, AV; Poluektova, ME1
Ji, W; Lü, JM; Ou, GF; Ren, H; Wang, LH; Wang, XZ; Yin, WB; Zhou, ZM1
Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE1
Basu, S; Faber, LP; Kim, AW; Liptay, MJ; Miller, C; Milman, S; Warren, WH1
Che, G; Gong, Y; Hou, M; Huang, M; Li, L; Li, T; Li, W; Liu, L; Liu, Y; Lu, Y; Ren, L; Tang, B; Wang, J; Xu, Y; Zhou, L; Zhu, J; Zou, B1
Capasso, I; Comella, G; Comella, P; D'Aiuto, G; D'Aiuto, M; Di Bonito, M; Frasci, G; Iodice, G; Lastoria, S; Montella, M; Oliviero, P; Petrillo, A; Ruffolo, P; Santangelo, M; Siani, C; Vizioli, L1
Rivera Rosado, LA; Yoshida, T; Zhang, B; Zhang, Y1
García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L1
Choi, IK; Gao, R; Kaul, SC; Kaur, K; Kim, I; Morrow, G; Ryu, J; Tanguay, RM; Wadhwa, R; Yun, CO1
Arslan, C; Kilickap, S1
Bains, M; Bajorin, DF; Bosl, GJ; Feldman, DR; Fischer, P; Ishill, N; Motzer, RJ; Patil, S; Reich, LM; Sheinfeld, J; Turkula, S1
Ishii, N; Matsuda, T; Morozumi, M; Takagi, D; Terao, T; Yamada, T; Yamashita, T; Yoshinaga, A1
Abolmaali, ND; Abramyuk, AM; Tokalov, SV1
Chen, JY; Li, J; Zhu, X1
Deguchi, T; Fujita, Y; Ito, M; Kojima, K; Nozawa, Y1
Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J1
Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P1
Behlendorf, T; Jahn, F; Jahn, P; Jordan, K; Kegel, T; Ruessel, J; Schmoll, HJ; Stein, A1
Billaud, EM; Bobin-Dubigeon, C; Boisdron-Celle, M; Boyer, JC; Chatelut, E; Concordet, D; Durdux, C; Etienne-Grimaldi, MC; Evrard, A; Floquet, A; Gladieff, L; Laffont, CM; Lafont, T; Lansiaux, A; Le Guellec, C; Mazières, J; Mousseau, M; Ollivier, F; Pinguet, F; Schmitt, A1
Albain, K; Bae, K; Curran, WJ; Gore, EM; Komaki, R; Machtay, M; Movsas, B; Paulus, R; Sause, WT1
Brandt, BH; Dittmar, T; Haverkampf, S; Meyer-Staeckling, S; Niggemann, B; Reith, G; Schwitalla, S; Seidel, J; Zänker, KS1
Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N1
Abonour, R; Einhorn, LH; Kesler, KA1
Athanasopoulos, A; Daladimos, T; Karabelis, A; Kosmas, C; Mylonakis, N; Theotikos, E; Tsakonas, G1
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK1
Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D1
Anisimov, AP; Cragg, MS; Erenpreisa, J; Huna, A; Ianzini, F; Kosmacek, EA; Salmina, K1
Lee, DW; Lee, HN; Lee, KH; Lee, YS; Park, EK; Park, JS1
Golshayan, A; Harrer, GW; Hussain, MH; Mills, GM; Smith, DC; Tangen, CM; Thompson, IM; Van Veldhuizen, PJ; Vogelzang, NJ1
Bascoul-Mollevi, C; Beyer, J; De Giorgi, U; Einhorn, L; Fléchon, A; Germà-Lluch, JR; Kollmannsberger, C; Kramar, A; Lorch, A; Lotz, JP; Margolin, K; Massard, C; Necchi, A; Powles, T1
Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A1
Hirakawa, K; Miwa, A; Qiu, H; Yashiro, M; Zhang, X1
Abrams, RA; Basu, S; Batus, M; Bonomi, P; Faber, LP; Fidler, MJ; Gielda, BT; Liptay, M; Marsh, JC; Warren, WH; Zusag, TW1
Anchisi, S; Bieri, S; Elhfidh, M; Khanfir, K; Matzinger, O; Mirimanoff, RO; Ozsahin, M; Zouhair, A1
Jeremić, B; Miličić, B; Milisavljevic, S3
Amin, NP; Camidge, DR; Gaspar, LE; Kavanagh, B; Miften, M; Raben, D; Rochford, N; Thornton, D1
Abdel-Hady Hemida, R; Abdel-Hady, el-S; El-Shamey, M; Gamal, A1
Blagden, S; Gabra, H; Graham, J; Sharma, R1
Bi, Y; Calhoun-Davis, T; Chen, X; Coletta, LD; Fokt, I; Klostergaard, J; Li, H; Liu, C; Priebe, W; Qin, J; Skora, S; Tang, DG; Yan, H; Zhang, Q1
Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS1
Brown, JB; Kadoyama, K; Kuwahara, A; Okuno, Y; Sakaeda, T; Yamamori, M1
Charoentum, C; Chewaskulyong, B; Permsuwan, U; Ruengorn, C; Thongprasert, S1
Bell-McGuinn, KM; Brogi, E; Elie, BT; Garfall, AL; Joyce, JA; Kester, JC; Olson, OC; Shree, T; Simpson, K; Zabor, EC1
Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X1
Korbakis, D; Scorilas, A1
Aass, N; Albers, P; Collette, L; Daugaard, G; De Santis, M; de Wit, R; Garin, A; Germa-Lluch, JR; Marreaud, S; Skoneczna, I; White, JD; Witjes, AJ1
Bi, N; Cao, J; Li, J; Li, W; Liang, J; Lv, J; Ou, G; Ren, H; Wang, L; Wu, S; Zhang, X; Zhou, Z1
Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y1
Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II1
Breitenbuecher, F; Guyot, M; Hoffarth, S; Höhn, Y; Meiler, J; Schuler, M; Wesarg, E1
Bernasconi, S; Bono, F; Broggini, M; Damia, G; Fruscio, R; Ganzinelli, M; Mangioni, C; Perego, P; Ricci, F; Russo, G; Signorelli, M1
Lim, L; Powles, T; Rashid, S1
Barriger, RB; Bradley, JD; De Petris, L; Kim, TH; Marks, LB; Moreno, M; Palma, DA; Ramella, S; Rengan, R; Rodrigues, G; Senan, S; Stitt, L; Tsujino, K1
Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T1
Bian, ML; Higuma, C; Isaka, K; Ito, H; Liang, J; Nishi, H; Sasaki, T1
Feng, DP; Gong, WH; Huang, T; Jiang, GJ; Li, XC; Li, XH; Zou, CP1
Arnould, T; De Backer, O; Flamant, L; Hayez, A; Michiels, C; Pierre, M; Poumay, Y; Roegiers, E; Sterpin, C1
Hao, J; Liu, GY; Wang, DH; Xu, YF; Yu, J; Yuan, BB1
Hayakawa, Y; Hirano, K; Iguchi, K; Ishii, K; Matsumoto, K; Sugimura, Y; Usui, S1
Kretzer, IF; Maranhão, RC; Maria, DA1
Eitaki, M; Inanami, O; Meike, S; Yamamori, T; Yasui, H1
Carmichael, C; Ferrell, B; Frankel, P; Hsu, J; Margolin, K; Pal, SK; Saikia, J; Stein, CA; Sun, V; Twardowski, P; Yamzon, J1
Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Osawa, M; Takigawa, N; Tanimoto, M; Yamane, H1
Backes, M; Bode-Erdmann, S; Greulich, S; Hebart, H; Kaufmann, M; Mahrholdt, H; Ong, P; Ott, G; Schumm, J1
Du, XH; Mao, WM; Wang, SY; Xu, YP; Zhang, SZ1
Spigel, DR1
Arnould, T; Fransolet, M; Genin, M; Leclere, L; Maincent, A; Michiels, C; Notte, A; Riquier, H; Sermeus, A1
Dimitroulis, J; Kosmas, Ch; Stathopoulos, GP; Stathopoulos, J; Trafalis, D; Tsavdaridis, D1
Godoy, HE; Lele, SB; Odunsi, K; Olawaiye, AB; Rauh-Hain, JA; Shahzad, MM1
Chen, W; He, Y; Peng, J; Song, W; Zhang, S1
Demura, Y; Kimura, H; Morikawa, M; Okazawa, H; Tsuchida, T; Umeda, Y1
Fragoulis, EG; Korbakis, D; Scorilas, A1
Herbst, RS; Isobe, T; Itasaka, S; Jacoby, JJ; Koo, PJ; Morgensztern, D; O'Reilly, MS; Onn, A; Shibuya, K; Shintani, T; Wu, W1
Kuwano, H; Murakawa, T; Murayama, T; Nagayama, K; Nakajima, J; Sano, A; Tsuchiya, T; Yoshida, Y1
Köhler, R; Krammer, PH; Li-Weber, M; Lüpertz, R; Merz, C; Müller, WW; Natoli, A1
Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G1
Chi, YH; Du, F; Jiang, WC; Song, Y; Sun, YK; Wang, JW; Yang, L; Zhou, AP1
Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T1
Angarita, FA; Meek, E; Rodríguez, JL; Sánchez, JO; Tawil, M; Torregrosa, L1
Duque, M; Gupta, A; Saif, MW1
Lee, DW; Lee, HN; Lee, JW; Lee, KH; Park, JS; Park, ST1
Chou, LC; Chung, CH; Huang, CH; Huang, LJ; Kuo, SC; Lee, FY; Lee, JC; Lien, JC; Way, TD; Wu, JC1
Bildat, S; Eberhardt, WE; Fischer, B; Gauler, TC; Grunenwald, D; Krbek, T; Le Chevalier, T; Lepechoux, C; Poettgen, C; Rodrigo, Hde L; Seeber, S; Stamatis, G; Stuschke, M; Theegarten, D; Welter, S1
Alavi, A; Bradley, JD; Cho, KH; DeNittis, A; Duan, F; Gorelick, JJ; Johnson, DW; Kim, SK; Komaki, R; Macapinlac, H; Machtay, M; Munden, R; Neumann, DR; Reddin, JS; Sherwin, N; Siegel, BA; Snyder, BS; Videtic, G; Wilf, LH1
Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS1
Arellano, M; Bumpers, K; Flowers, CR; Heffner, LT; Hutcherson, D; Kaufman, J; King, N; Langston, A; Lechowicz, MJ; Lonial, S; Nooka, A; Shenoy, PJ; Sinha, R; Waller, EK1
Bastide, C; Bruyère, F; Deville, JL; Flechon, A; Guy, L; Karsenty, G1
Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W1
Boutros, PC; Feigen, M; Harris, S; John, T; Lambin, P; Liew, MS; Mitchell, P; Sia, J; Starmans, MH; Tafreshi, A; White, S; Zimet, A1
Beuschlein, F; Hantel, C; Jung, S; Mussack, T; Reincke, M1
Furuse, H; Ishii, Y; Kai, F; Nagata, M; Otsuka, A; Ozono, S; Sugiyama, T; Suzuki, T; Takayama, T; Yajima, T1
Cheng, XL; Huang, L; Liao, LM; Lin, JX; Liu, AW; Wu, JB; Zheng, M1
Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y1
Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD1
Dolfi, SC; Haffty, BG; Hirshfield, KM; Jäger, AV; Medina, DJ; Yang, JM1
Batus, M; Bonomi, P; Dandekar, VK; Fidler, MJ; Kiel, K; Sher, DJ; Young, J1
Altieri, DC; Bosari, S; Faversani, A; Lopergolo, A; Moro, GP; Rivadeneira, D; Schultz, DC; Tosi, D; Vaira, V1
Bay, JO; Biron, P; Brindel, I; Bui, BN; Caty, A; de Revel, T; Delva, R; Dubot, C; Fizazi, K; Fléchon, A; Gaulet, M; Geoffrois, L; Gligorov, J; Gravis, G; Horn, E; Lotz, JP; Micléa, JM; Provent, S; Roubaud, G; Selle, F; Soares, DG; Temby, I; Wittnebel, S1
Adachi, S; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Sasaki, T; Satake, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A1
Harada, A; Matsuzaki, K; Mishima, M; Takeiri, A1
Ashton, E; Hoffman, J; Shafer, A; Szutowska, M1
Arce-Lara, C; Devisetty, K; Gore, EM; Kelley, MJ; Moran, A; Santana-Davila, R; Sparapani, R; Szabo, A; Whittle, J; Williams, CD1
Dragun, AE; Dunlap, NE; Jain, D; Meena, RA; Quillo, AR; Riley, EC; Shaughnessy, JN1
Chevreau, C; Culine, S; Delva, R; Eymard, JC; Fizazi, K; Fléchon, A; Geoffrois, L; Gravis, G; Habibian, M; Journeau, F; Kerbrat, P; Laplanche, A; Linassier, C; Logothetis, C; Malhaire, JP; Mardiak, J; Martin, AL; Pagliaro, L; Reckova, M; Rolland, F; Roubaud, G; Theodore, C1
Maneechawakajorn, J; Suksuperm, J1
Kadalayil, L; KhoshZaban, M; Kuku, S; Ledermann, J; Loddo, M; McCormack, M; Proctor, I1
Du, XL; Li, HQ; Lu, CH; Pan, CX; Sheng, XG; Wang, C; Yin, YJ1
Ayala, AG; Choi, EK; Divatia, M; Miles, BJ; Okoye, E; Ro, JY1
An, L; Chen, Y; Feng, F; Gao, X; Lu, Y; Qu, J; Sun, H; Wang, C; Wang, F; Yang, Y; Zeng, Z; Zhang, C1
Asada, H; Fujino, Y; Goto-Koshino, Y; Ohno, K; Tomiyasu, H; Tsujimoto, H1
Boetticher, NC; Strickler, JG; Toma, AA; Verma, R1
Chen, Y; Ding, J; Huan, XJ; Miao, ZH; Song, SS; Sun, YM; Tian, QT; Wang, W; Wang, YQ; Yang, CH; Yi, JM; Zhang, XF1
Wang, B; Xu, M; Xu, SF; Yu, XC1
Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T1
Baba, J; Ichikawa, K; Igarashi, N; Ishikawa, D; Kagamu, H; Kondo, R; Koshio, J; Koya, T; Miura, S; Nakata, K; Narita, I; Nozaki, K; Okajima, M; Saida, Y; Sato, K; Shoji, S; Tanaka, J; Tanaka, T; Watanabe, S; Yoshizawa, H1
Al-Massarani, G; Alammar, M; Banat, I; Najjar, F1
Fujisawa, M; Miyake, H; Nishikawa, M1
Gomez, D; Komaki, R; Lee, MS; Levy, LB; Liao, Z; Lu, C; Tang, C; Zhuang, Y1
Fang, J; Liu, LF; Wu, MJ; Yin, ZM; Yu, AJ; Yu, H; Zhu, JQ1
Chen, Y; He, HL; He, LJ; Lin, S; Luo, HQ; Pang, HW; Ren, PR; Shang, CL; Wen, QL; Wu, JB; Xiang, L; Yang, B; Yang, HR; Zhang, JW1
Dobelbower, M; Donavanik, V; Gomella, L; Grignon, D; Hamstra, DA; Hartford, AC; Hunt, D; Jones, CU; Kerlin, KJ; Kim, H; Kuban, DA; Michalski, J; Moughan, J; Pienta, KJ; Rajan, R; Rosenthal, SA; Rotman, M; Sandler, H; Sartor, AO; Seider, M; Shipley, WU; Zeitzer, K1
Brames, MJ; Einhorn, LH; Mulherin, BP1
Hanna, N; Jalal, SI; Mamdani, H1
Asaduzzaman, M; Coombes, RC; Cuella, R; Hu, Y; Li, K; Raguz, S; Shi, H; Yagüe, E; Zhou, Y1
Ball, DL; Bedő, J; Chabrot, M; Everitt, SJ; Hicks, RJ; Leimgruber, A; MacManus, M; Möller, A; Solomon, B; Wen, SW1
Aliustaoglu, M; Aydin, D; Ercelep, O; Gemici, C; Gumus, M; Isik, D; Korkmaz, T; Mayadagli, A; Mert, AG; Odabas, H; Ozcelik, M; Ozdemir, P; Seker, M; Surmeli, H; Yuksel, S1
Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H1
Bacon, CL; Bracken-Clarke, D; Browne, PV; Conneally, E; Daly, PA; Flynn, C; Gardiner, N; Hayden, PJ; Kennedy, MJ; Lee, G; McCaffrey, J; Ni Chonghaile, M; O'Donnell, DM; O'Kane, G; Power, D; Vandenberghe, E1
Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP1
Chanvorachote, P; Chaotham, C; Puchsaka, P1
Cripe, TP; Currier, MA; Falconi, M; Orienti, I; Phelps, M; Teti, G; Wang, J1
Hanai, K; Higure, T; Hoshi, A; Kawamura, Y; Nakajima, N; Nitta, M; Shimizu, Y; Terachi, T1
Beyer, J; Lorch, A1
Msaouel, P; Tu, SM; Zhang, M1
Hattori, Y; Hino, M; Kobayashi, Y; Kurahasi, T; Nakagawa, H; Wada, M1
Alvarez, MJ; Ambesi-Impiombato, A; Andrews, SJ; Califano, A; Dela Cruz, FS; Diolaiti, D; Forouhar, F; Glade Bender, JL; Kung, AL; Mansukhani, MM; Marks, LJ; Mitchell, CM; Modzelewski, B; Nagy, PL; Rainey, AR; Turk, AT; Yamashiro, DJ1
Daly, M; Kelly, K; Tam, K1
Behera, M; Belani, CP; Curran, WJ; Ernani, V; Higgins, KA; Khuri, FR; Owonikoko, TK; Pakkala, S; Pillai, RN; Ramalingam, SS; Saba, NF; Shin, DM; Steuer, CE1
Bi, N; Chen, D; Chen, M; Chen, W; Du, L; Feng, Q; He, J; Hui, Z; Jiang, W; Li, J; Liang, J; Liu, L; Lv, C; Lv, J; Shi, A; Shyr, Y; Wang, L; Wang, W; Wang, X; Wu, S; Xiao, Z; Xu, Y; Yin, W; Zhang, H; Zhang, T; Zhao, L; Zhou, Z1
Azuma, M; Goto, H; Hanibuchi, M; Kakiuchi, S; Kawano, H; Nishioka, Y; Ogushi, F; Otsuka, K; Saijo, A; Sakaguchi, S; Tezuka, T; Toyoda, Y1
Anwer, F; Chan, O; Hamdani, AA; Sokolova, A; Ullah, W1
Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ1
Daugel-Dauge, NO; Durnev, AD; Kulakova, AV; Pligina, KL; Zhanataev, AK1
Duan, R; Li, C; Wang, F; Yangi, JC1
Eze, C; Manapov, F1
Bi, N; Liang, J; Wang, L1
Bang, SM; Chang, H; Kim, JH; Kim, JW; Kim, MJ; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW1
Ai, W; Chen, Y; Huang, J; Li, D; Li, G; Si, L; Wu, S; Zhao, G1
Richie, JP1
Allan, E; Ayan, A; Barney, CL; Bazan, JG; DiCostanzo, D; Grecula, J; Haglund, KE; Otterson, GA; Scoville, N; Williams, T; Xu-Welliver, M1
Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C1
Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K1
Akashi, K; Ariyama, H; Baba, E; Doi, G; Harimoto, N; Itoh, S; Kohashi, K; Kusaba, H; Maehara, Y; Nio, K; Oda, Y; Odawara, J; Shimoda, S; Takayoshi, K; Tsuchihashi, K; Tsuruta, N; Yoshihiro, T1
Hamada, N; Nakanishi, Y; Okamoto, I; Otsubo, K1
Carden, MA; Greenberg, J; McCarty, JM; Perdahl-Wallace, E1
Sun, D; Tang, Y; Yao, J; Zhang, M; Zhao, H; Zhu, Z1
Nazha, B; Owonikoko, TK1
Aldrich, JD; Overman, MJ; Raghav, KPS; Varadhachary, GR; Wolff, RA1
Castellano, G; Torrens, F1
Breuer, A; Dal Maso, T; Le Calvé, B; Marx, S; Michiels, C; Van Gysel, M; Wouters, J1
Li, B; Song, Y; Zhang, Y; Zhao, D1
Dhagat, S; Eswari, JS; Yadav, M1
Cai, S; Cai, Y; Cheng, X; Dai, Z; Jia, H; Jiang, R; Luan, Y; Pu, H; Shi, T; Tang, J; Tu, D; Tu, R; Wang, H; Yang, H; Zang, R; Zhang, Y1
Adler, S; Aljumaily, R; Antal, JM; Beck, JT; Boccia, RV; Bulat, I; Chiu, VK; Csoszi, T; Domine Gomez, M; Dragnev, KH; Hamm, JT; Hanna, W; Hart, LL; Hoyer, RJ; Hussein, MA; Lai, AY; Lowczak, A; Maglakelidze, M; Malik, RK; Morris, SR; Nikolinakos, P; Owonikoko, TK; Richards, DA; Roberts, PJ; Rocha Lima, CM; Sawrycki, P; Schuster, SR; Sorrentino, JA; Weiss, JM; Yang, Z1
Das, M; Diehn, M; Hellyer, JA; Hoang, NT; Jeong, Y; Neal, JW; Niu, X; Padda, SK; Ramchandran, K; Stehr, H; Wakelee, H1
Belousov, MV; Gur'ev, AM; Lopatina, KA; Razina, TG; Sadrikina, LA; Safonova, EA; Zueva, EP1
Cao, P; Gong, Y; Liang, B; Liu, Y; Lu, Y; Luo, C; Wang, J; Wang, Y; Xu, Y; Xue, J; Yan, T; Zhou, L; Zhou, X; Zhou, Y1
Biasoni, D; Bisogno, G; Boldrini, R; Conte, M; Crocoli, A; D'Angelo, P; Dall'Igna, P; De Pasquale, MD; Inserra, A; Miele, E; Siracusa, F; Spreafico, F; Terenziani, M1
Barberi-Heyob, M; Frochot, C; Jouan-Hureaux, V; Lirdprapamongkol, K; Niamsiri, N; Pramual, S; Svasti, J1
Althouse, S; Anouti, B; Durm, G; Hanna, N1
Borok, MZ; Burger, H; Busakhala, NW; Campbell, TB; Caruso, SR; Godfrey, C; Hoagland, B; Hosseinipour, MC; Kosgei, J; Krown, SE; MacPhail, P; Matining, RM; Mngqibisa, R; Moser, CB; Mwelase, N; Nokta, M; Nyirenda, M; Okuku, FM; Oliver, VO; Samaneka, W1
Bi, N; Chen, D; Chen, M; Feng, Q; He, J; Hui, Z; Jiang, W; Li, J; Liang, J; Liu, L; Lv, C; Lv, J; Shi, A; Wang, J; Wang, L; Wang, W; Wang, X; Wu, S; Xiao, Z; Xu, Y; Yin, W; Zhang, H; Zhang, T; Zhao, L; Zhou, Z1
Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS1
Andrade, CF; Figueiró, F; Filippi-Chiela, E; Gonzalez, EA; Klamt, F; Nunes, V; Pilar, ES; Solari, JIG1
Fujiwara, M; Fukui, I; Hayashi, T; Komai, Y; Kouno, T; Numao, N; Takeda, H; Yamamoto, S; Yonese, J; Yuasa, T1
Bay, JO; Chatelut, E; Chevreau, C; Delmas, C; Delva, R; Filleron, T; Fléchon, A; Gravis, G; Gross-Goupil, M; Lafont, T; Lotz, JP; Marsili, S; Massart, C; Moeung, S; Thomas, F1
Akdeniz, N; Alan, Ö; Bilen, E; Ebinç, S; Ercelep, Ö; Işıkdoğan, A; Kaplan, MA; Karhan, O; Küçüköner, M; Laçin, Ş; Sezgin, Y; Teke, F; Urakçı, Z; Yumuk, PF1
Fujiwara, K; Goto, K; Harada, T; Hayashi, T; Kaneda, H; Kenmotsu, H; Kimura, M; Kogure, Y; Koike, T; Matsui, R; Nishio, M; Nogami, N; Seto, T; Shimizu, S; Shimokawa, M; Suzuki, K; Takiguchi, T1
de Carvalho Fraga, CA; de Souza, MG; Farias, LC; Guimarães, ALS; Guimarães, TA; Jones, KM; Xavier, GM1
Almeida, A; Bartosch, C; Cruz Pires, M; Peixinho, C1
Bay, JO; Chatelut, E; Chevreau, C; Ciccolini, J; Culine, S; Delva, R; Filleron, T; Fizazi, K; Flechon, A; Gallois, Y; Gravis, G; Gross-Goupil, M; Guitton, J; Lelièvre, B; Lotz, JP; Massard, C; Moeung, S; Mourey, L; Olivier, P; Paci, A; Thomas, F1
Adabi, M; Ghanbari, H; Hadjighassem, MR; Hosseini Najafabadi, MR; Khosravani, M; Maleki, H; Sadroddiny, E; Webster, TJ1
An, J; Huang, M; Huang, Y; Li, C; Li, L; Luo, S; Peng, Y; Wang, J; Wang, Z; Wu, L; Yang, H; Yang, X; Zhang, Y1
Chang, CH; Chang, YL; Chen, JS; Hsu, FM; Huang, YL; Lee, JM; Lin, CC; Ma, WL; Yang, JC1
Asher, R; Connolly, EA; Forgeson, G; Goh, J; Grimison, P; Hamad, N; Heller, GZ; Hill, S; Joshi, A; Kuchel, A; Lewin, J; Liow, E; McKenzie, J; Tan, A; Tan, H; Toner, G; Tran, B; Tung, ILY; Walpole, E; Wang, Y; Weickhardt, A; Wickham, A; Winstanley, MA; Wong, V1
Chatterjee, B; Ganti, S; Pandya, M1
Min, S; Zheng, Q; Zhou, Y1
Bassett, IV; Busakhala, N; Byakwaga, H; Freedberg, KA; Freeman, EE; Hajny Fernandez, ME; Hyle, EP; Kiprono, S; Laker-Oketta, M; Martin, JN; Maurer, T; McCann, NC; Pei, PP; Reddy, KP; Semeere, A1
Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S1
Cruz, A; de-Castro-Ríos, A; Lema-Atán, JÁ; Lendoiro, E; López-Rivadulla, M; Paniagua-González, L1
Abu-Gharbieh, E; Abuhelwa, AY; Ahmed, M; Alqudah, MAY; Alsoud, LO; Alzoubi, KH; Bustanji, Y; El-Awady, R; El-Huneidi, W; Ramadan, WS; Semreen, AM; Semreen, MH; Shara, M; Soares, NC1
Akimov, M; Boiko, S; Dudina, P; Ermolenko, Y; Gelperina, S; Kovshova, T; Malinovskaya, J; Mantrov, S; Merkulova, M; Moiseeva, N; Osipova, N; Senchikhin, I1
Che, Y; Chen, J; Chen, Z; Cheng, X; Chu, R; Huang, C; Jiang, J; Kong, B; Li, J; Li, K; Li, L; Liu, P; Pan, X; Song, K; Song, L; Wang, J; Xue, Y; Yao, S; Zhang, X; Zhao, Y1
Gillett, S; Hapuarachi, B; Ireson, J; Romanowski, C; Singh, K; Tidy, JA; Winter, MC1

Reviews

81 review(s) available for etoposide and paclitaxel

ArticleYear
Membrane transporters in drug development.
    Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3

    Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs

2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Coumarin-containing hybrids and their anticancer activities.
    European journal of medicinal chemistry, 2019, Nov-01, Volume: 181

    Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure-Activity Relationship

2019
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles

2019
Hypersensitivity reactions.
    Seminars in oncology, 1992, Volume: 19, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomycin; Chlorambucil; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Drug Hypersensitivity; Etoposide; Fluorouracil; Humans; Ifosfamide; Melphalan; Methotrexate; Mitomycins; Neoplasms; Paclitaxel; Pentostatin; Procarbazine; Teniposide

1992
Clinical reversal of multidrug resistance.
    Cancer treatment and research, 1994, Volume: 73

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Verapamil

1994
Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5 Suppl 6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy

1994
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
    Annals of the New York Academy of Sciences, 1995, Dec-29, Volume: 770

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids; Thiotepa

1995
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
    Harefuah, 1996, Volume: 131, Issue:1-2

    Topics: Altretamine; Antineoplastic Agents; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Ovarian Neoplasms; Paclitaxel; Recurrence; Tamoxifen

1996
Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature.
    Gynecologic oncology, 1996, Volume: 63, Issue:3

    Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Papillary; Dexamethasone; Etoposide; Female; Humans; Middle Aged; Neoplasm, Residual; Osteonecrosis; Ovarian Neoplasms; Paclitaxel

1996
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 16

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome

1996
Future trials in germ cell malignancy (GCM) of the testis.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1997, Volume: 23, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical Trials as Topic; Decision Making; Etoposide; Forecasting; Genetic Therapy; Germinoma; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Orchiectomy; Paclitaxel; Patient Participation; Quality of Life; Risk Factors; Safety; Salvage Therapy; Seminoma; Testicular Neoplasms

1997
Drug resistance in the treatment of sarcomas.
    Seminars in oncology, 1997, Volume: 24, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Paclitaxel; Platinum Compounds; Sarcoma

1997
Future directions in the chemotherapy of ovarian cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15

    Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine

1997
["State-of-the-art" chemotherapy for small-cell lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine

1997
Topotecan in combination chemotherapy.
    Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 20

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Paclitaxel; Suramin; Topoisomerase I Inhibitors; Topotecan

1997
The role of carboplatin in the treatment of small-cell lung cancer.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:1 Suppl 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Paclitaxel

1998
Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer.
    Seminars in oncology, 1998, Volume: 25, Issue:1 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Platinum Compounds

1998
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer.
    Seminars in oncology, 1998, Volume: 25, Issue:2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Mitoxantrone; Neoplasm Staging; Paclitaxel; Taxoids; Thiotepa

1998
Chemotherapy for gastric carcinoma: new and old options.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:10 Suppl 7

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil

1998
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome

1998
Paclitaxel in the treatment of hormone-refractory prostate cancer.
    Seminars in oncology, 1999, Volume: 26, Issue:1 Suppl 2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Estramustine; Etoposide; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms

1999
The evolving role of paclitaxel for patients with carcinoma of unknown primary site.
    Seminars in oncology, 1999, Volume: 26, Issue:1 Suppl 2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Etoposide; Humans; Neoplasms, Unknown Primary; Paclitaxel

1999
Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer.
    Seminars in radiation oncology, 1999, Volume: 9, Issue:2 Suppl 1

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel

1999
Ifosfamide in non-small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10 Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel

1999
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.
    Seminars in oncology, 1999, Volume: 26, Issue:5 Suppl 16

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine

1999
[Pharmacokinetic monitoring].
    Bulletin du cancer, 2000, Volume: 87, Issue:1

    Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan

2000
Chemoradiation in locally advanced non-small cell lung cancer.
    Cancer treatment and research, 2001, Volume: 105

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine

2001
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
    Cancer treatment and research, 2001, Volume: 105

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine

2001
Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
    Lung cancer (Amsterdam, Netherlands), 2001, Volume: 32, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endpoint Determination; Etoposide; Feasibility Studies; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Treatment Failure

2001
Salvage chemotherapy in relapsed germ cell tumors.
    World journal of urology, 2001, Volume: 19, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Testicular Neoplasms; Vinblastine

2001
Body surface area as a determinant of pharmacokinetics and drug dosing.
    Investigational new drugs, 2001, Volume: 19, Issue:2

    Topics: Adult; Animals; Anthropometry; Antineoplastic Agents; Area Under Curve; Body Surface Area; Carboplatin; Cardiac Output; Child; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney; Liver; Medical Oncology; Neoplasms; Paclitaxel; Taxoids

2001
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
    Seminars in oncology, 2001, Volume: 28, Issue:2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Topotecan

2001
Paclitaxel and docetaxel in prostate cancer.
    Hematology/oncology clinics of North America, 2001, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin

2001
European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer.
    Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Evaluation, Preclinical; Etoposide; Europe; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents

2001
Treatment of advanced ovarian cancer.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37 Suppl 9

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan

2001
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2001, Volume: 34 Suppl 4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine

2001
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
    Haematologica, 2002, Volume: 87, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Etoposide; Europe; Forecasting; Gastrointestinal Diseases; Germinoma; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Ifosfamide; Kidney Diseases; Male; Multicenter Studies as Topic; Neoplasms, Second Primary; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2002
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine

2002
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
    Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan

2002
Platinum compounds in the treatment of advanced breast cancer.
    Clinical breast cancer, 2001, Volume: 2, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Mastectomy; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Preoperative Care; Severity of Illness Index; Treatment Outcome; Vinblastine; Vinorelbine

2001
Epithelial ovarian cancer.
    Current treatment options in oncology, 2002, Volume: 3, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine

2002
[Gemcitabine].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine

2002
[Carboplatin].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome

2002
[Chemotherapy for elderly patients with lung cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 5

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine

2002
Platinum drugs in the treatment of non-small-cell lung cancer.
    British journal of cancer, 2002, Oct-07, Volume: 87, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel

2002
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine

2002
Adjuvant and neoadjuvant treatments for NSCLC.
    Lung cancer (Amsterdam, Netherlands), 2002, Volume: 38 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Radiotherapy, Adjuvant; Survival; Taxoids

2002
[Chemotherapy for prostate cancers].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine

2002
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
    Cancer investigation, 2003, Volume: 21, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine

2003
An advance in small-cell lung cancer treatment--more or less.
    Journal of the National Cancer Institute, 2003, Aug-06, Volume: 95, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Greece; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States; Vincristine

2003
The role of topotecan in the treatment of advanced cervical cancer.
    Gynecologic oncology, 2003, Volume: 90, Issue:3 Pt 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Synergism; Etoposide; Female; Humans; Paclitaxel; Topotecan; Uterine Cervical Neoplasms

2003
Ifosfamide in advanced/disseminated breast cancer.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Etoposide; Female; Humans; Ifosfamide; Neoplasm Staging; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine

2003
[Molecular pathogenesis of lung cancers and the preservative therapy].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Mar-10, Volume: 93, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle Proteins; Cisplatin; Enzyme Inhibitors; Etoposide; Gefitinib; Gene Targeting; Genes, bcl-2; Genes, p53; Genetic Therapy; Humans; Lung Neoplasms; Mass Screening; Mutation; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant

2004
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Length of Stay; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancoast Syndrome; Pneumonectomy; Postoperative Complications; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, High-Energy; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine

2004
[Treatment of platinum-resistant ovarian cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome

2004
Recurrent ovarian cancer: how important is it to treat to disease progression?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan

2004
[Second-line chemotherapy for recurrent ovarian cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids

2005
[The second-line chemotherapy for urological cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Male; Methotrexate; Paclitaxel; Survival Rate; Testicular Neoplasms; Treatment Outcome; Urologic Neoplasms; Vinblastine

2005
Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
    European urology, 2005, Volume: 48, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Salvage Therapy; Testicular Neoplasms; Vinblastine

2005
[Progress in therapy for testicular tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lymph Node Excision; Male; Paclitaxel; Taxoids; Testicular Neoplasms

2006
Chemoradiation paradigm for the treatment of lung cancer.
    Nature clinical practice. Oncology, 2006, Volume: 3, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic

2006
Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
    Cancer treatment reviews, 2007, Volume: 33, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine

2007
[Testis germ cell tumours: which chemotherapy, for which patients?].
    Annales d'urologie, 2007, Volume: 41, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Ifosfamide; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Positron-Emission Tomography; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Seminoma; Testicular Neoplasms; Testis; Vinblastine

2007
[Chemotherapy in lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate

2007
Double high-dose chemotherapy and stem cell transplantation in adult Wilms' tumor.
    Future oncology (London, England), 2010, Volume: 6, Issue:11

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cyclophosphamide; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Melphalan; Paclitaxel; Radiography; Salvage Therapy; Topotecan; Transplantation, Autologous; Wilms Tumor; Young Adult

2010
Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy.
    Current treatment options in oncology, 2012, Volume: 13, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Salvage Therapy; Testicular Neoplasms; Therapeutic Equipoise

2012
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
    International journal of radiation oncology, biology, physics, 2013, Feb-01, Volume: 85, Issue:2

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Decision Trees; Etoposide; Europe; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; North America; Paclitaxel; Radiation Pneumonitis; Radiotherapy Dosage

2013
Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
    JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Etoposide; Humans; Paclitaxel; Pancreatic Neoplasms; Receptor, IGF Type 1; TOR Serine-Threonine Kinases; Treatment Outcome

2013
[Chemotherapy in male external genital organs (testicular and penile cancer)].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cryopreservation; Etoposide; Fluorouracil; Humans; Ifosfamide; Male; Methotrexate; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Orchiectomy; Paclitaxel; Penile Neoplasms; Spermatozoa; Testicular Neoplasms; Vinblastine

2013
De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Cystoscopy; Disease Progression; Etoposide; Fatal Outcome; Humans; Immunohistochemistry; Laparoscopy; Leuprolide; Lymph Node Excision; Lymphatic Metastasis; Male; Meningeal Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Pelvis; Prostatic Neoplasms; Robotic Surgical Procedures; Time Factors; Tomography, X-Ray Computed; Transurethral Resection of Prostate; Treatment Outcome

2014
Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration.
    Current treatment options in oncology, 2015, Volume: 16, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Patient Selection; Precision Medicine; Radiotherapy, Adjuvant; Risk Factors

2015
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
    Gynecologic oncology, 2016, Volume: 140, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult

2016
High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how.
    World journal of urology, 2017, Volume: 35, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Patient Selection; Salvage Therapy; Testicular Neoplasms; Vinblastine

2017
Treatment of Locally Advanced Non-Small Cell Lung Cancer.
    Hematology/oncology clinics of North America, 2017, Volume: 31, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage

2017
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
    JAMA oncology, 2017, Aug-01, Volume: 3, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Thorax

2017
Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
    Respiratory investigation, 2018, Volume: 56, Issue:4

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Etoposide; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Risk Assessment; Risk Factors

2018
Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma.
    Protein and peptide letters, 2021, Volume: 28, Issue:7

    Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Brazil; Carcinogenesis; Carcinoma, Squamous Cell; Cell Proliferation; Computational Biology; Etoposide; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mouth Neoplasms; Neoplasm Proteins; Paclitaxel; Plant Extracts; Plants, Medicinal; Vinblastine

2021
High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres.
    BJU international, 2022, Volume: 130 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Testicular Neoplasms

2022
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
    BMC cancer, 2022, Jun-20, Volume: 22, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Humans; Irinotecan; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Pemetrexed; Vinorelbine

2022
Leptomeningeal disease as a presenting feature of gestational trophoblastic neoplasia: A review and recommendations for management.
    Gynecologic oncology, 2023, Volume: 172

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dactinomycin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Methotrexate; Paclitaxel; Placenta; Pregnancy; Quality of Life; Retrospective Studies; Vincristine

2023

Trials

145 trial(s) available for etoposide and paclitaxel

ArticleYear
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Premedication; Taxoids; Treatment Outcome

1995
A phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia

1995
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:4 Suppl 9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cohort Studies; Drug Tolerance; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia

1995
Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer. Eastern Cooperative Oncology Group.
    Journal of the National Cancer Institute. Monographs, 1995, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Paclitaxel

1995
Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposide.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Adenoid Cystic; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Sarcoma

1995
Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report.
    Seminars in oncology, 1995, Volume: 22, Issue:4 Suppl 9

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Tolerance; Etoposide; Feasibility Studies; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Thorax

1995
Paclitaxel by 1-hour infusion in combination chemotherapy of stage III non-small cell lung cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:4 Suppl 9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Radiotherapy; Remission Induction

1995
Clinical reversal of multidrug resistance.
    Cancer treatment and research, 1994, Volume: 73

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Verapamil

1994
Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:6

    Topics: Adult; Aged; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Salvage Therapy; Survival Analysis

1995
Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Survival Analysis

1996
Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
    Cancer, 1996, Jun-15, Volume: 77, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Outpatients; Paclitaxel; Survival Analysis

1996
Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Seminars in oncology, 1995, Volume: 22, Issue:6 Suppl 15

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Remission Induction

1995
A phase I study of etoposide phosphate plus paclitaxel.
    Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 13

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel

1996
Combinations of paclitaxel and etoposide in the treatment of lung cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Tumor Cells, Cultured

1996
Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 16

    Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Treatment Outcome

1996
Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.
    Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 16

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia

1996
The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 16

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome

1996
Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:4 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel

1997
Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6

    Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Humans; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Analysis

1997
Phase I study of paclitaxel and oral etoposide in previously untreated non-small-cell and extensive small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel

1997
A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:4 Suppl 12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel

1997
Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
    Seminars in oncology, 1997, Volume: 24, Issue:4 Suppl 12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis

1997
Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation.
    Seminars in oncology, 1997, Volume: 24, Issue:4 Suppl 12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Diseases; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Radiotherapy; Radiotherapy Dosage

1997
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:4 Suppl 12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Pilot Projects

1997
A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:4 Suppl 12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage

1997
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:4 Suppl 12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis

1997
Paclitaxel, carboplatin, and oral etoposide: a phase II trial in limited-stage small cell lung cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:4 Suppl 12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel

1997
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15

    Topics: Adenocarcinoma; Administration, Oral; Alopecia; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; DNA Replication; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microtubules; Nuclear Matrix; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Remission Induction; Tumor Cells, Cultured

1997
Paclitaxel in salvage therapy for germ cell tumors.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Cells; Carboplatin; Cisplatin; Cohort Studies; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Follow-Up Studies; Germinoma; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Testicular Neoplasms; Treatment Outcome

1997
Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:12

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Thrombocytopenia

1997
One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Rate; Treatment Outcome

1997
A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).
    Lung cancer (Amsterdam, Netherlands), 1998, Volume: 19, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel

1998
Paclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:1 Suppl 2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome

1998
Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies.
    American journal of clinical oncology, 1998, Volume: 21, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Filgrastim; Germinoma; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recombinant Proteins

1998
Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome

1998
Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Treatment Outcome

1998
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 1998, Volume: 32, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Treatment Outcome

1998
Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.
    Cancer, 1999, Jun-01, Volume: 85, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Etoposide; Female; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome

1999
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms; Paclitaxel

1999
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Quality of Life; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome

1999
Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel

1999
A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Time Factors

1999
Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
    International journal of cancer, 1999, Dec-10, Volume: 83, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Etoposide; Germinoma; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Testicular Neoplasms

1999
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Treatment Failure

2000
Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bone marrow transplantation, 2000, Volume: 25, Issue:2

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Treatment Outcome

2000
Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis

2000
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Etoposide; Female; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukapheresis; Male; Middle Aged; Paclitaxel; Prospective Studies; Salvage Therapy; Survival Analysis

2000
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:6

    Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cryotherapy; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Taxoids

2000
Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Gynecologic oncology, 2000, Volume: 77, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome

2000
Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Survival Analysis

2000
Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Thrombocytopenia

2000
Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours?
    Acta oncologica (Stockholm, Sweden), 2000, Volume: 39, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Taxoids

2000
A randomized Phase II trial in patients with carcinoma of an unknown primary site.
    Cancer, 2001, Feb-01, Volume: 91, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Etoposide; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome

2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study.
    American journal of clinical oncology, 2000, Volume: 23, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel

2000
Combination of paclitaxel and etoposide in the treatment of advanced non-small cell lung cancer: a phase I-II study.
    Journal of chemotherapy (Florence, Italy), 2001, Volume: 13, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel

2001
Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2001, Volume: 32, Issue:1

    Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome

2001
Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
    Lung cancer (Amsterdam, Netherlands), 2001, Volume: 32, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endpoint Determination; Etoposide; Feasibility Studies; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Treatment Failure

2001
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:4

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting

2001
Factors determining the actual received dose intensity in a program of multicyclic dose-intensive alternating chemotherapy with sequential stem cell support.
    Acta haematologica, 2001, Volume: 105, Issue:3

    Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunomagnetic Separation; Middle Aged; Models, Biological; Ovarian Neoplasms; Paclitaxel; Stem Cells; Time Factors; Transplantation, Autologous; Treatment Outcome

2001
Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Aug-01, Volume: 19, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel

2001
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:8

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting

2001
Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
    Bone marrow transplantation, 2001, Volume: 28, Issue:2

    Topics: Adult; Aged; Antiemetics; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Lorazepam; Male; Middle Aged; Multiple Myeloma; Ondansetron; Paclitaxel; Taxoids; Transplantation, Autologous

2001
Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma.
    Acta haematologica, 2001, Volume: 105, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Transplantation, Autologous

2001
Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
    Bone marrow transplantation, 2001, Volume: 28, Issue:3

    Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infections; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome

2001
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.
    Journal of the National Cancer Institute, 2002, Feb-06, Volume: 94, Issue:3

    Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Random Allocation; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome

2002
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia.
    Oncology, 2002, Volume: 62, Issue:2

    Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Hypothermia, Induced; Ifosfamide; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Severity of Illness Index; Treatment Outcome

2002
Intensive chemotherapy with whole blood stem-cell support and concurrent chest radiotherapy in small cell lung cancer: a phase I/II trial.
    Lung cancer (Amsterdam, Netherlands), 2002, Volume: 36, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chi-Square Distribution; Combined Modality Therapy; Disease Progression; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Survival Analysis; Treatment Outcome

2002
[Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome

2002
Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:1

    Topics: Adult; Aged; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome

2003
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:1

    Topics: Adult; Aged; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Time Factors; Treatment Outcome

2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-01, Volume: 21, Issue:5

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Ketoconazole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome

2003
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Apr-15, Volume: 21, Issue:8

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Health Status; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Time Factors; Treatment Outcome; United States

2003
Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Cancer, 2003, May-15, Volume: 97, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Illinois; Indiana; Iowa; Lung Neoplasms; Male; Middle Aged; Minnesota; Nebraska; Neoplasm Staging; North Dakota; Paclitaxel; South Dakota; Survival Analysis; Topotecan; Treatment Outcome

2003
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; United States

2003
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan

2003
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Cancer, 2003, Jul-15, Volume: 98, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Survival Rate; Treatment Outcome

2003
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
    Journal of the National Cancer Institute, 2003, Aug-06, Volume: 95, Issue:15

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine

2003
Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity.
    Medical oncology (Northwood, London, England), 2003, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Etoposide; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Treatment Failure

2003
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Cancer, 2003, Nov-15, Volume: 98, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Estramustine; Etoposide; Fatigue; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Sepsis; Survival Analysis; Treatment Outcome

2003
Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome

2004
[Prognostic and predictive factors of patients with cancer of unknown origin treated with a paclitaxel-based chemotherapy].
    Medicina clinica, 2004, Feb-21, Volume: 122, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Prognosis; Survival Rate

2004
Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours.
    British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Germinoma; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Survival Analysis; Testicular Neoplasms; Treatment Outcome

2004
Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2004, Volume: 44, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine

2004
Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2004, Volume: 44, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Synergism; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome

2004
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
    The oncologist, 2004, Volume: 9, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome

2004
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Etoposide; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Stem Cell Transplantation; Testicular Neoplasms; Transplantation, Autologous; Treatment Outcome

2005
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Treatment Outcome

2005
Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group.
    British journal of cancer, 2005, Feb-28, Volume: 92, Issue:4

    Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Turkey

2005
Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
    Gynecologic oncology, 2005, Volume: 97, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel

2005
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quality of Life

2005
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recombinant Proteins; Survival Rate; Time Factors

2005
Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis

2005
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    The oncologist, 2005, Volume: 10, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel; Topotecan

2005
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2005, Volume: 11, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prognosis; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome

2005
Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel

2006
Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus.
    European journal of obstetrics, gynecology, and reproductive biology, 2007, Volume: 131, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Endometrial Neoplasms; Epirubicin; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Treatment Outcome; Uterus

2007
Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study.
    British journal of cancer, 2006, Mar-13, Volume: 94, Issue:5

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Radiation Injuries; Survival Analysis; Treatment Outcome

2006
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study.
    British journal of cancer, 2006, May-08, Volume: 94, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Epirubicin; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome

2006
Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vincristine

2006
Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-01, Volume: 24, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome

2006
Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer.
    Bone marrow transplantation, 2006, Volume: 38, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Melphalan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Treatment Outcome

2006
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Recurrence; Stem Cells; Time Factors; Vinblastine; Vinorelbine

2006
Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Etoposide; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Treatment Outcome

2006
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jan-01, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Stem Cell Transplantation; Treatment Outcome

2007
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
    International journal of radiation oncology, biology, physics, 2007, Mar-15, Volume: 67, Issue:4

    Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality Control; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topotecan

2007
Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.
    Neoplasma, 2007, Volume: 54, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Embryonal; Choriocarcinoma; Cisplatin; Etoposide; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Prospective Studies; Teratocarcinoma; Testicular Neoplasms

2007
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Severity of Illness Index; Survival Rate; Topotecan; Treatment Outcome

2007
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
    Clinical genitourinary cancer, 2007, Volume: 5, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Estramustine; Etoposide; Feasibility Studies; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome

2007
Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:16

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cause of Death; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis

2007
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Journal of the National Cancer Institute, 2007, Nov-07, Volume: 99, Issue:21

    Topics: Aged; Algorithms; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Confidence Intervals; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estramustine; Etoposide; Humans; Ketoconazole; Logistic Models; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine

2007
Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Dec-20, Volume: 25, Issue:36

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Survival Analysis; Testicular Neoplasms

2007
Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study.
    Oncology reports, 2008, Volume: 20, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance

2008
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-ris
    International journal of radiation oncology, biology, physics, 2009, Mar-01, Volume: 73, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Estramustine; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Paclitaxel; Prostatic Neoplasms; Thromboembolism

2009
A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel

2009
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

    Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Italy; Middle Aged; Paclitaxel; Preoperative Care; Taxoids

2010
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-01, Volume: 28, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Retreatment; Salvage Therapy

2010
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
    Bone marrow transplantation, 2011, Volume: 46, Issue:6

    Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Granisetron; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Paclitaxel; Treatment Outcome; Vomiting; Young Adult

2011
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
    International journal of radiation oncology, biology, physics, 2012, Jan-01, Volume: 82, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Radiotherapy Dosage; Relative Biological Effectiveness; Retrospective Studies; Survival Analysis; Treatment Failure; Vinblastine

2012
Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Radiotherapy, Adjuvant; Survival Rate; Uterine Cervical Neoplasms

2011
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.
    Urology, 2011, Volume: 77, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Estramustine; Etoposide; Humans; Injections, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Risk Factors

2011
Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
    International journal of radiation oncology, biology, physics, 2012, Mar-01, Volume: 82, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Retrospective Studies; Treatment Outcome

2012
Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients.
    Cancer, 2011, Jul-01, Volume: 117, Issue:13

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Proportional Hazards Models; Treatment Outcome

2011
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
    BMC cancer, 2011, Jul-11, Volume: 11

    Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Granulosa Cell Tumor; Humans; Middle Aged; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Peripheral Nervous System Diseases; Salvage Therapy; Tamoxifen; Thrombocytopenia; Treatment Outcome

2011
Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
    Asia-Pacific journal of clinical oncology, 2011, Volume: 7, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel

2011
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-10, Volume: 30, Issue:8

    Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease-Free Survival; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Treatment Outcome

2012
Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2012, Volume: 77, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Radiation Pneumonitis; Treatment Outcome

2012
Combination of three cytotoxic agents in small-cell lung cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Paclitaxel; Small Cell Lung Carcinoma

2013
Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
    Journal of magnetic resonance imaging : JMRI, 2013, Volume: 38, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Diffusion Magnetic Resonance Imaging; Early Detection of Cancer; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome

2013
Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Radiotherapy; Time Factors

2013
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate

2013
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicente
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survivors; Treatment Outcome

2013
Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-20, Volume: 31, Issue:30

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome

2013
A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Thiotepa; Treatment Failure; Young Adult

2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:13

    Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Chorionic Gonadotropin; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; International Agencies; Lenograstim; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Precision Medicine; Prognosis; Recombinant Proteins; Survival Rate; Testicular Neoplasms; Young Adult

2014
Do Cell-Cycle Phase-Specific Markers Predict Disease Grade, Stage, and Outcome in Cervical Carcinoma?
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Uterine Cervical Neoplasms; Young Adult

2015
Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in Combination With Regional Positive Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: A Phase 1 Clinical Trial.
    International journal of radiation oncology, biology, physics, 2015, Aug-01, Volume: 92, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumothorax; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Remission Induction; Safety; Survival Rate; Time Factors

2015
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
    International journal of radiation oncology, biology, physics, 2015, Oct-01, Volume: 93, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Early Termination of Clinical Trials; Estramustine; Etoposide; Humans; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors

2015
Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiography; Spleen

2015
Ongoing Clinical Trials in Testicular Cancer: The TIGER Trial.
    Oncology research and treatment, 2016, Volume: 39, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Internationality; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prevalence; Risk Factors; Salvage Therapy; Survival Analysis

2016
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 04-01, Volume: 28, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models

2017
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
    British journal of cancer, 2019, Volume: 121, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Docetaxel; Etoposide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Progression-Free Survival; Proportional Hazards Models; Survival Rate; Treatment Outcome; Young Adult

2019
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 10-01, Volume: 30, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Myeloid Cells; Paclitaxel; Prognosis; Pyrimidines; Pyrroles; Small Cell Lung Carcinoma; Survival Rate; Tissue Distribution

2019
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
    Lancet (London, England), 2020, 04-11, Volume: 395, Issue:10231

    Topics: Adult; Africa; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomycin; Developing Countries; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Paclitaxel; Progression-Free Survival; Sarcoma, Kaposi; Vincristine

2020
Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.
    Pharmaceutical research, 2020, Jul-16, Volume: 37, Issue:7

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Monitoring; Etoposide; Female; Genotype; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Pharmacogenetics; Pharmacogenomic Testing; Young Adult

2020
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
    Cancer medicine, 2021, Volume: 10, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult

2021

Other Studies

459 other study(ies) available for etoposide and paclitaxel

ArticleYear
Cell-based screen for identification of inhibitors of tubulin polymerization.
    Journal of natural products, 1996, Volume: 59, Issue:12

    Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Formazans; Glioma; Rats; Tubulin; Tumor Cells, Cultured

1996
Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport.
    Biochimica et biophysica acta, 1997, May-22, Volume: 1326, Issue:1

    Topics: Adenosine Triphosphate; Anthracyclines; ATP-Binding Cassette Transporters; Binding Sites; Biological Transport; Cell Membrane; Daunorubicin; Glutathione; Humans; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured

1997
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
    Journal of medicinal chemistry, 2001, May-24, Volume: 44, Issue:11

    Topics: Animals; Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Quinoxalines; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured

2001
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.
    Journal of natural products, 2001, Volume: 64, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine

2001
Rational use of in vitro P-glycoprotein assays in drug discovery.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:2

    Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera

2001
Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).
    Molecular pharmacology, 2003, Volume: 63, Issue:2

    Topics: Biological Transport; Cells, Cultured; Cyclosporine; Estradiol; Glycocholic Acid; Humans; Kinetics; Leukotriene Antagonists; Leukotriene C4; Multidrug Resistance-Associated Proteins; Osmotic Pressure; Propionates; Quinolines; Recombinant Proteins; Transfection

2003
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
    Pharmaceutical research, 2003, Volume: 20, Issue:8

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blotting, Western; Cells, Cultured; Diffusion; Humans; Intestinal Absorption; Intestinal Mucosa; Models, Biological; Permeability; Pharmaceutical Preparations; Pharmacokinetics

2003
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
    Biochemical and biophysical research communications, 2004, Mar-19, Volume: 315, Issue:4

    Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity

2004
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
    Bioorganic & medicinal chemistry letters, 2004, Feb-23, Volume: 14, Issue:4

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular

2004
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
    Bioorganic & medicinal chemistry letters, 2005, Sep-15, Volume: 15, Issue:18

    Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride

2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity.
    Journal of medicinal chemistry, 2006, Jun-15, Volume: 49, Issue:12

    Topics: Acridines; Aminoacridines; Aniline Compounds; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Nitrogen Mustard Compounds; Structure-Activity Relationship; Transplantation, Heterologous

2006
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Aroyl hydrazones of 2-phenylindole-3-carbaldehydes as novel antimitotic agents.
    Bioorganic & medicinal chemistry, 2008, Jun-15, Volume: 16, Issue:12

    Topics: Antimitotic Agents; Benzoates; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Hydrazones; Indoles; Pyridines

2008
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
    Journal of medicinal chemistry, 2008, Dec-25, Volume: 51, Issue:24

    Topics: Anisoles; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Inhibitory Concentration 50; Models, Chemical; Naphthalenes; Neoplasms; Structure-Activity Relationship; Tubulin; Tubulin Modulators

2008
ent-Kaurane diterpenoids from Isodon scoparius.
    Journal of natural products, 2009, Volume: 72, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Diterpenes, Kaurane; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Humans; Isodon; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Plants, Medicinal

2009
Synthesis of aristolactam analogues and evaluation of their antitumor activity.
    Bioorganic & medicinal chemistry letters, 2009, Jun-01, Volume: 19, Issue:11

    Topics: Antineoplastic Agents; Aporphines; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams

2009
ent-Kaurane diterpenoids from Isodon pharicus.
    Journal of natural products, 2009, Volume: 72, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Diterpenes, Kaurane; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Humans; Isodon; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Plants, Medicinal

2009
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
    Nature chemical biology, 2009, Volume: 5, Issue:10

    Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration.
    Journal of medicinal chemistry, 2010, Apr-08, Volume: 53, Issue:7

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Doxorubicin; Etoposide; Female; Humans; Inhibitory Concentration 50; Kinetics; Male; Mice; Peptides

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:11

    Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:2

    Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity

2011
Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylseleno-imidocarbamates.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carbamates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50

2011
Identification, structural properties and chelating capacity of miltipolone as a broad-spectrum inhibitor to cancer cells.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Diterpenes; Humans; Iron; Iron Chelating Agents; Isomerism; Models, Molecular; Molecular Conformation; Tropolone; Water

2011
A modular approach to trim cellular targets in anticancer drug discovery.
    Bioorganic & medicinal chemistry letters, 2011, Nov-15, Volume: 21, Issue:22

    Topics: Anaphase; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Drug Discovery; Humans; Metaphase; Neoplasms; Oxidation-Reduction; Pyrimidines; Structure-Activity Relationship

2011
5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
    Journal of medicinal chemistry, 2011, Dec-22, Volume: 54, Issue:24

    Topics: Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colchicine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Hydroxyquinolines; Quinolines; Stilbenes; Structure-Activity Relationship; Sulfones; Tubulin Modulators

2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
    Bioorganic & medicinal chemistry, 2012, Nov-15, Volume: 20, Issue:22

    Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship

2012
Bioactive barrigenol type triterpenoids from the leaves of Xanthoceras sorbifolia Bunge.
    European journal of medicinal chemistry, 2013, Volume: 60

    Topics: Molecular Structure; Plant Leaves; Sapindaceae; Triterpenes

2013
Structural variations on antitumour agents derived from bisacylimidoselenocarbamate. A proposal for structure-activity relationships based on the analysis of conformational behaviour.
    European journal of medicinal chemistry, 2013, Volume: 66

    Topics: Antineoplastic Agents; Carbamates; HT29 Cells; Humans; MCF-7 Cells; Models, Molecular; Molecular Conformation; Organoselenium Compounds; Structure-Activity Relationship

2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
The synthesis and anticancer activity of analogs of the indole phytoalexins brassinin, 1-methoxyspirobrassinol methyl ether and cyclobrassinin.
    Bioorganic & medicinal chemistry, 2013, Nov-01, Volume: 21, Issue:21

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Jurkat Cells; Magnetic Resonance Spectroscopy; MCF-7 Cells; Phytoalexins; Sesquiterpenes; Stereoisomerism; Thiocarbamates

2013
Furanylazaindoles: potent anticancer agents in vitro and in vivo.
    Journal of medicinal chemistry, 2013, Oct-24, Volume: 56, Issue:20

    Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Female; Heterocyclic Compounds, 2-Ring; HT29 Cells; Humans; Indoles; Inhibitory Concentration 50; Mice, Nude; Molecular Structure; Neoplasms; Polymerization; Sulfonamides; Tubulin; Xenograft Model Antitumor Assays

2013
Trichodermone, a spiro-cytochalasan with a tetracyclic nucleus (7/5/6/5) skeleton from the plant endophytic fungus Trichoderma gamsii.
    Journal of natural products, 2014, Jan-24, Volume: 77, Issue:1

    Topics: Antineoplastic Agents; Cytochalasins; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Panax notoginseng; Trichoderma

2014
Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones.
    European journal of medicinal chemistry, 2014, Apr-22, Volume: 77

    Topics: Antimitotic Agents; Benzophenones; Cell Line, Tumor; Cell Proliferation; Colchicine; Dose-Response Relationship, Drug; HT29 Cells; Human Umbilical Vein Endothelial Cells; Humans; KB Cells; Molecular Structure; Polymerization; Structure-Activity Relationship; Tubulin

2014
Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei.
    Journal of natural products, 2014, Jun-27, Volume: 77, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Benzodioxoles; Caspase 3; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Glycosides; HT29 Cells; Humans; Lactones; Lignans; Mice; Molecular Structure; Naphthalenes; Nuclear Magnetic Resonance, Biomolecular; Phyllanthus; Vietnam

2014
Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors.
    Bioorganic & medicinal chemistry letters, 2014, Aug-01, Volume: 24, Issue:15

    Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; Heterocyclic Compounds, 4 or More Rings; Humans; MCF-7 Cells; Molecular Structure; Phenanthrolines; Polymerization; Structure-Activity Relationship; Tubulin; Tubulin Modulators

2014
Design, synthesis and antiproliferative activity of a novel class of indole-2-carboxylate derivatives.
    European journal of medicinal chemistry, 2014, Aug-18, Volume: 83

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Inhibitory Concentration 50; Intracellular Space; Poly(ADP-ribose) Polymerases; Proteolysis; Reactive Oxygen Species; Structure-Activity Relationship

2014
Concise syntheses of 7-anilino-indoline-N-benzenesulfonamides as antimitotic and vascular disrupting agents.
    Bioorganic & medicinal chemistry, 2014, Sep-01, Volume: 22, Issue:17

    Topics: Antineoplastic Agents; Capillaries; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Indoles; KB Cells; Mitosis; Molecular Structure; Polymerization; Structure-Activity Relationship; Sulfonamides; Tubulin; Tubulin Modulators

2014
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
    European journal of medicinal chemistry, 2015, Mar-06, Volume: 92

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3

2015
Triphenylphosphonium Cations of the Diterpenoid Isosteviol: Synthesis and Antimitotic Activity in a Sea Urchin Embryo Model.
    Journal of natural products, 2015, Jun-26, Volume: 78, Issue:6

    Topics: Animals; Antimitotic Agents; Antineoplastic Agents; Cations; Disease Models, Animal; Diterpenes; Diterpenes, Kaurane; Humans; Mediterranean Sea; Mitochondria; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Organophosphorus Compounds; Sea Urchins; Structure-Activity Relationship

2015
Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes.
    Bioorganic & medicinal chemistry, 2015, Aug-01, Volume: 23, Issue:15

    Topics: Angiogenesis Inhibitors; Antimitotic Agents; Benzene; Binding Sites; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Colchicine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; HT29 Cells; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Structure-Activity Relationship; Tubulin Modulators

2015
Some Anticancer Agents Act on Human Serum Paraoxonase-1 to Reduce Its Activity.
    Chemical biology & drug design, 2016, Volume: 88, Issue:2

    Topics: Antineoplastic Agents; Aryldialkylphosphatase; Electrophoresis, Polyacrylamide Gel; Humans

2016
Anticancer activity studies of cubebin isolated from Piper cubeba and its synthetic derivatives.
    Bioorganic & medicinal chemistry letters, 2016, Apr-01, Volume: 26, Issue:7

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Humans; Lignans; Models, Molecular; Neoplasms; Piper; Seeds

2016
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
    Bioorganic & medicinal chemistry letters, 2016, 07-15, Volume: 26, Issue:14

    Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; MCF-7 Cells; Molecular Structure; Podophyllotoxin; Structure-Activity Relationship

2016
Design and synthesis of 1,2,3-triazolo linked benzo[d]imidazo[2,1-b]thiazole conjugates as tubulin polymerization inhibitors.
    Bioorganic & medicinal chemistry, 2017, 07-01, Volume: 25, Issue:13

    Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Imidazoles; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Polymerization; Structure-Activity Relationship; Thiazoles; Triazoles; Tubulin

2017
One-pot synthesis and biological evaluation of N-(aminosulfonyl)-4-podophyllotoxin carbamates as potential anticancer agents.
    Bioorganic & medicinal chemistry letters, 2017, 07-01, Volume: 27, Issue:13

    Topics: Antineoplastic Agents; Carbamates; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Podophyllotoxin; Structure-Activity Relationship

2017
Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
    Bioorganic & medicinal chemistry letters, 2017, 09-01, Volume: 27, Issue:17

    Topics: Acetates; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Esters; Humans; MCF-7 Cells; Molecular Structure; Piperazine; Piperazines; Podophyllotoxin; Polymerization; Structure-Activity Relationship; Tubulin

2017
Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
    European journal of medicinal chemistry, 2018, Jan-01, Volume: 143

    Topics: Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Molecular Structure; Polymerization; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tubulin

2018
Synthesis and biological evaluation of cyclopeptide GG-8-6 and its analogues as anti-hepatocellular carcinoma agents.
    Bioorganic & medicinal chemistry, 2018, 02-01, Volume: 26, Issue:3

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Liver Neoplasms; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred BALB C; Mice, Nude; Peptides, Cyclic; Protein Structure, Tertiary; Structure-Activity Relationship; Transplantation, Heterologous

2018
Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones.
    Bioorganic & medicinal chemistry, 2018, 05-15, Volume: 26, Issue:9

    Topics: Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Etoposide; Glycosides; Humans; Lactones; Lignans; Molecular Structure; Naphthalenes; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors

2018
In Vitro and in Vivo Antitumor Effects of Plant-Derived Miliusanes and Their Induction of Cellular Senescence.
    Journal of medicinal chemistry, 2019, 02-14, Volume: 62, Issue:3

    Topics: Animals; Annonaceae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Cyclohexanols; Cyclohexanones; Female; Humans; Male; Mice, Inbred BALB C; Molecular Structure; Signal Transduction; Spiro Compounds; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2019
Design, synthesis and evaluation of antiproliferative activity of fluorinated betulinic acid.
    Bioorganic & medicinal chemistry, 2019, 07-01, Volume: 27, Issue:13

    Topics: Betulinic Acid; Cell Proliferation; Humans; Molecular Structure; Pentacyclic Triterpenes; Triterpenes

2019
Anti-cancer potential of novel glycosylated 1,4-substituted triazolylchalcone derivatives.
    Bioorganic & medicinal chemistry letters, 2019, 10-01, Volume: 29, Issue:19

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Chalcone; Click Chemistry; Cycloaddition Reaction; Drug Screening Assays, Antitumor; Female; Glycosylation; Humans; Molecular Structure; Structure-Activity Relationship; Triazoles

2019
Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
    Bioorganic & medicinal chemistry, 2021, 04-01, Volume: 35

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship

2021
Cardiostimulatory and antiarrhythmic activity of tubulin-binding agents.
    Proceedings of the National Academy of Sciences of the United States of America, 1992, Feb-15, Volume: 89, Issue:4

    Topics: Alkaloids; Animals; Anti-Arrhythmia Agents; Cells, Cultured; Doxorubicin; Etoposide; Heart Rate; In Vitro Techniques; Microtubules; Myocardial Contraction; Nocodazole; Paclitaxel; Podophyllotoxin; Rats; Tubulin; Vinca Alkaloids

1992
Monoclonal antibody MRK16 reverses the multidrug resistance of multidrug-resistant transgenic mice.
    Cancer research, 1992, Aug-15, Volume: 52, Issue:16

    Topics: Alkaloids; Animals; Antibodies, Monoclonal; Daunorubicin; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Immunotoxins; Leukocyte Count; Mice; Mice, Transgenic; Paclitaxel; Pseudomonas aeruginosa; Vinblastine; Vincristine

1992
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Cell Death; Cisplatin; Docetaxel; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Ovarian Neoplasms; Paclitaxel; Rhodamines; Taxoids; Tumor Cells, Cultured

1992
[Treatment of recurrent ovarian cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infusions, Parenteral; Lymph Node Excision; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovariectomy; Paclitaxel

1992
[Recent advances in ovarian cancer chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:12

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Infusions, Parenteral; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Taxoids

1992
In vitro release of hydrophobic drugs from polyanhydride disks.
    Ophthalmic surgery, 1991, Volume: 22, Issue:11

    Topics: Alkaloids; Cell Division; Cells, Cultured; Decanoic Acids; Delayed-Action Preparations; Dicarboxylic Acids; Drug Implants; Etoposide; Fibroblasts; Floxuridine; Fluorouracil; Glaucoma; Humans; Mercaptopurine; Paclitaxel; Polymers; Postoperative Complications; Vincristine

1991
Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro.
    Cancer research, 1987, Feb-15, Volume: 47, Issue:4

    Topics: Alkaloids; Cell Line; Colchicine; DNA; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; In Vitro Techniques; Maytansine; Microtubules; Paclitaxel; Podophyllotoxin; Time Factors; Vinblastine

1987
Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid.
    Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:12

    Topics: Apoptosis; Calcimycin; Cell Cycle; Cell Survival; Child, Preschool; Cholera Toxin; Colforsin; DNA, Neoplasm; Enzyme Inhibitors; Ethers, Cyclic; Etoposide; Flow Cytometry; HL-60 Cells; Humans; Male; Mitosis; Nocodazole; Okadaic Acid; Paclitaxel; Phosphoprotein Phosphatases; Retinoblastoma; Tetradecanoylphorbol Acetate; Tretinoin; Tumor Cells, Cultured

1995
Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer.
    Human gene therapy, 1994, Volume: 5, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Clinical Protocols; Drug Resistance; Etoposide; Genetic Vectors; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Informed Consent; Interleukin-3; Interleukin-6; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancytopenia; Recombinant Fusion Proteins; Recombinant Proteins; Retroviridae; Stem Cell Factor; Transplantation, Autologous; Vinblastine

1994
Tubulin alterations in taxol-induced apoptosis parallel those observed with other drugs.
    Biochemical pharmacology, 1995, May-17, Volume: 49, Issue:10

    Topics: Apoptosis; Cell Line; Centrosome; Etoposide; Methotrexate; Paclitaxel; RNA; Tubulin

1995
In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms.
    Anti-cancer drugs, 1995, Volume: 6, Issue:1

    Topics: Adenosine Triphosphate; Adult; Antineoplastic Agents; Choriocarcinoma; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Hydatidiform Mole; Paclitaxel; Pregnancy; Trophoblastic Neoplasms; Tumor Cells, Cultured; Uterine Neoplasms; Vincristine

1995
Hypersensitivity reactions from taxol and etoposide.
    Journal of the National Cancer Institute, 1993, Dec-15, Volume: 85, Issue:24

    Topics: Adult; Cross Reactions; Drug Hypersensitivity; Etoposide; Humans; Male; Paclitaxel

1993
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Journal of the National Cancer Institute, 1994, Oct-19, Volume: 86, Issue:20

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Computer Simulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Etoposide; Humans; Paclitaxel; Teratocarcinoma; Topotecan; Tumor Cells, Cultured; Vincristine

1994
Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
    Cancer, 1993, Nov-01, Volume: 72, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; DNA, Neoplasm; Doxorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Female; Flow Cytometry; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured

1993
Glaucoma filtration surgery in nonhuman primates using taxol and etoposide in polyanhydride carriers.
    Investigative ophthalmology & visual science, 1993, Volume: 34, Issue:11

    Topics: Animals; Anterior Eye Segment; Drug Carriers; Drug Delivery Systems; Etoposide; Fibrosis; Glaucoma; Intraocular Pressure; Laser Therapy; Macaca fascicularis; Male; Paclitaxel; Polymers; Sclera; Sclerostomy

1993
Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A.
    Cancer research, 1993, Nov-01, Volume: 53, Issue:21

    Topics: Amsacrine; Animals; Biological Transport; Brefeldin A; Cell Survival; Cyclopentanes; DNA Damage; DNA Repair; Doxorubicin; Drug Synergism; Endoplasmic Reticulum; Etoposide; Golgi Apparatus; Kinetics; Leukemia L1210; Mice; Microtubules; Nocodazole; Paclitaxel; Temperature; Tumor Cells, Cultured; Tumor Stem Cell Assay

1993
17 beta-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter.
    Cancer research, 1993, Nov-15, Volume: 53, Issue:22

    Topics: Cholestasis; Doxorubicin; Drug Resistance; Estradiol; Estriol; Etoposide; Humans; Leukemia, Myeloid; Paclitaxel; Sarcoma; Tumor Cells, Cultured; Vinblastine

1993
Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway.
    Molecular medicine (Cambridge, Mass.), 1995, Volume: 1, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Count; Cell Line; Cell Nucleus; Cells, Cultured; Etoposide; Fluorescent Antibody Technique; G2 Phase; HeLa Cells; Humans; Kinetics; Mice; Mitosis; Paclitaxel; Phenotype; Prophase; Rats; Tubulin; Tumor Suppressor Protein p53

1995
Genetic toxicity in relation to receptor-mediated carcinogenesis.
    Mutation research, 1995, Volume: 333, Issue:1-2

    Topics: Aniline Compounds; Animals; Carcinogens; Etoposide; Humans; Mutagens; Paclitaxel; Receptors, Cell Surface

1995
Modification of chemo-radiosensitivity of a human lung cancer cell line by introduction of the glutathione S-transferase pi gene.
    Japanese journal of clinical oncology, 1996, Volume: 26, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Doxorubicin; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione Transferase; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured

1996
Effects of Taxol on choriocarcinoma cells.
    American journal of obstetrics and gynecology, 1995, Volume: 173, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Choriocarcinoma; Chorionic Gonadotropin; Cycloheximide; Etoposide; Female; Humans; Methotrexate; Paclitaxel; Pregnancy; Tumor Cells, Cultured; Uterine Neoplasms

1995
Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine.
    Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:6

    Topics: Antineoplastic Agents; Doxorubicin; Drug Resistance, Multiple; Etoposide; Guanidines; Humans; Paclitaxel; Polymers; Sarcoma; Spermine; Tumor Cells, Cultured; Vinblastine

1996
Degradation of radioiodinated B cell monoclonal antibodies: inhibition via a FCgamma-receptor-II-mediated mechanism and by drugs.
    Cancer immunology, immunotherapy : CII, 1996, Volume: 42, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antigens, CD; Antigens, CD19; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; B-Lymphocytes; Biological Transport; Burkitt Lymphoma; Calcium Channel Blockers; Cell Adhesion Molecules; Chloroquine; Colchicine; Etoposide; Humans; Immunoglobulin Isotypes; Immunotoxins; Iodine Radioisotopes; Lectins; Leukemia, B-Cell; Mice; Monensin; Paclitaxel; Radioimmunotherapy; Receptors, IgG; Sialic Acid Binding Ig-like Lectin 2; Verapamil; Vinblastine; Vincristine

1996
Treatment of resistant gestational choriocarcinoma with taxol: a report of two cases.
    Gynecologic oncology, 1996, Volume: 61, Issue:1

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Choriocarcinoma; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Drug Resistance, Neoplasm; Etoposide; Female; Frontal Lobe; Humans; Liver Neoplasms; Lung Neoplasms; Methotrexate; Middle Aged; Paclitaxel; Platinum; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms; Vincristine

1996
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3

    Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Ehrlich Tumor; Central Nervous System Neoplasms; DNA Topoisomerases, Type II; Etoposide; Female; Injections, Intraperitoneal; Lethal Dose 50; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Paclitaxel; Razoxane; Structure-Activity Relationship

1996
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pilot Projects; Remission Induction; Sarcoma; Thrombocytopenia

1996
Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
    British journal of cancer, 1996, Volume: 74, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Humans; Ifosfamide; Ovarian Neoplasms; Paclitaxel; Tritium; Tumor Cells, Cultured

1996
Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo.
    Urology, 1996, Volume: 48, Issue:1

    Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Division; Cell Survival; Cells, Cultured; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Rats

1996
Chemotherapy enhancer passes first test.
    Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:11

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials, Phase I as Topic; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Neoplasms; Paclitaxel

1995
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
    British journal of cancer, 1996, Volume: 74, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cisplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Female; Humans; Irinotecan; Mice; Mice, Nude; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Paclitaxel; Thiotepa; Topoisomerase I Inhibitors; Transplantation, Heterologous

1996
Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells.
    International journal of cancer, 1996, Sep-04, Volume: 67, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Base Sequence; bcl-2-Associated X Protein; bcl-X Protein; Breast Neoplasms; Cyclosporine; Doxorubicin; Drug Resistance, Multiple; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tumor Cells, Cultured; Verapamil; Vincristine

1996
Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.
    Cancer research, 1996, Sep-15, Volume: 56, Issue:18

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Membrane; Cell Survival; Dibenzocycloheptenes; Drug Resistance, Multiple; Etoposide; Humans; Kinetics; Leukemia P388; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Protein Binding; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine

1996
Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines.
    Lung cancer (Amsterdam, Netherlands), 1996, Volume: 15, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Vinblastine

1996
Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
    Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 1996, Volume: 7, Issue:11

    Topics: Antineoplastic Agents; Bleomycin; Bryostatins; Carcinoma; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Female; Head and Neck Neoplasms; Herpes Simplex Virus Protein Vmw65; Humans; Lactones; Lung Neoplasms; Macrolides; Ovarian Neoplasms; Paclitaxel; Phorbol 12,13-Dibutyrate; Protein Kinase C; Signal Transduction; Tumor Cells, Cultured

1996
An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo.
    Journal of photochemistry and photobiology. B, Biology, 1996, Volume: 35, Issue:3

    Topics: Animals; Apoptosis; Carmustine; Colonic Neoplasms; DNA Fragmentation; Doxorubicin; Etoposide; Mice; Paclitaxel; Photochemotherapy; Protoporphyrins

1996
BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.
    Proceedings of the National Academy of Sciences of the United States of America, 1996, Nov-26, Volume: 93, Issue:24

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carboplatin; Cell Cycle; Cell Line; Cell Survival; Etoposide; Female; Humans; Hydroxyurea; Immunoblotting; Kinetics; Mice; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Transfection; Tumor Suppressor Protein p53; Vincristine

1996
Extended multidrug resistance in haemopoietic cells.
    British journal of haematology, 1996, Volume: 95, Issue:4

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Hematopoietic Stem Cells; HL-60 Cells; Humans; Leukemia, Myeloid; Paclitaxel; Tumor Cells, Cultured; Vinblastine

1996
Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
    Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Interactions; Etoposide; Fluorouracil; Mice; Mice, Inbred C3H; Paclitaxel; Radiation-Sensitizing Agents; Tirapazamine; Triazines

1997
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
    Cancer research, 1997, Mar-01, Volume: 57, Issue:5

    Topics: Antineoplastic Agents; Cisplatin; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Female; Glutathione; Humans; Mitomycin; Ovarian Neoplasms; Paclitaxel; Regression Analysis; Tumor Cells, Cultured

1997
Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.
    Anti-cancer drugs, 1997, Volume: 8, Issue:2

    Topics: Adenosine Triphosphatases; Affinity Labels; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Heat-Shock Proteins; Humans; Mice; Paclitaxel; Piperidines; Pyridines; Tacrolimus Binding Proteins; Transfection; Tumor Cells, Cultured; Vincristine

1997
Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
    Urological research, 1997, Volume: 25, Issue:1

    Topics: Androgens; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorescent Dyes; Genes, MDR; Male; Methotrexate; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Rhodamine 123; Rhodamines; Tumor Cells, Cultured; Verapamil; Vinblastine

1997
Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide.
    Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:6

    Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polysorbates; Surface-Active Agents; Taxoids

1997
Reversal activity of cyclosporin A and its metabolites M1, M17 and M21 in multidrug-resistant cells.
    International journal of cancer, 1997, May-29, Volume: 71, Issue:5

    Topics: Affinity Labels; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Cell Membrane; Chromatography, High Pressure Liquid; Cyclosporine; Dihydropyridines; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Etoposide; Humans; Hydroxylation; Kinetics; Methylation; Molecular Structure; Paclitaxel; Photochemistry; Tumor Cells, Cultured

1997
Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
    Cancer research, 1997, Aug-15, Volume: 57, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carmustine; Cisplatin; Cyclin-Dependent Kinases; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Flavonoids; Fluorouracil; Humans; Lung Neoplasms; Paclitaxel; Piperidines; Tumor Stem Cell Assay

1997
Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
    Anti-cancer drugs, 1997, Volume: 8, Issue:7

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Cycle; Cell Survival; DNA Topoisomerases, Type II; Doxorubicin; Drug Interactions; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lung Neoplasms; Paclitaxel; Polymerase Chain Reaction; Rhodamines; Stomach Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vincristine

1997
New drugs for small-cell lung cancer.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vincristine

1997
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.
    Journal of the National Cancer Institute, 1997, Oct-15, Volume: 89, Issue:20

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carrier Proteins; Cell Survival; Chromosome Mapping; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Cisplatin; Colonic Neoplasms; DNA Repair; Drug Resistance, Multiple; Etoposide; Humans; Mutagenesis; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Repetitive Sequences, Nucleic Acid; Tumor Cells, Cultured

1997
A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs.
    Human gene therapy, 1997, Oct-10, Volume: 8, Issue:15

    Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Cloning, Molecular; Drug Resistance, Multiple; Etoposide; Folic Acid Antagonists; Gene Expression; Genetic Vectors; Hematopoietic Stem Cells; Humans; Methotrexate; Paclitaxel; Proviruses; Retroviridae; Tetrahydrofolate Dehydrogenase; Transformation, Genetic; Trimetrexate; Tumor Cells, Cultured; Vinblastine

1997
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.
    British journal of cancer, 1998, Volume: 77, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Cell Separation; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Repair; DNA, Neoplasm; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Melphalan; Paclitaxel; Tamoxifen; Thioguanine; Tumor Cells, Cultured; Tumor Stem Cell Assay

1998
Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured

1998
Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel.
    International journal of cancer, 1998, May-29, Volume: 76, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bacterial Proteins; Carcinoma, Small Cell; Chlorambucil; Cisplatin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Paclitaxel; RNA, Messenger; Serine Endopeptidases; Tumor Cells, Cultured; Vinblastine

1998
Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs.
    Anti-cancer drugs, 1998, Volume: 9, Issue:4

    Topics: Animals; Antineoplastic Agents; Bleomycin; Carboplatin; Cell Line; Cell Survival; Cisplatin; Cricetinae; Cricetulus; Daunorubicin; Doxorubicin; Drug Screening Assays, Antitumor; Electroporation; Etoposide; Lung; Paclitaxel

1998
A unique interaction between polyamine and multidrug resistance (P-glycoprotein) transporters in cultured Chinese hamster ovary cells transfected with mouse mdr-1 gene.
    Biochemical pharmacology, 1998, Jul-15, Volume: 56, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; CHO Cells; Cricetinae; Cricetulus; Doxorubicin; Etoposide; Flow Cytometry; Mice; Paclitaxel; Protein Binding; Spermidine; Transfection

1998
"Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.
    Cancer research, 1998, Aug-01, Volume: 58, Issue:15

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; bcl-X Protein; Binding Sites; Blotting, Western; Cytarabine; Cytochrome c Group; Cytosol; DNA, Neoplasm; Etoposide; HL-60 Cells; Humans; Mutation; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Conformation; Protein Structure, Tertiary; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transfection

1998
Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 1998, Volume: 19, Issue:5

    Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Butyrates; Butyric Acid; Camptothecin; Carboplatin; Cisplatin; DNA Damage; Drug Screening Assays, Antitumor; Etoposide; Humans; Paclitaxel; Retinoblastoma; Suramin; Tumor Cells, Cultured

1998
Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel

1998
Role of E2F-1 in chemosensitivity.
    Cancer research, 1998, Oct-01, Volume: 58, Issue:19

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Survival; Cloning, Molecular; Culture Media, Serum-Free; DNA-Binding Proteins; Doxorubicin; E2F Transcription Factors; E2F1 Transcription Factor; Etoposide; Fibrosarcoma; Humans; Irinotecan; Paclitaxel; Recombinant Proteins; Retinoblastoma-Binding Protein 1; Tetrahydrofolate Dehydrogenase; Transcription Factor DP1; Transcription Factors; Transfection; Tumor Cells, Cultured

1998
Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells.
    Cancer research, 1998, Oct-15, Volume: 58, Issue:20

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptotic Protease-Activating Factor 1; bcl-2-Associated X Protein; Etoposide; HL-60 Cells; Humans; Paclitaxel; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2

1998
In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
    British journal of cancer, 1998, Volume: 78, Issue:8

    Topics: Amifostine; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cell Cycle; Cell Division; Cells, Cultured; Docetaxel; Doxorubicin; Etoposide; Hematopoietic Stem Cells; Humans; Leukocytes, Mononuclear; Paclitaxel; Taxoids; Time Factors

1998
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carrier Proteins; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Adducts; DNA Damage; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Melphalan; Methylnitronitrosoguanidine; Mutagenesis; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Thioguanine; Tumor Cells, Cultured

1997
Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:6

    Topics: 3T3 Cells; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Doxorubicin; Drug Resistance, Multiple; Etoposide; Gene Expression Regulation; Genetic Vectors; HeLa Cells; Humans; Methylnitronitrosoguanidine; Mice; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Prohibitins; Recombinant Proteins; Retroviridae; Transfection; Vincristine

1997
Evidence against a direct role for the induction of c-jun expression in the mediation of drug-induced apoptosis in human acute leukemia cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Cytarabine; Etoposide; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, jun; HL-60 Cells; Humans; Leukemia, B-Cell; Mitoxantrone; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Recombinant Proteins; Transfection; Tumor Cells, Cultured

1995
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.
    Anti-cancer drugs, 1998, Volume: 9, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine

1998
Indirect-response model for the time course of leukopenia with anticancer drugs.
    Clinical pharmacology and therapeutics, 1998, Volume: 64, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Mathematical Computing; Middle Aged; Models, Theoretical; Paclitaxel; Time Factors

1998
Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
    Cancer chemotherapy and pharmacology, 1999, Volume: 43, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Fenretinide; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured

1999
Hepatic artery administration of paclitaxel.
    Cancer investigation, 1999, Volume: 17, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cimetidine; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Etoposide; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication

1999
Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
    Japanese journal of cancer research : Gann, 1998, Volume: 89, Issue:12

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Injections, Intravenous; Lung Neoplasms; Male; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Nitrosourea Compounds; Paclitaxel; Vinblastine

1998
Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
    Proceedings of the National Academy of Sciences of the United States of America, 1999, Mar-30, Volume: 96, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Bleomycin; Camptothecin; Cell Division; Cisplatin; Cross-Linking Reagents; Dioxoles; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Humans; Isoquinolines; Male; Mitomycin; Models, Molecular; Molecular Structure; Neoplasm Proteins; Paclitaxel; Phthalimides; Structure-Activity Relationship; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured

1999
Cytotoxicity of 2-chlorodeoxadenosine (cladribine, 2-cdA) in combination with other chemotherapy drugs against two lymphoma cell lines.
    Leukemia & lymphoma, 1999, Volume: 33, Issue:1-2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chlorambucil; Cisplatin; Cladribine; Drug Screening Assays, Antitumor; Etoposide; Humans; Lymphoma, B-Cell; Paclitaxel; Tumor Cells, Cultured

1999
Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents.
    The Journal of biological chemistry, 1999, Apr-16, Volume: 274, Issue:16

    Topics: Apoptosis; Cell Line; Cytarabine; DNA Damage; Enzyme Activation; Etoposide; Humans; Hydrolysis; MAP Kinase Kinase Kinase 1; Microtubules; Mutagens; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Vinblastine

1999
Extracellular matrix inhibits apoptosis and enhances endothelial cell differentiation by a NfkappaB-dependent mechanism.
    Journal of cellular biochemistry, 1999, Jun-01, Volume: 73, Issue:3

    Topics: Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Differentiation; Cell Line; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytoplasm; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endothelium, Vascular; Estradiol; Etoposide; Extracellular Matrix; Humans; I-kappa B Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Nucleic Acid Synthesis Inhibitors; Oligonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Tetrazolium Salts; Thiazoles; Time Factors; Transfection

1999
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Oncogene, 1999, Apr-01, Volume: 18, Issue:13

    Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Cycle; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Protein Processing, Post-Translational; Receptor, ErbB-2; Recombinant Proteins; Thiotepa; Topoisomerase II Inhibitors; Transplantation, Heterologous; Trastuzumab; Treatment Outcome; Vinblastine

1999
Mitochondrial changes during the apoptotic process of HeLa cells exposed to cisplatin.
    Biochemistry and molecular biology international, 1999, Volume: 47, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cisplatin; Etoposide; Flow Cytometry; HeLa Cells; Humans; Mitochondria; Paclitaxel

1999
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:4

    Topics: Alkyl and Aryl Transferases; Cell Survival; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Humans; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Piperidines; Pyridines; Sensitivity and Specificity; Tumor Cells, Cultured; Tumor Stem Cell Assay

1999
Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells.
    International journal of oncology, 1999, Volume: 15, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cisplatin; DNA Fragmentation; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Taxoids; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation

1999
Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.
    Pharmaceutical research, 1999, Volume: 16, Issue:9

    Topics: Animals; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Caco-2 Cells; Cattle; Contrast Media; Doxorubicin; Drug Resistance, Neoplasm; Endothelium, Vascular; Enzyme Inhibitors; Etoposide; Excipients; Fluorescein; Humans; Intestinal Absorption; Loperamide; Micelles; Microcirculation; Paclitaxel; Poloxamer; Tritium; Valproic Acid; Zidovudine

1999
Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:5

    Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Paclitaxel; Time Factors; Tumor Cells, Cultured

1999
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine

2000
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.
    International journal of cancer, 2000, Mar-01, Volume: 85, Issue:5

    Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Carboplatin; Cell Division; Cell Line; Cell Line, Transformed; Cell Survival; Cisplatin; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Doxorubicin; Epithelial Cells; Etoposide; Female; Genes, erbB-2; Humans; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Receptor, ErbB-2; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured

2000
Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.
    Cancer, 2000, Mar-15, Volume: 88, Issue:6

    Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Clinical Protocols; Decision Making; Diagnostic Imaging; Etoposide; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Paclitaxel; Practice Patterns, Physicians'; Radiation Oncology; Radiotherapy, Adjuvant; United States

2000
1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Survival; Ceramides; Cyclosporins; Drug Synergism; Enzyme Inhibitors; Etoposide; Glucosyltransferases; Morpholines; Neuroblastoma; Paclitaxel; Tumor Cells, Cultured; Vincristine

2000
The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis.
    Cancer research, 2000, Mar-15, Volume: 60, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptotic Protease-Activating Factor 1; BH3 Interacting Domain Death Agonist Protein; Carrier Proteins; Caspase 3; Caspase 8; Caspase 9; Caspases; Cytochrome c Group; Cytosol; Enzyme Precursors; Etoposide; Fibroblasts; Gene Expression Regulation; HL-60 Cells; Humans; Intracellular Membranes; Membrane Potentials; Mice; Mitochondria; Paclitaxel; Proteins; Recombinant Fusion Proteins

2000
Doxazosin: a new cytotoxic agent for prostate cancer?
    BJU international, 2000, Volume: 85, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxazosin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured

2000
A novel combination of paclitaxel, etoposide, and cyclophosphamide for stem cell mobilization and tumor cytoreduction in ovarian cancer.
    Journal of hematotherapy & stem cell research, 2000, Volume: 9, Issue:2

    Topics: Alopecia; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Carcinoma, Papillary; Cyclophosphamide; Endometrial Neoplasms; Etoposide; Female; Fever; Hematopoietic Stem Cell Mobilization; Humans; Klebsiella Infections; Leukapheresis; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Serous Membrane; Taxoids

2000
Management of patients with cancer of unknown primary site.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma; Etoposide; Evaluation Studies as Topic; Female; Humans; Male; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Survival Rate; Taxoids

2000
In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Etoposide; Fluorouracil; Gemcitabine; Humans; Mitomycin; Models, Chemical; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine

2000
Differential expression of sphingolipids in MRP1 overexpressing HT29 cells.
    International journal of cancer, 2000, Jul-15, Volume: 87, Issue:2

    Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Survival; Ceramides; Colchicine; Colonic Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Etoposide; Fluoresceins; Galactosylceramides; Glucosylceramides; HT29 Cells; Humans; Immunoblotting; Immunohistochemistry; Microscopy, Confocal; Microtubules; Mitosis; Multidrug Resistance-Associated Proteins; Paclitaxel; Propionates; Quinolines; Signal Transduction; Sphingolipids; Vincristine

2000
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6

    Topics: Animals; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Nucleus; Docetaxel; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Fluorescent Dyes; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Transplantation; Paclitaxel; Phantoms, Imaging; Prostatic Neoplasms; Sodium; Sodium Chloride; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured

2000
MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells.
    British journal of cancer, 2000, Volume: 83, Issue:7

    Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Multidrug Resistance-Associated Proteins; Mutation; Neoplasm Proteins; Paclitaxel; Phenotype; Rhodamine 123; RNA, Messenger; Sarcoma; Tritium; Tumor Cells, Cultured; Uterine Neoplasms; Vault Ribonucleoprotein Particles; Vinblastine

2000
Mobilization and transplantation of peripheral blood stem cells.
    Stem cells (Dayton, Ohio), 1998, Volume: 16 Suppl 1

    Topics: Antigens, CD34; Blood Transfusion; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Cytokines; Erythrocytes; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Lymphoma, Non-Hodgkin; Paclitaxel; Platelet Transfusion; Regression Analysis; Retrospective Studies; Transplantation, Autologous

1998
An evaluation of the permeability of chemotherapy gloves to three cancer chemotherapy drugs.
    Oncology nursing forum, 1999, Volume: 26, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carmustine; Equipment Design; Etoposide; Gloves, Protective; Humans; Latex; Nitriles; Occupational Exposure; Paclitaxel; Permeability; Time Factors

1999
[Roles of p53 in chemotherapy of glioblastoma].
    [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 2000, Volume: 75, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cisplatin; Etoposide; Flow Cytometry; Glioblastoma; Nimustine; Paclitaxel; Polymerase Chain Reaction; Temperature; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2000
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
    The Journal of biological chemistry, 2001, Mar-16, Volume: 276, Issue:11

    Topics: Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA; DNA Damage; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; I-kappa B Proteins; Irinotecan; Leupeptins; Lung Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Peptide Hydrolases; Proteasome Endopeptidase Complex; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors

2001
Carcinoma of unknown primary site.
    Cancer, 2000, Dec-15, Volume: 89, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasms, Unknown Primary; Paclitaxel; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting

2000
Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
    Anti-cancer drugs, 2000, Volume: 11, Issue:10

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Luminescent Measurements; Paclitaxel; Topotecan; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vulvar Neoplasms

2000
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
    Revista espanola de medicina nuclear, 2001, Volume: 20, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Fatal Outcome; Follow-Up Studies; Gallium Radioisotopes; Gastrectomy; Gastroscopy; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Methylprednisolone; Mitoxantrone; Neoplasm Recurrence, Local; Paclitaxel; Prednisone; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Adjuvant; Stomach Neoplasms; Stomach Ulcer; Tomography, X-Ray Computed; Vincristine

2001
DNase I mediates internucleosomal DNA degradation in human cells undergoing drug-induced apoptosis.
    European journal of immunology, 2001, Volume: 31, Issue:3

    Topics: Apoptosis; Cell Nucleus; Cell Survival; Cycloheximide; Dactinomycin; Deoxyribonuclease I; DNA; DNA Fragmentation; Etoposide; fas Receptor; Gene Targeting; Humans; Jurkat Cells; Kinetics; Nucleosomes; Paclitaxel; Transfection; Tumor Cells, Cultured

2001
Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells.
    The Journal of cell biology, 2001, Jan-22, Volume: 152, Issue:2

    Topics: Amino Acid Sequence; Animals; Antibodies; Antibodies, Monoclonal; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Carrier Proteins; Cytochrome c Group; Erythrocytes; Etoposide; HeLa Cells; Humans; Ion Channels; Mammals; Membrane Proteins; Mitochondria; Mitochondria, Liver; Mitochondrial Proteins; Molecular Sequence Data; Paclitaxel; Porins; Protein Conformation; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred Strains; Recombinant Proteins; Staurosporine; Transfection; Voltage-Dependent Anion Channels

2001
Evaluation of GL331 in combination with paclitaxel: GL331's interference with paclitaxel-induced cell cycle perturbation and apoptosis.
    Anti-cancer drugs, 2001, Volume: 12, Issue:3

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Calcium-Binding Proteins; Carrier Proteins; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Nucleus; Cyclin B; Cyclin B1; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Antagonism; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Etoposide; Flow Cytometry; Fungal Proteins; Humans; Nasopharyngeal Neoplasms; Nuclear Proteins; Paclitaxel; Precipitin Tests; Protein Kinases; Tetrazolium Salts; Thiazoles; Toxicity Tests; Tumor Cells, Cultured

2001
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.
    Japanese journal of clinical oncology, 2001, Volume: 31, Issue:2

    Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prospective Studies; Topotecan

2001
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2001, Volume: 32, Issue:2

    Topics: Amino Acid Substitution; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Isoenzymes; Ki-67 Antigen; Life Tables; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Mutation, Missense; Neoplasm Proteins; Paclitaxel; Point Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Teniposide; Topotecan; Treatment Outcome; Vault Ribonucleoprotein Particles

2001
Thymidine incorporation is highly predictive of colony formation and can be used for high-throughput screening.
    BioTechniques, 2001, Volume: 30, Issue:5

    Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Chickens; CHO Cells; Colonic Neoplasms; Colony-Forming Units Assay; Cricetinae; Drug Screening Assays, Antitumor; Etoposide; Humans; Hydroxyurea; Kidney Neoplasms; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Thymidine; Tritium; Tumor Cells, Cultured

2001
PKCdelta is required for mitochondrial-dependent apoptosis in salivary epithelial cells.
    The Journal of biological chemistry, 2001, Aug-10, Volume: 276, Issue:32

    Topics: Adenoviridae; Animals; Apoptosis; Blotting, Western; Brefeldin A; Caspase 3; Caspase 9; Caspases; Cell Line; Cell Separation; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epithelial Cells; Etoposide; Flow Cytometry; Genes, Dominant; Isoenzymes; Lac Operon; Mitochondria; Mutation; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Protein Isoforms; Protein Kinase C; Protein Kinase C-delta; Protein Synthesis Inhibitors; Radiation-Sensitizing Agents; Rats; Salivary Glands; Time Factors; Ultraviolet Rays

2001
Using solution phase hydrogen/deuterium (H/D) exchange to determine the origin of non-covalent complexes observed by electrospray ionization mass spectrometry: in solution or in vacuo?
    Journal of the American Society for Mass Spectrometry, 2001, Volume: 12, Issue:7

    Topics: Algorithms; Antineoplastic Agents; Deuterium; Doxorubicin; Etoposide; Hydrogen; Molecular Weight; Paclitaxel; Spectrometry, Mass, Electrospray Ionization

2001
Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis.
    European journal of cell biology, 2001, Volume: 80, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Bleomycin; Cells, Cultured; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Endothelium, Vascular; Etoposide; Glutathione; Humans; Immunohistochemistry; L-Lactate Dehydrogenase; Malondialdehyde; Necrosis; Oxidative Stress; Paclitaxel; Peptidyl-Dipeptidase A; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Umbilical Veins

2001
Paclitaxel and lung cancer: new preparation. No therapeutic progress.
    Prescrire international, 2000, Volume: 9, Issue:46

    Topics: Antineoplastic Agents, Phytogenic; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Teniposide; Treatment Outcome

2000
Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Fluorouracil; Imidazoles; Mammary Neoplasms, Experimental; Melphalan; Mice; Mice, Inbred BALB C; Paclitaxel; Quinolines; Tirapazamine; Triazines; Tumor Cells, Cultured

2001
[Outpatient chemotherapy for advanced lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids

2001
Activation of HTLV-I long terminal repeat by stress-inducing agents and protection of HTLV-I-infected T-cells from apoptosis by the viral tax protein.
    Experimental cell research, 2001, Nov-15, Volume: 271, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carcinogens; Cell Line; Cisplatin; Etoposide; Gene Expression Regulation; Gene Products, tax; Genes, Reporter; Human T-lymphotropic virus 1; Humans; Methylcholanthrene; Paclitaxel; Protein Isoforms; Protein Kinase C; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; T-Lymphocytes; Terminal Repeat Sequences; Tetracycline; Tetradecanoylphorbol Acetate; Transfection

2001
S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function.
    The Journal of biological chemistry, 2002, Jan-11, Volume: 277, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line; Checkpoint Kinase 1; DNA Repair; Doxorubicin; Doxycycline; Enzyme Inhibitors; Etoposide; Flow Cytometry; G2 Phase; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Topoisomerase I Inhibitors; Topotecan

2002
Trafficking of CD34+ cells into the peripheral circulation during collection of peripheral blood stem cells by apheresis.
    Bone marrow transplantation, 2001, Volume: 28, Issue:7

    Topics: Acute Disease; Adult; Antigens, CD34; Blood Cell Count; Blood Component Removal; Blood Platelets; Cyclophosphamide; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Male; Middle Aged; Monocytes; Multiple Myeloma; Paclitaxel; Prospective Studies; Recombinant Proteins; Transplantation, Autologous

2001
Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:3

    Topics: Antineoplastic Agents; Cell Division; Cyanides; Etoposide; Guanidines; Humans; Paclitaxel; Time Factors; Topotecan; Tumor Cells, Cultured

2001
Effect of mesna on lethal effect and hematological toxicity of taxol and vepeside in mice.
    Bulletin of experimental biology and medicine, 2001, Volume: 132, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Etoposide; Male; Mesna; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Paclitaxel; Protective Agents; Time Factors

2001
Management of a 16-year-old boy with adenocarcinoma at the esophageal gastric junction.
    Medical and pediatric oncology, 2001, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Differential; Doxorubicin; Esophagogastric Junction; Etoposide; Fluorouracil; Humans; Male; Methotrexate; Paclitaxel; Stomach Neoplasms

2001
Brain metastases from fallopian tube carcinoma responsive to intra-arterial carboplatin and intravenous etoposide: a case report.
    Journal of neuro-oncology, 2001, Volume: 55, Issue:3

    Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Carboplatin; Carotid Arteries; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dacarbazine; Etoposide; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Physical Examination; Rupture, Spontaneous; Temozolomide; Temporal Lobe; Vertebral Artery

2001
Chemotherapy and pregnancy.
    Clinical obstetrics and gynecology, 2002, Volume: 45, Issue:1

    Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cytarabine; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Fetus; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Topotecan; Trastuzumab; Vinblastine; Vincristine

2002
[Globalization of anti-cancer therapies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms

2002
Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
    Cancer treatment reviews, 2001, Volume: 27, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Etoposide; Germinoma; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Salvage Therapy; Testicular Neoplasms; Vinblastine

2001
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:3

    Topics: Animals; Antineoplastic Agents; Biological Availability; Cisplatin; Deoxycytidine; Diffusion; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Membranes, Artificial; Mice; Neoplasm Staging; Paclitaxel; Polytetrafluoroethylene; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine

2002
Protein kinase Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells.
    The Journal of clinical investigation, 2002, Volume: 109, Issue:6

    Topics: Acetophenones; Antineoplastic Agents, Phytogenic; Apoptosis; Benzopyrans; Caspase Inhibitors; Caspases; Cell Fractionation; Ceramides; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Isoenzymes; Male; Mitochondria; Paclitaxel; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C-delta; Signal Transduction; Sphingomyelins; Tumor Cells, Cultured

2002
Extragonadal seminoma after renal transplantation and immunosuppression; treatment in the presence of renal dysfunction: a case report and literature review.
    Medical oncology (Northwood, London, England), 2001, Volume: 18, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chromosome Aberrations; Chromosomes, Human, Pair 12; Diagnosis, Differential; Disease Progression; Etoposide; Fatal Outcome; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Paclitaxel; Pelvic Neoplasms; Seminoma

2001
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2002, Volume: 40, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine

2002
Caspase cleavage product lacking amino-terminus of IkappaBalpha sensitizes resistant cells to TNF-alpha and TRAIL-induced apoptosis.
    Journal of cellular biochemistry, 2002, Volume: 85, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Aspartic Acid; beta-Galactosidase; Blotting, Western; Caspases; DNA Primers; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fibroblasts; Humans; I-kappa B Proteins; Luciferases; Membrane Glycoproteins; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2002
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:5

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Bradykinin; Bradykinin Receptor Antagonists; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cisplatin; Dimerization; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Gefitinib; Humans; Infusion Pumps; Injections, Intralesional; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Quinazolines; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays

2002
Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells.
    Biochemical and biophysical research communications, 2002, Jun-07, Volume: 294, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Etoposide; G1 Phase; Humans; Insulin-Like Growth Factor Binding Protein 3; Paclitaxel; Resting Phase, Cell Cycle; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Up-Regulation

2002
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
    Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:6

    Topics: Adenocarcinoma, Clear Cell; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Coloring Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione; Humans; Inhibitory Concentration 50; Irinotecan; Mitochondrial Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured

2002
Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells.
    Molecular medicine (Cambridge, Mass.), 2002, Volume: 8, Issue:2

    Topics: Animals; Antibody Specificity; Antineoplastic Agents; Antioxidants; Cysteine; Doxorubicin; Etoposide; Humans; Hydrogen Peroxide; Immune Sera; Male; Mice; Oxidative Stress; Paclitaxel; Peroxidases; Peroxiredoxin III; Peroxiredoxins; Prostatic Neoplasms; Protein Isoforms; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2002
Impact of maintenance chemotherapy on disease-free survival in patients with stage Ic and II epithelial ovarian cancer.
    European journal of gynaecological oncology, 2002, Volume: 23, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Japan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies

2002
Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.
    The Journal of biological chemistry, 2002, Nov-15, Volume: 277, Issue:46

    Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Carrier Proteins; Caspase 3; Caspase 7; Caspase 9; Caspases; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Irinotecan; Mitochondrial Proteins; Molecular Sequence Data; Paclitaxel; Peptides; Protein Binding; Protein Structure, Tertiary; Proteins; Recombinant Fusion Proteins; Sequence Homology, Amino Acid; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein

2002
The role of MAPK pathways in the action of chemotherapeutic drugs.
    Carcinogenesis, 2002, Volume: 23, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Ceramides; Enzyme Activation; Enzyme Inhibitors; Etoposide; Female; Flavonoids; HeLa Cells; Humans; Imidazoles; MAP Kinase Signaling System; Microtubules; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Paclitaxel; Pyridines; Skin Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay

2002
[Localization of primary small cell carcinoma with liver metastasis: a rare combination of colonic adenocarcinoma and undifferentiated small cell carcinoma].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2002, Volume: 73, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Colectomy; Colon; Colonic Neoplasms; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Neoplasms, Multiple Primary; Neoplasms, Unknown Primary; Paclitaxel; Taxoids; Time Factors; Vincristine

2002
VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland.
    Clinical lymphoma, 2002, Volume: 3, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma; Lymphoma, Mantle-Cell; Middle Aged; Paclitaxel; Prednisone; Rituximab; Time Factors; Topotecan; Treatment Outcome; Vincristine

2002
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Chromones; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Etoposide; Flow Cytometry; Humans; Immunoblotting; Morpholines; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tamoxifen; Time Factors; Transfection; Trastuzumab; Tumor Cells, Cultured

2002
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-15, Volume: 20, Issue:24

    Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Deoxycytidine; Docetaxel; Etoposide; Humans; Irinotecan; Leukocytes; Models, Biological; Neutrophils; Paclitaxel; Taxoids; Vinblastine

2002
Bcl-rambo beta, a special splicing variant with an insertion of an Alu-like cassette, promotes etoposide- and Taxol-induced cell death.
    FEBS letters, 2003, Jan-16, Volume: 534, Issue:1-3

    Topics: Alu Elements; Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; Brain; Cell Death; Cells, Cultured; DNA Transposable Elements; Etoposide; Exons; HeLa Cells; Humans; Lymph Nodes; Molecular Sequence Data; Myocardium; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; RNA Splicing

2003
[Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pneumonectomy; Taxoids; Tumor Cells, Cultured

2003
In regard to hyperfractionation for non-small-cell lung cancer: fire, ready, aim!
    International journal of radiation oncology, biology, physics, 2003, Apr-01, Volume: 55, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic

2003
Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells.
    Anti-cancer drugs, 2003, Volume: 14, Issue:4

    Topics: Animals; Antineoplastic Agents; Blotting, Northern; Caveolin 1; Caveolin 2; Caveolins; Cell Cycle; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Immunoblotting; Paclitaxel; RNA, Messenger; Up-Regulation

2003
Overexpression of interleukin-2 receptor alpha in a human squamous cell carcinoma of the head and neck cell line is associated with increased proliferation, drug resistance, and transforming ability.
    Journal of cellular biochemistry, 2003, Jul-01, Volume: 89, Issue:4

    Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Division; Cell Line, Transformed; Cyclin-Dependent Kinases; Cyclins; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Head and Neck Neoplasms; Humans; Interleukin-2 Receptor alpha Subunit; Janus Kinase 3; Multienzyme Complexes; Paclitaxel; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Receptors, Interleukin; Tumor Cells, Cultured; Ubiquitin

2003
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
    Cancer research, 2003, Jul-15, Volume: 63, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromones; Cisplatin; Drug Synergism; Enzyme Inhibitors; Etoposide; Glioma; Humans; Microtubules; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Tumor Cells, Cultured; Vincristine

2003
EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs.
    Biochemical and biophysical research communications, 2003, Aug-01, Volume: 307, Issue:3

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carcinoma; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Epstein-Barr Virus Nuclear Antigens; Etoposide; Female; G2 Phase; Genetic Therapy; Humans; Kinetics; Mitosis; Ovarian Neoplasms; Paclitaxel; Receptor, ErbB-2; Topoisomerase II Inhibitors; Tumor Cells, Cultured

2003
Chemotherapy and antiangiogenesis--drug-specific, dose-related effects.
    Acta oncologica (Stockholm, Sweden), 2003, Volume: 42, Issue:4

    Topics: Animals; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Endothelial Growth Factors; Etoposide; Fluorouracil; Humans; Injections, Intravenous; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Mesentery; Methotrexate; Neovascularization, Physiologic; Paclitaxel; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Weight Gain

2003
Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel.
    Anti-cancer drugs, 2003, Volume: 14, Issue:7

    Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glutathione; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured

2003
Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-15, Volume: 21, Issue:18

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Rate; Uterine Cervical Neoplasms

2003
Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Cancer research, 2003, Sep-01, Volume: 63, Issue:17

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Breast Neoplasms; Camptothecin; Caspases; Doxorubicin; Drug Synergism; Enzyme Activation; Etoposide; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vinblastine; Vincristine; Xenograft Model Antitumor Assays

2003
Caspase-3-mediated cleavage of Cdc6 induces nuclear localization of p49-truncated Cdc6 and apoptosis.
    Molecular biology of the cell, 2003, Volume: 14, Issue:10

    Topics: Active Transport, Cell Nucleus; Amino Acid Motifs; Annexin A5; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Caspases; CDC2-CDC28 Kinases; Cell Membrane; Cell Nucleus; Cyclin-Dependent Kinase 2; DNA Replication; Etoposide; Flow Cytometry; Ginsenosides; HeLa Cells; Humans; Membrane Glycoproteins; Nuclear Localization Signals; Paclitaxel; Phosphorylation; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2003
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
    Cancer research, 2003, Oct-01, Volume: 63, Issue:19

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bleomycin; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cisplatin; DNA Damage; Etoposide; G2 Phase; Humans; Microtubules; Mitosis; Paclitaxel; Vinblastine; Vinorelbine

2003
Topotecan as first-line therapy for small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan

2003
Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-15, Volume: 9, Issue:13

    Topics: Animals; Antibodies, Monoclonal; Blotting, Western; Body Weight; Bombesin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cell Division; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Flow Cytometry; Humans; Immunotherapy; Interferon-gamma; Lung Neoplasms; Mice; Mice, SCID; Models, Chemical; Monocytes; Neoplasm Transplantation; Paclitaxel; Protein Binding; Receptors, Bombesin; Thymidine

2003
Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls.
    Cancer, 2003, Nov-15, Volume: 98, Issue:10

    Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Treatment Outcome

2003
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT).
    Annals of hematology, 2004, Volume: 83, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Cisplatin; Etoposide; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Myelodysplastic Syndromes; Neoplasms, Germ Cell and Embryonal; Neoplasms, Second Primary; Paclitaxel

2004
Chemotherapeutic potential of plant alkaloids and multidrug resistance mechanisms in malignant fibrous histiocytoma of the heart.
    Oncology reports, 2004, Volume: 11, Issue:3

    Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Separation; Cell Survival; Cells, Cultured; Coloring Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Heart Neoplasms; Histiocytoma, Benign Fibrous; Humans; Inhibitory Concentration 50; Paclitaxel; Phenotype; Plant Extracts; Soft Tissue Neoplasms; Tetrazolium Salts; Thiazoles; Vault Ribonucleoprotein Particles; Vincristine

2004
Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.
    Gynecologic oncology, 2004, Volume: 92, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Doxorubicin; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Quality of Life; Topotecan

2004
Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:2

    Topics: Animals; Antibodies; Cadherins; Cell Cycle; Cell Line, Tumor; Drug Resistance; Etoposide; Fluorouracil; Humans; Mice; Neoplasms; Paclitaxel; Protein Kinase C; Protein Kinase C beta; Spheroids, Cellular; Vinblastine

2004
Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:3

    Topics: Acetophenones; Antineoplastic Agents, Phytogenic; Apoptosis; Benzopyrans; Blotting, Western; Carcinoma, Small Cell; Caspase 3; Caspase 9; Caspases; Cell Death; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Immunoblotting; Lung Neoplasms; Membrane Potentials; Mitochondria; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Time Factors

2004
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Cancer, 2004, Jun-15, Volume: 100, Issue:12

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan

2004
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
    Oncology reports, 2004, Volume: 12, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome

2004
Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Sep-15, Volume: 22, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Necrosis; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retroperitoneal Neoplasms; Retrospective Studies; Testicular Neoplasms

2004
Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet.
    The Journal of reproductive medicine, 2004, Volume: 49, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Salvage Therapy; Uterine Neoplasms

2004
Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway.
    Experimental cell research, 2005, Jan-15, Volume: 302, Issue:2

    Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; cdc25 Phosphatases; Cell Cycle; Cell Line, Transformed; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cisplatin; Cyclin E; DNA; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Flow Cytometry; Humans; Kinetics; Osteosarcoma; Paclitaxel; Protein Kinases; Protein Serine-Threonine Kinases; Radiation, Ionizing; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Ultraviolet Rays

2005
[Paclitaxel and cisplatin combined with etoposide chemotherapy in non-small cell lung cancer with brain metastases].
    Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:11 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate

2004
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Etoposide; Follow-Up Studies; Germany; Germinoma; Humans; Ifosfamide; Leukemia, Myeloid, Acute; Male; Mediastinal Neoplasms; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Testicular Neoplasms; Translocation, Genetic; Transplantation, Autologous

2005
Differential effects of RhoA signaling on anticancer agent-induced cell death.
    Oncology reports, 2005, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Death; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Lovastatin; Paclitaxel; rhoA GTP-Binding Protein; Signal Transduction; Transfection; Tumor Cells, Cultured; Vincristine

2005
Identification of a novel cardenolide (2''-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses.
    Journal of medicinal chemistry, 2005, Feb-10, Volume: 48, Issue:3

    Topics: Animals; Antineoplastic Agents; Calotropis; Camptothecin; Cardenolides; Cell Line, Tumor; Cell Proliferation; Cerebral Cortex; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Maximum Tolerated Dose; Mice; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Sodium-Potassium-Exchanging ATPase; Structure-Activity Relationship; Swine; Thiazoles

2005
Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6

    Topics: Androgens; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Drug Therapy, Combination; Enzyme Activation; Etoposide; Humans; JNK Mitogen-Activated Protein Kinases; Male; Organoselenium Compounds; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Tumor Cells, Cultured

2005
Sensitization for anticancer drug-induced apoptosis by betulinic Acid.
    Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Betulinic Acid; Caspases; Cells, Cultured; Cisplatin; Complement Membrane Attack Complex; Complement System Proteins; Cytochromes c; Dactinomycin; Doxorubicin; Drug Synergism; Enzyme Activation; Etoposide; Fibroblasts; Glycoproteins; Humans; Membrane Potentials; Mitochondria; Mutation; Neoplasms; Paclitaxel; Pentacyclic Triterpenes; Proto-Oncogene Proteins c-bcl-2; Triterpenes; Tumor Stem Cell Assay; Tumor Suppressor Protein p53

2005
Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.
    Journal of virology, 2005, Volume: 79, Issue:9

    Topics: Aphidicolin; Camptothecin; Cell Cycle; Cell Division; Cell Line; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; G2 Phase; HIV; HIV Infections; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Time Factors; Transduction, Genetic; Virus Replication

2005
Acquisition of anoikis resistance in human osteosarcoma cells does not alter sensitivity to chemotherapeutic agents.
    BMC cancer, 2005, Apr-13, Volume: 5

    Topics: Anoikis; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Separation; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Extracellular Matrix; Flow Cytometry; Humans; Hypoxia; Neoplasm Metastasis; Osteosarcoma; Paclitaxel; Propidium; Vinblastine

2005
NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-15, Volume: 11, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Peptide Fragments; Taxoids; Time Factors; Tissue Distribution; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays

2005
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
    International journal of cancer, 2005, Sep-20, Volume: 116, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line; Docetaxel; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Paclitaxel; Probenecid; Taxoids; Vinblastine

2005
The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Gynecologic oncology, 2005, Volume: 97, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Docetaxel; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Sex Cord-Gonadal Stromal Tumors; Taxoids

2005
Cytogenetic damage in lymphocytes of patients undergoing therapy for small cell lung cancer and ovarian carcinoma.
    Toxicology and applied pharmacology, 2005, Dec-01, Volume: 209, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Kinetics; Leukocyte Count; Lung Neoplasms; Lymphocytes; Male; Micronuclei, Chromosome-Defective; Micronucleus Tests; Middle Aged; Ovarian Neoplasms; Paclitaxel

2005
Effect of particle size of nanospheres and microspheres on the cellular-association and cytotoxicity of paclitaxel in 4T1 cells.
    Pharmaceutical research, 2005, Volume: 22, Issue:5

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Boron Compounds; Brain; Cattle; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Cyclosporine; Deoxyglucose; Drug Screening Assays, Antitumor; Endocytosis; Endothelium, Vascular; Etoposide; Lactic Acid; Microspheres; Nanotubes; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers

2005
Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce apoptosis.
    Apoptosis : an international journal on programmed cell death, 2005, Volume: 10, Issue:3

    Topics: Amaryllidaceae Alkaloids; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspases; Cells, Cultured; Etoposide; Fibroblasts; Humans; Intracellular Membranes; Isoquinolines; Mitochondria; Neuroblastoma; Paclitaxel; Permeability; Proteasome Endopeptidase Complex; Reactive Oxygen Species; Tumor Cells, Cultured

2005
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
    Mutation research, 2005, Jun-06, Volume: 583, Issue:2

    Topics: Animals; Area Under Curve; Azure Stains; Bone Marrow Cells; Chromosome Aberrations; Chromosome Painting; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Infusions, Intravenous; Macaca mulatta; Neutropenia; Paclitaxel; Thiotepa

2005
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Docetaxel; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Survival Rate; Taxoids

2005
Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-15, Volume: 11, Issue:12

    Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Cell Line, Tumor; Cell Survival; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gemcitabine; Genes, Tumor Suppressor; Humans; Mutation, Missense; Nuclear Proteins; Paclitaxel; Plasmids; Polymorphism, Genetic; Transfection; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vinblastine

2005
Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation.
    Molecular cancer research : MCR, 2005, Volume: 3, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Blotting, Western; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Etoposide; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Neoplasms; Paclitaxel; Phosphorus Radioisotopes; Phosphorylation; Piperazines; Precipitin Tests; Pyrimidines; RNA Helicases; RNA Interference; Stilbenes; Tumor Necrosis Factor-alpha

2005
Detection of numerical chromosomal aberrations by flow cytometry: a novel process for identifying aneugenic agents.
    Mutation research, 2005, Aug-01, Volume: 585, Issue:1-2

    Topics: Adult; Aneugens; Cells, Cultured; Chromosome Aberrations; Etoposide; Female; Flow Cytometry; Griseofulvin; Humans; Lymphocytes; Male; Mitomycin; Mitosis; Mutagenicity Tests; Paclitaxel; Polyploidy

2005
Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution.
    Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Creatinine; Cyclophosphamide; Decision Making; Etoposide; Female; Humans; Lung Neoplasms; Male; Medical Records; Middle Aged; Multiple Organ Failure; Neoplasm Staging; Paclitaxel; Platelet Count; Survival Rate; Treatment Outcome

2005
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Cancer research, 2005, Aug-01, Volume: 65, Issue:15

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan

2005
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
    Oncology reports, 2005, Volume: 14, Issue:4

    Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Bisbenzimidazole; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Neuronal Apoptosis-Inhibitory Protein; Paclitaxel; Phenotype; Prostatic Neoplasms; Survivin; Taxoids; Tetrazolium Salts; Time Factors; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein

2005
Induction of apoptotic cell death specifically in rat and human cancer cells by pancratistatin.
    Artificial cells, blood substitutes, and immobilization biotechnology, 2005, Volume: 33, Issue:3

    Topics: Amaryllidaceae Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Etoposide; Fibroblasts; Humans; Isoquinolines; Neoplasms; Paclitaxel; Rats

2005
Prophylactic cranial irradiation in limited-stage small-cell lung cancer: a retrospective analysis.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Hospitals, Community; Humans; Lung Neoplasms; Male; Middle Aged; North Dakota; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Treatment Refusal

2004
[Peritoneal dissemination of scirrhous type 4 gastric cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:10

    Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Etoposide; Female; Gastrectomy; Humans; Immunotherapy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur

2005
[Surgical treatment for locally advanced lung cancer; therapeutic response of induction chemotherapy and postoperative chemotherapy].
    Kyobu geka. The Japanese journal of thoracic surgery, 2005, Volume: 58, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Postoperative Period; Survival Rate

2005
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-15, Volume: 11, Issue:20

    Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Chlorambucil; Cisplatin; Cross-Linking Reagents; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Fanconi Anemia Complementation Group C Protein; Fanconi Anemia Complementation Group G Protein; Fanconi Anemia Complementation Group Proteins; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Melphalan; Mice; Mice, Nude; Mitomycin; Mutation; Paclitaxel; Pancreatic Neoplasms; Time Factors; Vinblastine; Xenograft Model Antitumor Assays

2005
[International study on testicular cancer: EORTC 30983: randomized phase II/III study of Taxol-BEP versus BEP in patients with Intermediate Prognosis Germ Cell Cancer].
    Der Urologe. Ausg. A, 2005, Volume: 44, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Etoposide; Humans; Internationality; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Randomized Controlled Trials as Topic; Testicular Neoplasms; Treatment Outcome

2005
Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Feb-01, Volume: 12, Issue:3 Pt 1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Etoposide; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oligoribonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Sensitivity and Specificity; Trastuzumab; Tumor Cells, Cultured

2006
Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs.
    Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Curcumin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Glutathione Transferase; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; Rhodamines; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Verapamil; Vinblastine

2006
Metastatic choriocarcinoma successfully treated with paclitaxel and carboplatin after interstitial lung disease induced by EMA-CO.
    Gynecologic oncology, 2006, Volume: 102, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Methotrexate; Paclitaxel; Uterine Neoplasms; Vincristine

2006
Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome

2006
[Current data concerning neoadjuvant chemotherapy].
    Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Humans; Ifosfamide; Lung; Lung Neoplasms; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk; Time Factors

2006
Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells.
    Journal of cellular biochemistry, 2006, Oct-15, Volume: 99, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Aorta; Cell Proliferation; Cells, Cultured; Etoposide; Fibroblasts; Humans; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Paclitaxel; Proto-Oncogene Proteins c-akt; Saphenous Vein; Tubulin Modulators

2006
Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death.
    Cell death and differentiation, 2007, Volume: 14, Issue:2

    Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain-Derived Neurotrophic Factor; Cell Death; Cisplatin; Down-Regulation; Enzyme Activation; Etoposide; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Membrane Proteins; Mitogen-Activated Protein Kinases; Molecular Mimicry; Neuroblastoma; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Isoforms; Proto-Oncogene Proteins; Receptor, trkB; RNA, Messenger; RNA, Small Interfering

2007
Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer.
    The Annals of thoracic surgery, 2006, Volume: 82, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Pleural Diseases; Pneumonectomy; Pneumonia; Pneumonia, Aspiration; Postoperative Complications; Pulmonary Embolism; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Tract Fistula; Retrospective Studies; Survival Analysis; Treatment Outcome

2006
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Drug Combinations; Etoposide; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur

2006
[Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2006, Jun-15, Volume: 44, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Child; Etoposide; Female; Follow-Up Studies; Humans; Male; Osteosarcoma; Oxides; Paclitaxel; Sarcoma, Ewing; Treatment Outcome

2006
Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
    International journal of cancer, 2006, Nov-15, Volume: 119, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Aurora Kinases; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; Female; Fluorescent Antibody Technique; Humans; Immunoblotting; Immunoprecipitation; Ovarian Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Tumor Suppressor Protein p53

2006
Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS.
    Biological chemistry, 2006, Volume: 387, Issue:8

    Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 9; Cell Line, Tumor; Etoposide; fas Receptor; Gene Expression Regulation, Neoplastic; Humans; Muscle Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Time Factors

2006
[Lung cancer with bone metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:8

    Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids

2006
[A non-seminomatous extra-gonadal germ cell tumor responding to intensive treatment: a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Retroperitoneal Neoplasms

2006
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:3

    Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan

2008
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-15, Volume: 12, Issue:18

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Interactions; Etoposide; Female; Humans; Liver; Male; Middle Aged; Models, Theoretical; Neutropenia; Neutrophils; Paclitaxel; Sex Characteristics; Taxoids; Topotecan

2006
DNA cleavage and Trp53 differentially affect SINE transcription.
    Genes, chromosomes & cancer, 2007, Volume: 46, Issue:3

    Topics: Antineoplastic Agents; Cisplatin; DNA Cleavage; DNA Damage; Etoposide; Genomic Instability; Humans; Paclitaxel; Short Interspersed Nucleotide Elements; Thiobarbiturates; Topoisomerase II Inhibitors; Transcription, Genetic; Tumor Suppressor Protein p53; Up-Regulation; Vincristine

2007
Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:12

    Topics: Amino Acid Chloromethyl Ketones; Amsacrine; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Enzyme Inhibitors; Etoposide; HL-60 Cells; Humans; Paclitaxel; Reactive Oxygen Species; Topoisomerase II Inhibitors; Tubulin Modulators; Vinblastine

2006
Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:12

    Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Etoposide; Fluorouracil; Humans; Male; Paclitaxel; Prostatic Neoplasms; RNA, Catalytic; Stathmin

2006
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
    Cancer science, 2007, Volume: 98, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Catechin; Cell Line, Tumor; Cell Survival; Cisplatin; Down-Regulation; Doxorubicin; Etoposide; Female; HeLa Cells; Humans; Inhibitor of Differentiation Protein 1; Liver Neoplasms; Male; Mechlorethamine; Methotrexate; Mitomycin; Nasopharyngeal Neoplasms; Paclitaxel; Prostatic Neoplasms; Vincristine

2007
Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells.
    Basic & clinical pharmacology & toxicology, 2007, Volume: 100, Issue:2

    Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Apoptosis; beta-Galactosidase; Capsid Proteins; Cell Line, Tumor; Cell Survival; DNA, Viral; Drug Synergism; Etoposide; Genetic Vectors; Humans; Paclitaxel; Transfection

2007
Data acquisition for the histoculture drug response assay in lung cancer.
    The Journal of thoracic and cardiovascular surgery, 2007, Volume: 133, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Probability; Retrospective Studies; Sensitivity and Specificity; Tumor Cells, Cultured

2007
Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.
    Biochimica et biophysica acta, 2007, Volume: 1770, Issue:4

    Topics: Anthracyclines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Survival; Cisplatin; Colchicine; Cytoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electrophoresis; Etoposide; Female; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Membrane Potentials; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Phenotype

2007
Ectopic Cushing's syndrome due to concurrent corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secreted by malignant gastrinoma.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2007, Volume: 115, Issue:1

    Topics: Adrenocorticotropic Hormone; Adult; Antineoplastic Combined Chemotherapy Protocols; Corticotropin-Releasing Hormone; Cushing Syndrome; Duodenal Neoplasms; Etoposide; Female; Gastrinoma; Humans; Hydrocortisone; Liver Neoplasms; Paclitaxel; Pancreatic Neoplasms

2007
Poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as polymeric emulsifier for the preparation of biodegradable nanoparticles.
    Journal of pharmaceutical sciences, 2007, Volume: 96, Issue:7

    Topics: Acetates; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Drug Compounding; Emulsifying Agents; Etoposide; Freeze Drying; Kinetics; Lactates; Magnesium Chloride; Methylene Chloride; Nanoparticles; Paclitaxel; Polyethylene Glycols; Polystyrenes; Polyvinyls; Solubility; Solvents; Technology, Pharmaceutical; Water

2007
[Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:4

    Topics: Adult; Antineoplastic Agents; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Cell Survival; Cells, Cultured; Cisplatin; Cyclophosphamide; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms

2007
[Outpatient chemotherapy for lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:4

    Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine

2007
Bcl-2 gene silencing in pediatric epithelial liver tumors.
    The Journal of surgical research, 2008, Volume: 144, Issue:1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Child; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelium; Etoposide; Gene Silencing; Genetic Therapy; Humans; Liver Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Transfection

2008
XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics.
    Cancer biology & therapy, 2007, Volume: 6, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Paclitaxel; RNA Interference; X-Linked Inhibitor of Apoptosis Protein

2007
Developmental chemotherapy and management of recurrent ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10 Suppl

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

2003
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:7

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Docetaxel; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine

2007
[Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Survival Rate

2007
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    International journal of cancer, 2007, Dec-01, Volume: 121, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Biphenyl Compounds; Butylated Hydroxytoluene; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Electrophoresis; Etoposide; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Nitrophenols; Paclitaxel; Permeability; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides

2007
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
    Molecular immunology, 2008, Volume: 45, Issue:5

    Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Cell Line, Tumor; Etoposide; Female; Gene Expression Regulation; Humans; Paclitaxel; T-Lymphocytes

2008
Activation of Cdc2 contributes to apoptosis in HPV E6 expressing human keratinocytes in response to therapeutic agents.
    Journal of molecular biology, 2007, Nov-23, Volume: 374, Issue:2

    Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; CDC2 Protein Kinase; Cells, Cultured; DNA Primers; Enzyme Activation; Etoposide; Flow Cytometry; Humans; Immunoblotting; Keratinocytes; Oncogene Proteins, Viral; Paclitaxel; Proteomics; Repressor Proteins; RNA, Small Interfering; Transformation, Genetic; Tumor Suppressor Protein p53

2007
Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Gynecologic oncology, 2008, Volume: 108, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate

2008
Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
    Cancer biology & therapy, 2008, Volume: 7, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D; Cyclins; Cyclophosphamide; Doxorubicin; Drug Synergism; Etoposide; Gossypol; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Prednisolone; Tumor Suppressor Protein p53; Vincristine

2008
Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience.
    The Journal of reproductive medicine, 2007, Volume: 52, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Dactinomycin; Etoposide; Female; Humans; Hydatidiform Mole; Korea; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Prospective Studies; Registries; Retrospective Studies; Risk Factors; Salvage Therapy; Severity of Illness Index; Uterine Neoplasms

2007
The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
    The Canadian journal of urology, 2007, Volume: 14, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bleomycin; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Humans; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Secondary Prevention; Testicular Neoplasms; Treatment Outcome

2007
Germ-cell tumors.
    The New England journal of medicine, 2007, Oct-25, Volume: 357, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Remission Induction; Salvage Therapy; Testicular Neoplasms

2007
[Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].
    Orvosi hetilap, 2007, Dec-09, Volume: 148, Issue:49

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan; Treatment Outcome

2007
Lipid nanocapsules for intracellular drug delivery of anticancer drugs.
    Journal of nanoscience and nanotechnology, 2007, Volume: 7, Issue:12

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Etoposide; Humans; Lipids; Microscopy, Confocal; Nanocapsules; Paclitaxel

2007
Ornithine decarboxylase attenuates leukemic chemotherapy drugs-induced cell apoptosis and arrest in human promyelocytic HL-60 cells.
    Leukemia research, 2008, Volume: 32, Issue:10

    Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cisplatin; Etoposide; Glutathione; HL-60 Cells; Humans; Leukemia; Membrane Potential, Mitochondrial; Ornithine Decarboxylase; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Putrescine; Reactive Oxygen Species

2008
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infections; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Premedication; Retrospective Studies; Transplantation, Autologous

2008
Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Gestational Trophoblastic Disease; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis

2008
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Cancer, 2008, Sep-15, Volume: 113, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome

2008
S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3.
    Oncology reports, 2008, Volume: 20, Issue:2

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Calcium-Binding Proteins; Cell Proliferation; Epirubicin; Etoposide; Female; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tumor Cells, Cultured

2008
Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop.
    Journal of cellular and molecular medicine, 2009, Volume: 13, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cathepsin D; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Immunoblotting; Lysosomes; Membrane Potential, Mitochondrial; Microscopy, Fluorescence; Ovarian Neoplasms; Paclitaxel; Protein Transport; RNA Interference; Signal Transduction

2009
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Down-Regulation; Doxorubicin; Etoposide; Female; Fluorescent Antibody Technique; Fluorouracil; Genes, p53; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Protein Kinases; Pyrazines; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays

2008
Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
    Pediatric blood & cancer, 2008, Volume: 51, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Neuroblastoma; Paclitaxel; Survival Rate; Topotecan; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult

2008
Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
    International journal of radiation oncology, biology, physics, 2009, Mar-01, Volume: 73, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; ROC Curve; Small Cell Lung Carcinoma; Tumor Burden; Vinblastine; Vinorelbine

2009
Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol.
    Biological chemistry, 2008, Volume: 389, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cisplatin; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Paclitaxel; RNA, Messenger

2008
Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation.
    Onkologie, 2008, Volume: 31, Issue:8-9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome

2008
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-15, Volume: 14, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays

2008
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
    Oncology, 2009, Volume: 76, Issue:5

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine

2009
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Infusions, Parenteral; Interferon alpha-2; Interferon-alpha; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Retrospective Studies; Survival Analysis; Thiotepa

2009
Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms.
    Toxicological sciences : an official journal of the Society of Toxicology, 2009, Volume: 110, Issue:2

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromosome Aberrations; Cisplatin; Cluster Analysis; DNA Adducts; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Gene Expression Profiling; Gene Expression Regulation; Humans; Laboratories; Mutagenicity Tests; Mutagens; Observer Variation; Paclitaxel; Polymerase Chain Reaction; Reproducibility of Results; Risk Assessment; Sodium Chloride; Spindle Apparatus; Time Factors

2009
Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs.
    Journal of experimental & clinical cancer research : CR, 2009, May-27, Volume: 28

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Doxorubicin; Drug Resistance, Neoplasm; Esophageal Neoplasms; Etoposide; Fluorouracil; Humans; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured; X-Rays

2009
The stage of offspring of female rats after treatment with cytostatics of various groups.
    Bulletin of experimental biology and medicine, 2008, Volume: 146, Issue:4

    Topics: Animals; Carboplatin; Cisplatin; Cytostatic Agents; Drug Administration Schedule; Epirubicin; Etoposide; Female; Male; Paclitaxel; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Time Factors

2008
[Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Topotecan

2009
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan

2010
The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy.
    The Annals of thoracic surgery, 2009, Volume: 88, Issue:3

    Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Pulmonary Diffusing Capacity; Radiotherapy Dosage; Retrospective Studies

2009
A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease.
    International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome

2010
Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Molecular cancer research : MCR, 2009, Volume: 7, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; STAT5 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Transfection

2009
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine

2010
Proproliferative functions of Drosophila small mitochondrial heat shock protein 22 in human cells.
    The Journal of biological chemistry, 2010, Feb-05, Volume: 285, Issue:6

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Drosophila Proteins; Drug Resistance, Neoplasm; Etoposide; Female; Fibroblasts; Heat-Shock Proteins; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondrial Proteins; Neoplasms, Experimental; Nocodazole; Paclitaxel; Transfection; Transplantation, Heterologous; Tumor Suppressor Protein p53

2010
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis: how much is it true?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Paclitaxel; Preoperative Care; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome

2010
[Case of far-advanced retroperitoneal extra-gonadal germ cell tumor responding to intensive treatment including multi-drug chemotherapy with peripheral blood stem cell transplantation and residual tumor removal].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2010, Volume: 101, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Lymph Node Excision; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Retroperitoneal Neoplasms; Treatment Outcome

2010
Protection of p53 wild type cells from taxol by genistein in the combined treatment of lung cancer.
    Nutrition and cancer, 2010, Volume: 62, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Genistein; Humans; Lung Neoplasms; Paclitaxel; Tumor Suppressor Protein p53

2010
Discovering breast cancer drug candidates from biomedical literature.
    International journal of data mining and bioinformatics, 2010, Volume: 4, Issue:3

    Topics: Antineoplastic Agents; Breast Neoplasms; Data Mining; Doxorubicin; Drug Discovery; Etoposide; Female; Humans; Internet; MEDLINE; Paclitaxel; Publications

2010
MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
    The Prostate, 2010, Oct-01, Volume: 70, Issue:14

    Topics: 3' Untranslated Regions; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Etoposide; Humans; Male; MicroRNAs; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sirtuin 1; Tumor Suppressor Protein p53

2010
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
    Toxicology in vitro : an international journal published in association with BIBRA, 2010, Volume: 24, Issue:8

    Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan

2010
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
    Oncology reports, 2010, Volume: 24, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide

2010
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cell Proliferation; Deoxycytidine; Etoposide; Female; France; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Paclitaxel; Platelet Count; Prospective Studies; Risk Assessment; Risk Factors; Thrombocytopenia; Young Adult

2010
Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells.
    Clinical & experimental metastasis, 2011, Volume: 28, Issue:1

    Topics: Breast Neoplasms; Cell Fusion; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial Cells; Etoposide; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Humans; Hybrid Cells; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Structure-Activity Relationship; Tumor Cells, Cultured

2011
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
    Anticancer research, 2010, Volume: 30, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine

2010
Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide for patients with relapsed primary mediastinal nonseminomatous germ cell tumors: benefit from chemotherapy, surgery, or both?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-10, Volume: 28, Issue:35

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Humans; Mediastinal Neoplasms; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Testicular Neoplasms

2010
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2011
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:11

    Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan

2010
Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation.
    Cell biology international, 2011, Volume: 35, Issue:7

    Topics: Autophagy; Cell Line, Tumor; Chromatin; Chromatin Assembly and Disassembly; DNA Fragmentation; DNA Replication; Etoposide; Gamma Rays; Genome, Human; Homeodomain Proteins; Humans; Mitosis; Nanog Homeobox Protein; Neoplasms; Octamer Transcription Factor-3; Paclitaxel; Ploidies; Tumor Suppressor Protein p53

2011
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-01, Volume: 29, Issue:16

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Databases, Factual; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Thiotepa; Vinblastine; Young Adult

2011
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
    Gynecologic oncology, 2011, Volume: 122, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome

2011
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
    Cancer letters, 2011, Aug-01, Volume: 307, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Endonucleases; Etoposide; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinolines; Receptor, Fibroblast Growth Factor, Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2011
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome

2011
Sequential or concomitant chemotherapy in limited stage small-cell lung cancer.
    Swiss medical weekly, 2011, Volume: 141

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome

2011
Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Small Cell Lung Carcinoma; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome

2011
Fertility sparing surgery for ovarian tumors in children and young adults.
    Archives of gynecology and obstetrics, 2012, Volume: 285, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Chemotherapy, Adjuvant; Child; Cisplatin; Etoposide; Female; Fertility Preservation; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Ovarian Cysts; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prospective Studies; Young Adult

2012
Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms.
    PloS one, 2011, Volume: 6, Issue:9

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Etoposide; Fluorescent Antibody Technique; Humans; Hyaluronan Receptors; Immunoblotting; Male; Mice; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Retinoblastoma-Binding Protein 2; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine

2011
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed

2011
Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
    Journal of experimental & clinical cancer research : CR, 2011, Oct-05, Volume: 30

    Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Asparaginase; Bayes Theorem; Data Mining; Docetaxel; Drug Hypersensitivity; Etoposide; Humans; Paclitaxel; Pharmacovigilance; Procarbazine; Prognosis; Taxoids; Teniposide; United States; United States Food and Drug Administration

2011
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
    Genes & development, 2011, Dec-01, Volume: 25, Issue:23

    Topics: Animals; Antineoplastic Agents; Cathepsins; Cell Line, Tumor; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Etoposide; Female; Lung Neoplasms; Macrophages; Mammary Neoplasms, Animal; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neoplasm Invasiveness; Paclitaxel

2011
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil

2012
Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cisplatin; Etoposide; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Muscle Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms

2012
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2011, Volume: 12, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured

2011
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate

2012
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Synergism; Etoposide; Humans; Immunoblotting; Lung Neoplasms; Paclitaxel; Protein Kinase C; Signal Transduction; Staurosporine; Time Factors

2012
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.
    Cell cycle (Georgetown, Tex.), 2012, May-15, Volume: 11, Issue:10

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma; Cell Differentiation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Female; Fluorescent Antibody Technique, Indirect; Humans; Mesenchymal Stem Cells; Neoplasm Proteins; Neoplastic Stem Cells; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured

2012
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
    European journal of gynaecological oncology, 2012, Volume: 33, Issue:3

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids

2012
The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth.
    Oncology reports, 2012, Volume: 28, Issue:4

    Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Reference Values; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase Inhibitors; Topotecan; Ubiquitin-Conjugating Enzymes; Uterine Cervical Neoplasms

2012
Synergistic increase in the sensitivity of osteosarcoma cells to thermochemotherapy with combination of paclitaxel and etoposide.
    Molecular medicine reports, 2012, Volume: 6, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Etoposide; fas Receptor; Humans; Osteosarcoma; Paclitaxel; Temperature

2012
TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells.
    BMC cancer, 2012, Sep-06, Volume: 12

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Cells, Cultured; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Keratinocytes; Liver Neoplasms; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcriptome

2012
[Sensitivity to chemotherapeutic drugs of polyploid tumor cells induced by a spindle poison nocodazole].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Fluorouracil; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Nocodazole; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyploidy; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Taxoids; Vincristine

2012
Characterization of the low pH/low nutrient-resistant LNCaP cell subline LNCaP-F10.
    Oncology reports, 2012, Volume: 28, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Death-Associated Protein Kinases; DNA Fragmentation; Docetaxel; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin; Taxoids; Transplantation, Heterologous

2012
Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion.
    Cellular oncology (Dordrecht), 2012, Volume: 35, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cholesterol, LDL; Drug Delivery Systems; Etoposide; Fat Emulsions, Intravenous; Female; Flow Cytometry; Injections, Intraperitoneal; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanoparticles; Paclitaxel

2012
Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells.
    BMC cancer, 2012, Oct-12, Volume: 12

    Topics: Actins; Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Movement; Cisplatin; Cytoskeleton; Etoposide; Guanine Nucleotide Exchange Factors; Humans; Myosin Light Chains; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Rho Guanine Nucleotide Exchange Factors; rho-Associated Kinases; rhoA GTP-Binding Protein; Stomach Neoplasms; Vincristine

2012
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cardiovascular Diseases; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Quality of Life; Stem Cell Transplantation; Surveys and Questionnaires; Survivors; Treatment Outcome; Young Adult

2013
Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.
    Cancer science, 2013, Volume: 104, Issue:1

    Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Anthracyclines; Antigens, CD; Biomarkers, Tumor; Camptothecin; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Glycoproteins; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Paclitaxel; Peptides; Receptors, Urokinase Plasminogen Activator; Retinal Dehydrogenase; RNA, Messenger; Small Cell Lung Carcinoma

2013
Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
    Circulation, 2012, Oct-30, Volume: 126, Issue:18

    Topics: Adrenal Cortex Hormones; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Delayed Diagnosis; Diagnostic Errors; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Heart Neoplasms; Hemangiosarcoma; Humans; Ifosfamide; Indazoles; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Myocardium; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Pericarditis; Pericardium; Protein Kinase Inhibitors; Pulmonary Embolism; Pyrimidines; Remission Induction; Sulfonamides; Vincristine

2012
The 2002 AJCC TNM classification is a better predictor of primary small cell esophageal carcinoma outcome than the VALSG staging system.
    Chinese journal of cancer, 2013, Volume: 32, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Etoposide; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, High-Energy; Retrospective Studies; Societies, Medical; Survival Rate; United States

2013
Treatment update in small-cell lung cancer: from limited to extensive disease.
    Current treatment options in oncology, 2012, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Topotecan

2012
Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Line, Tumor; DNA Damage; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Models, Biological; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Tumor Suppressor Protein p53

2012
Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer.
    European journal of gynaecological oncology, 2012, Volume: 33, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doxorubicin; Endometrial Neoplasms; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel

2012
Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy.
    Diagnostic pathology, 2012, Nov-27, Volume: 7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Neuroendocrine; Cystectomy; Etoposide; Female; Gallbladder Neoplasms; Hepatectomy; Humans; Immunohistochemistry; Liver Neoplasms; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasms, Complex and Mixed; Octreotide; Paclitaxel; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2012
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
    Anti-cancer drugs, 2013, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Leucovorin; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms

2013
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Paclitaxel; Small Cell Lung Carcinoma; Tumor Cells, Cultured

2013
Outcomes of combined modality therapy for patients with stage III or IV mediastinal malignant germ cell tumors.
    Surgery today, 2014, Volume: 44, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Thoracic Surgical Procedures; Time Factors; Treatment Outcome; Young Adult

2014
Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs.
    International journal of cancer, 2013, Oct-15, Volume: 133, Issue:8

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Cell Line, Tumor; Doxorubicin; Enzyme Activation; Etoposide; Fluorouracil; Hodgkin Disease; Humans; Interleukin-13; Interleukin-4; Mitomycin; Paclitaxel; Promoter Regions, Genetic; Reed-Sternberg Cells; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT6 Transcription Factor

2013
[Analysis of drug therapy of lung cancer in Hungary].
    Magyar onkologia, 2013, Volume: 57, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan

2013
[Neuroendocrine tumors: analysis of 252 cases].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoid Tumor; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Cisplatin; Digestive System Neoplasms; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Retrospective Studies; Sex Factors; Survival Rate; Young Adult

2013
Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature.
    World journal of surgical oncology, 2013, Jun-05, Volume: 11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Etoposide; Female; Humans; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Review Literature as Topic

2013
Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stage IIB cervical cancer?
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms

2013
CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo.
    Oncology reports, 2013, Volume: 30, Issue:4

    Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Furans; HSP90 Heat-Shock Proteins; Humans; Indazoles; Mice; Mice, SCID; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Pyrazoles; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2013
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate

2013
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recurrence; Retreatment; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult

2013
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
    Oncology, 2013, Volume: 85, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome

2013
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
    Cancer medicine, 2013, Volume: 2, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel

2013
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Endocrine-related cancer, 2014, Volume: 21, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Mitotane; Paclitaxel; Polyethylene Glycols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
[Salvage therapy for castration-refractory prostate cancer resistant to docetaxel].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2013, Volume: 104, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Streptonigrin; Taxoids; Tegafur; Uracil

2013
Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients.
    BMC cancer, 2014, Feb-27, Volume: 14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Uterine Cervical Neoplasms; Young Adult

2014
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
    European journal of gynaecological oncology, 2013, Volume: 34, Issue:6

    Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2013
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:5

    Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine

2014
Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs.
    Cancer letters, 2014, Aug-01, Volume: 350, Issue:1-2

    Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Etoposide; Female; Fulvestrant; Humans; MCF-7 Cells; Paclitaxel; Proto-Oncogene Proteins c-mdm2; Receptors, Estrogen; RNA, Messenger; Tumor Suppressor Protein p53

2014
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
    American journal of clinical oncology, 2015, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chest Pain; Cohort Studies; Cough; Dyspnea; Esophagitis; Etoposide; Female; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Pemetrexed; Radiation Injuries; Radiation Pneumonitis; Retrospective Studies; Treatment Outcome

2015
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
    Breast cancer research : BCR, 2014, May-30, Volume: 16, Issue:3

    Topics: Alternative Splicing; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; High-Throughput Screening Assays; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Naphthoquinones; Paclitaxel; Receptor, ErbB-2; Survivin; Tumor Suppressor Protein p53

2014
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:1

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Mammaplasty; Mastectomy, Subcutaneous; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Perforator Flap; Retrospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Young Adult

2015
The predominant role of apoptosis in γH2AX formation induced by aneugens is useful for distinguishing aneugens from clastogens.
    Mutation research. Genetic toxicology and environmental mutagenesis, 2014, Sep-01, Volume: 771

    Topics: Aneugens; Apoptosis; Cells, Cultured; DNA Damage; Etoposide; Histones; Humans; Micronucleus Tests; Mitomycin; Mutagens; Paclitaxel; Vinblastine

2014
Attempted conservative management of a placental site trophoblastic tumor: a case report.
    Connecticut medicine, 2014, Volume: 78, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Lymph Node Excision; Methotrexate; Paclitaxel; Pregnancy; Trophoblastic Tumor, Placental Site; Uterine Neoplasms; Vincristine

2014
Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Feb-20, Volume: 33, Issue:6

    Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; United States; United States Department of Veterans Affairs

2015
Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer.
    Clinical breast cancer, 2015, Volume: 15, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy

2015
Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2014, Volume: 97 Suppl 11

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Quality of Life

2014
The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Prognosis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Remission Induction; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms

2015
MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Current cancer drug targets, 2015, Volume: 15, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Sorafenib

2015
Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
    The Journal of veterinary medical science, 2015, Volume: 77, Issue:6

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Dog Diseases; Dogs; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Histiocytic Sarcoma; Melphalan; Methotrexate; Nimustine; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vincristine

2015
Education and imaging. Gastrointestinal: Gastric involvement in disseminated lymphadenopathic Kaposi sarcoma.
    Journal of gastroenterology and hepatology, 2015, Volume: 30, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Doxorubicin; Endoscopy, Digestive System; Etoposide; Humans; Interferons; Male; Paclitaxel; Palliative Care; Sarcoma, Kaposi; Stomach Neoplasms

2015
Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.
    Oncotarget, 2015, Apr-20, Volume: 6, Issue:11

    Topics: Animals; Apoptosis; Binding Sites; Binding, Competitive; Carbolines; Cell Line, Tumor; Colchicine; Colonic Neoplasms; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Superhelical; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Metaphase; Mice; Mice, Nude; Microtubules; Molecular Structure; Neoplasm Proteins; Paclitaxel; Topoisomerase II Inhibitors; Tubulin; Tubulin Modulators; Vincristine

2015
Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma.
    Journal of nanobiotechnology, 2015, Mar-21, Volume: 13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Carriers; Etoposide; Humans; Lactic Acid; Nanoparticles; Osteosarcoma; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer

2015
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
    Journal of oncology practice, 2015, Volume: 11, Issue:4

    Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine

2015
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
    Journal of immunology (Baltimore, Md. : 1950), 2015, Jul-15, Volume: 195, Issue:2

    Topics: Adoptive Transfer; Animals; Cisplatin; Cyclophosphamide; Cytotoxins; Deoxycytidine; Drug Resistance; Etoposide; Female; Fibrosarcoma; Gemcitabine; Lymph Nodes; Lymphocyte Depletion; Lymphopenia; Methylcholanthrene; Mice; Mice, Inbred C57BL; Mice, Knockout; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Vidarabine; Whole-Body Irradiation

2015
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
    The International journal of biological markers, 2015, Nov-11, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine

2015
Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
    International journal of clinical oncology, 2016, Volume: 21, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Camptothecin; Cisplatin; Etoposide; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Retreatment; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult

2016
Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer.
    American journal of clinical oncology, 2017, Volume: 40, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Etoposide; Female; Hemoglobins; Humans; Leukopenia; Logistic Models; Lung Neoplasms; Lymphopenia; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Severity of Illness Index; Survival Rate; Taxoids; Thrombocytopenia

2017
Effects and toxicity of neoadjuvant chemotherapy preoperative followed by adjuvant chemoradiation in small cell neurdendocrine cervical carcinoma.
    European journal of gynaecological oncology, 2015, Volume: 36, Issue:3

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Female; Hepatic Insufficiency; Humans; Hysterectomy; Ifosfamide; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Renal Insufficiency; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms; Vincristine

2015
Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    American journal of clinical oncology, 2015, Volume: 38, Issue:4

    Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Remission Induction; Retroperitoneal Neoplasms; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Testicular Neoplasms; Treatment Outcome

2015
MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300.
    Oncology reports, 2016, Volume: 35, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Breast; Cadherins; Cell Line, Transformed; Colchicine; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; E1A-Associated p300 Protein; Epithelial Cells; Etoposide; Gamma Rays; Humans; MicroRNAs; Multigene Family; Neoplasm Proteins; Paclitaxel; Phenotype; RNA, Neoplasm; Transduction, Genetic; Tumor Stem Cell Assay

2016
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Retrospective Studies; Taxoids

2016
A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen.
    Bone marrow transplantation, 2016, Volume: 51, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Prognosis; Prospective Studies; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome; Young Adult

2016
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Biochimica et biophysica acta, 2016, Volume: 1860, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice, SCID; MicroRNAs; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quercetin; Receptor, Notch1; Signal Transduction; Sorafenib; Transfection; Xenograft Model Antitumor Assays

2016
α-Lipoic acid sensitizes lung cancer cells to chemotherapeutic agents and anoikis via integrin β1/β3 downregulation.
    International journal of oncology, 2016, Volume: 49, Issue:4

    Topics: Anoikis; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Down-Regulation; Drug Synergism; Drug Therapy; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Integrin beta1; Integrin beta3; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Reactive Oxygen Species; Thioctic Acid

2016
Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules.
    Pharmaceutical research, 2016, Volume: 33, Issue:11

    Topics: Amines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; Drug Interactions; Etoposide; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Mice, Nude; Micelles; N-Acetylneuraminic Acid; Nanoparticles; Paclitaxel; Particle Size; Solubility; Surface Properties; Surface-Active Agents

2016
A Case of Mixed Germ Cell Tumor in the Intramedullary Spinal-cord.
    The Tokai journal of experimental and clinical medicine, 2016, Sep-20, Volume: 41, Issue:3

    Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bleomycin; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Guillain-Barre Syndrome; Humans; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Paraplegia; Spinal Cord Neoplasms; Tomography, X-Ray Computed

2016
Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transitional Cell; Choriocarcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pelvic Neoplasms; Remission Induction; Ureteral Neoplasms

2017
Complete response to paclitaxel, ifosfamide, and cisplatin therapy in a case of ovarian ependymoma.
    The journal of obstetrics and gynaecology research, 2016, Volume: 42, Issue:11

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Ependymoma; Etoposide; Female; Humans; Ifosfamide; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Treatment Outcome; Young Adult

2016
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.
    Genome medicine, 2016, 10-31, Volume: 8, Issue:1

    Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Mutational Analysis; Etoposide; Fatal Outcome; Genomics; Humans; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Paclitaxel; Rare Diseases; Scalp; Xenograft Model Antitumor Assays

2016
Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
    Respiratory investigation, 2017, Volume: 55, Issue:2

    Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; Etoposide; Feasibility Studies; Female; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Respiratory Insufficiency; Retrospective Studies; Tegafur

2017
Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report.
    Journal of medical case reports, 2017, Apr-11, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Fluid Therapy; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Rhabdomyolysis; Testicular Neoplasms; Transplantation, Autologous; Treatment Outcome; Young Adult

2017
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
    The European respiratory journal, 2017, Volume: 49, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine

2017
Induced Aneugenic Effects in Mouse Oocytes In Vivo.
    Bulletin of experimental biology and medicine, 2017, Volume: 163, Issue:4

    Topics: Aneugens; Aneuploidy; Animals; Cisplatin; Colchicine; Doxorubicin; Etoposide; Melphalan; Mice; Oocytes; Paclitaxel; Polyploidy

2017
Polymer-lipid hybrid nanoparticles-based paclitaxel and etoposide combinations for the synergistic anticancer efficacy in osteosarcoma.
    Colloids and surfaces. B, Biointerfaces, 2017, Nov-01, Volume: 159

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Etoposide; Humans; Nanoparticles; Osteosarcoma; Paclitaxel; Polymers

2017
Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 09-01, Volume: 28, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel

2017
Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 12-01, Volume: 28, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Survival Analysis

2017
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
    Medicine, 2017, Volume: 96, Issue:42

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome

2017
Simultaneous LC-MS/MS bioanalysis of etoposide and paclitaxel in mouse tissues and plasma after oral administration of self-microemulsifying drug-delivery systems.
    Biomedical chromatography : BMC, 2018, Volume: 32, Issue:6

    Topics: Administration, Oral; Animals; Chromatography, Liquid; Drug Delivery Systems; Drug Stability; Emulsions; Etoposide; Linear Models; Male; Mice; Paclitaxel; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tissue Distribution

2018
Re: Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients with Intermediate- or Poor-Risk Germ Cell Tumors.
    The Journal of urology, 2017, Volume: 198, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Ifosfamide; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Testicular Neoplasms; Treatment Outcome

2017
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
    International journal of radiation oncology, biology, physics, 2018, 03-01, Volume: 100, Issue:3

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Organs at Risk; Paclitaxel; Probability; Radiation Dosage; Retrospective Studies; ROC Curve; Small Cell Lung Carcinoma; Thoracic Vertebrae

2018
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
    Thoracic cancer, 2018, Volume: 9, Issue:5

    Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome

2018
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
    Medical oncology (Northwood, London, England), 2018, Apr-02, Volume: 35, Issue:5

    Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate

2018
Successful chemotherapeutic treatment for metastatic littoral cell angioma: A case report.
    Medicine, 2018, Volume: 97, Issue:15

    Topics: Antineoplastic Agents, Phytogenic; Biopsy; Cytotoxins; Etoposide; Female; Fluorodeoxyglucose F18; Hemangioma; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Middle Aged; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals; Splenectomy; Splenic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Vincristine

2018
Autologous stem-cell transplant for metastatic renal medullary carcinoma.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:9

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Doxorubicin; Etoposide; Humans; Ifosfamide; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Sickle Cell Trait; Transplantation, Autologous

2018
Paclitaxel and etoposide-loaded Poly (lactic-co-glycolic acid) microspheres fabricated by coaxial electrospraying for dual drug delivery.
    Journal of biomaterials science. Polymer edition, 2018, Volume: 29, Issue:16

    Topics: Antineoplastic Agents, Phytogenic; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Interactions; Drug Liberation; Etoposide; Humans; Microspheres; Paclitaxel; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer

2018
The clinical conundrum of managing relapsed small cell lung cancer.
    Cancer, 2019, 04-01, Volume: 125, Issue:7

    Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan

2019
Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma.
    The oncologist, 2019, Volume: 24, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate

2019
Structure-Activity Relationships of Cytotoxic Lactones as Inhibitors and Mechanisms of Action.
    Current drug discovery technologies, 2020, Volume: 17, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Sesquiterpenes; Structural Homology, Protein; Structure-Activity Relationship; Topotecan; Tubulin; Tubulin Modulators

2020
Potentialization of anticancer agents by identification of new chemosensitizers active under hypoxia.
    Biochemical pharmacology, 2019, Volume: 162

    Topics: Antineoplastic Agents; Apoptosis; Cell Hypoxia; DNA Fingerprinting; Drug Synergism; Etoposide; Hep G2 Cells; Humans; Paclitaxel; Thiosemicarbazones

2019
Outcomes of fertility-sparing surgery in ovarian juvenile granulosa cell tumor.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2019, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Child; Cisplatin; Etoposide; Female; Fertility Preservation; Granulosa Cell Tumor; Humans; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome; Young Adult

2019
Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands.
    Current drug discovery technologies, 2020, Volume: 17, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-myb; Sesquiterpenes; Structure-Activity Relationship; Topotecan

2020
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 01-01, Volume: 26, Issue:1

    Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Neoplasm Staging; NF-E2-Related Factor 2; Paclitaxel; Prognosis; Spheroids, Cellular; Survival Rate

2020
Correction of Damaging Effects of Cisplatin-Containing Polychemotherapy on the Intestinal Epithelium with Tussilago farfara L. Polysaccharides.
    Bulletin of experimental biology and medicine, 2019, Volume: 167, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cisplatin; Eosine Yellowish-(YS); Etoposide; Female; Hematoxylin; Histocytochemistry; Intestinal Mucosa; Irinotecan; Mice; Mice, Inbred C57BL; Paclitaxel; Plant Extracts; Polysaccharides; Tussilago

2019
Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020, Volume: 196, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Logistic Models; Lung; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Respiratory Function Tests; Retrospective Studies; Risk; ROC Curve; Sensitivity and Specificity; Severity of Illness Index

2020
Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate

2020
Overcoming the diverse mechanisms of multidrug resistance in lung cancer cells by photodynamic therapy using pTHPP-loaded PLGA-lipid hybrid nanoparticles.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2020, Volume: 149

    Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Lipids; Lung Neoplasms; Nanoparticles; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Polylactic Acid-Polyglycolic Acid Copolymer; Porphyrins

2020
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
    Clinical lung cancer, 2020, Volume: 21, Issue:3

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase II as Topic; Consolidation Chemotherapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate

2020
Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
    BMC cancer, 2020, Apr-06, Volume: 20, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase III as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate

2020
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer.
    European journal of cancer care, 2020, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan

2020
Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
    BMC cancer, 2020, May-26, Volume: 20, Issue:1

    Topics: A549 Cells; Adenocarcinoma of Lung; Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Apoptosis; Autophagy; Calreticulin; Carboplatin; Caspase 3; Cell Survival; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; HMGB1 Protein; Humans; Immunogenic Cell Death; Lung Neoplasms; Paclitaxel; Prognosis

2020
Cisplatin, Gemcitabine, and Paclitaxel as a Salvage Second-Line Therapy for Metastatic Germ-Cell Cancer.
    Clinical genitourinary cancer, 2021, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Treatment Outcome

2021
Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer.
    International journal of clinical oncology, 2020, Volume: 25, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome

2020
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    BMC pharmacology & toxicology, 2020, 10-06, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Capecitabine; Carboplatin; Dexamethasone; Etoposide; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Oxaliplatin; Paclitaxel; Pre-Exposure Prophylaxis; Serotonin 5-HT3 Receptor Antagonists; Vomiting

2020
Placental site trophoblastic tumour: five challenges of patient clinical management.
    BMJ case reports, 2021, Jan-28, Volume: 14, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chorionic Gonadotropin; Cisplatin; Consolidation Chemotherapy; Dactinomycin; Etoposide; Female; Humans; Hysterectomy; Lung Neoplasms; Lymph Node Excision; Methotrexate; Paclitaxel; Pregnancy; Puerperal Disorders; Salpingectomy; Trophoblastic Tumor, Placental Site; Uterine Neoplasms

2021
Effect of Paclitaxel/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma.
    International journal of pharmaceutics, 2021, Jul-15, Volume: 604

    Topics: Animals; Cell Line, Tumor; Drug Carriers; Etoposide; Glioblastoma; Nanoparticles; Paclitaxel; Polyethylene Glycols; Rats; Survival Rate

2021
Therapeutic strategy analysis of patients with advanced stage high-grade neuroendocrine cervical cancer: A real-world multicenter study.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2022, Volume: 158, Issue:3

    Topics: Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Uterine Cervical Neoplasms

2022
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens.
    Cancer medicine, 2022, Volume: 11, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Liver Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Thymoma; Thymus Neoplasms

2022
Self-emulsifying Drug Delivery System for Oral Anticancer Therapy: Constraints and Recent Development.
    Current pharmaceutical design, 2022, Volume: 28, Issue:31

    Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Chemistry, Pharmaceutical; Docetaxel; Doxorubicin; Drug Delivery Systems; Emulsions; Etoposide; Fluorouracil; Humans; Paclitaxel; Solubility; Surface-Active Agents

2022
Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis.
    The Lancet. Global health, 2022, Volume: 10, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Bleomycin; Cost-Benefit Analysis; Etoposide; HIV Infections; Humans; Kenya; Paclitaxel; Sarcoma, Kaposi; Vincristine

2022
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
    Journal of pharmaceutical and biomedical analysis, 2022, Nov-30, Volume: 221

    Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water

2022
LC-MS-MS Determination of Cytostatic Drugs on Surfaces and in Urine to Assess Occupational Exposure.
    Journal of analytical toxicology, 2023, Jan-24, Volume: 46, Issue:9

    Topics: Chromatography, Liquid; Cyclophosphamide; Cytostatic Agents; Epirubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Occupational Exposure; Paclitaxel; Tandem Mass Spectrometry; Vinorelbine

2023
Metabolomics Analysis Revealed Significant Metabolic Changes in Brain Cancer Cells Treated with Paclitaxel and/or Etoposide.
    International journal of molecular sciences, 2022, Nov-11, Volume: 23, Issue:22

    Topics: Brain Neoplasms; Etoposide; Glioblastoma; Humans; Paclitaxel; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry

2022
Co-delivery of paclitaxel and etoposide prodrug by human serum albumin and PLGA nanoparticles: synergistic cytotoxicity in brain tumour cells.
    Journal of microencapsulation, 2023, Volume: 40, Issue:4

    Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Etoposide; Humans; Mice; Nanoparticles; Paclitaxel; Prodrugs; Serum Albumin, Human

2023
Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study.
    Journal of gynecologic oncology, 2023, Volume: 34, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Conservative Treatment; Etoposide; Female; Humans; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Pregnancy; Prognosis; Retrospective Studies; Young Adult

2023